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ABSTRACT 
Therapeutic hypothermia, active cooling of a patient to a core body temperature of 32-34°C, is a 
neuroprotective therapy that is employed in critically ill patients to prevent further neuronal 
damage following an acute injury. While undergoing therapeutic hypothermia, critically ill 
patients are also administered a multitude of medications, which puts them at high risk for 
adverse drug events. The majority of these drugs undergo hepatic elimination via cytochrome 
P450 (CYP450) metabolic pathways and/or many also undergo active transport via the ATP-
Binding Cassette (ABC) drug transporter pathways. In order to safely and effectively treat this 
critically ill population, it is imperative to understand how therapeutic hypothermia effects drug 
metabolism and drug transport. Therefore, the overarching aim of this dissertation was to expand 
what is currently known about the effects of therapeutic hypothermia on CYP450-mediated drug 
metabolism in a pediatric clinical study evaluating phenytoin elimination and to pre-clinically 
investigate the effects of hypothermia on drug transport via the ATP-binding cassette drug 
transporter pathways. Specifically, therapeutic hypothermia led to an overall decrease in the 
metabolism of phenytoin by reducing the maximum velocity of the enzymatic reaction. 
Furthermore, therapeutic hypothermia led to a decrease in the active drug transport of three ATP-
Binding Cassette transporters (ABC), which play a significant role in the transport of drugs in 
various tissues throughout the body. Specifically, hypothermia to 33°C led to a decrease of 
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ABCB1, ABCG2, and ABCC1 by 28, 32, and 26% in permeability flux assays in MDCKII 
overexpressed-cells.   
 Collectively, this work demonstrates that therapeutic hypothermia decreases drug 
metabolism in pediatrics following cardiac arrest. Further, it provides evidence of a decrease in 
ABC drug transport activity in vitro. Future research should investigate the effect of therapeutic 
hypothermia on drug transport activity in clinical studies. Additionally, studies should 
investigate the effects of therapeutic hypothermia versus injury/disease on drug 
pharmacokinetics in order to optimize the therapeutic benefits of medications by customizing 
dosing based on disease and therapeutic intervention in these critically ill patients. 
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ABBREVIATIONS 
ABC:  ATP-binding cassette 
ADE:  adverse drug event 
ADR:  adverse drug risk 
AED:  anti-epileptic drugs 
ALBL:  albumin 
ALBH: hepatic albumin 
ALTH: alanine aminotransferase 
ASTH:  aspartate aminotransferase 
AUC:  area under the curve 
BCRP:  breast cancer resistance protein 
BILIH: bilirubin 
BLQ:  below limit of quantification 
BUNH: blood urea nitrogen 
CA:  cardiac arrest 
CDER: Center for Drug Evaluation and Research 
Cls:  systemic clearance 
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ClTOT:  total clearance 
Cmax:  maximum concentration 
Cmin:  minimum concentration 
Concs:  concentrations 
CRH:  corticotropin-releasing hormone 
CV:  coefficient of variation 
CWRES: conditional weighted residuals 
CYP450: cytochrome-P450 
DV:  dependent varaiable 
ECMO: extra-corporeal membrane oxygenation  
ERα: efflux ratio; ratio of the initial rate of B→A flux divided by the initial rate of 
A→B flux 
FDA:  Food and Drug Administration 
FITC:  fluorescein isothiocyanate 
FD-4:  fluorescein isothiocyanate-dextran 
GI:  gastrointestinal  
GoF:  goodness-of-fit 
HACA: hypothermia after cardiac arrest 
HIE:  hypoxic-ischemic encephalopathy 
HPLC:  high-performance liquid chromatography 
HSP:  heat-shock protein 
ICG:  indocyanine green 
ICU:  intensive care unit 
 3 
IS:  internal standard 
ICP:  intracranial pressure  
IPRED: individual predicted 
IRES:  individual residuals 
IWRES: individual weighted residual 
Km:  Michaelis-Menten rate constant 
ke:  elimination rate constant 
LEV:  levetiracetam 
LEV-d6: levetiracetam-d6 
LLOD: lower limit of detection 
LLOQ: lower limit of quantification 
MDCK: Madin-Darby canine kidney 
MDCKII: Madin-Darby canine kidney-II 
MDR1: multidrug resistance protein-1 
MRP1:  multidrug resistance related protein-1 
MF:  matrix factor 
MS/MS: tandem mass spectrometry 
NONMEM: nonlinear mixed-effects modeling 
OCT:  organic cation transporter 
OFV:  objective function value 
 4 
Papp:  observed permeability 
PC:  prediction corrected 
pcVPC: prediction corrected visual predictive check 
P-gp:  p-glycoprotein 
PLC:  phospholipase C 
PHY:  phenytoin 
PHY-d10 : phenytoin-d10 
PopPK: population pharmacokinetic 
PsN:  Perl-speaks NONMEM 
PSP:  phenolsulfonphthalein 
QC:  quality control 
Q:  inter-compartmental clearance 
RCT:  randomized control trial 
RE:  relative error 
ROSC:  return of spontaneous circulation 
RSE:  relative standard error of the estimate 
SLC:  solute carrier 
t1/2:  elimination half-life 
TBI:  traumatic brain injury 
TDM:  therapeutic drug monitoring 
TEER:  transepithelial electrical resistance 
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TH:   therapeutic hypothermia 
TJ:  tight junction 
TTM:  targeted temperature management 
UPLC:  ultra-performance liquid chromatography 
V1:  volume of the central compartment 
V2:  volume of the peripheral compartment 
VD:  volume of distribution 
Vmax:  maximum velocity of metabolism 
VPC:  visual predictive check 
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1.1 THERAPEUTIC HYPOTHERMIA 
This section provides a brief discussion on the background of therapeutic hypothermia (TH), its 
implementation and use in critical care, the optimal depth and duration for therapeutic cooling, 
the current recommended guidelines for TH, and the physiologic effects of TH. 
1.1.1 Background on Therapeutic Hypothermia 
Following an ischemic injury, critically ill patients are at high risk for clinical neurological 
injury, which contributes to overall morbidity and mortality in these patients (Narayan, Michel et 
al. 2002, Rea, Pearce et al. 2004, De Keyser, Uyttenboogaart et al. 2005). Approximately 
200,000-500,000 patients have an out-of-hospital cardiac arrest each year (Rea, Pearce et al. 
2004).  In addition, approximately 16,000 pediatric patients suffer a CA each year in the United 
States (Binks and Nolan 2010, Tress, Kochanek et al. 2010). Of those that survive these severe 
initial injuries, neurological damage is a common sequelae leading to significant disability and 
lost cognitive function (Levy, Caronna et al. 1985, Jorgensen and Holm 1998). However, limited 
drug therapy options are available to provide neuro-protection and prevent secondary injury after 
resuscitation (Laver, Farrow et al. 2004).      
Therapeutic hypothermia is a neuroprotective therapy that is employed to prevent 
neuronal damage following an acute injury (Karibe, Chen et al. 1994, Lei, Tan et al. 1994, 
Aibiki, Maekawa et al. 1999, Bernard, Gray et al. 2002). While the use of therapeutic 
hypothermia to prevent neuronal injury is not a new therapy, the implementation of therapeutic 
hypothermia has increased and evolved over the past two decades as new research has emerged.    
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From 2000 to 2010 the use of TH in the intensive care unit (ICU) increased largely as a 
result of two pivotal randomized control trials (RCTs), which demonstrated a decrease in 
mortality and an improvement in neurological outcome in patients experiencing out-of-hospital 
cardiac arrest (CA) (Bernard, Gray et al. 2002, Group 2002, Shankaran and Laptook 2007). The 
Hypothermia After Cardiac Arrest (HACA) study investigated the effect of therapeutic 
hypothermia (32 – 34°C for 24 hours) on neurological outcomes and mortality in resuscitated 
patients following a CA due to ventricular fibrillation. The HACA study showed improved 
neurological outcomes in out-of-hospital CA patients who were cooled as compared to those 
who were not cooled (Risk Ratio: 1.4, p<0.009). Further, hypothermic CA patients had a 
decrease in mortality as compared to the normothermic group (Risk Ratio = 0.74; confidence 
interval = 0.58-0.95). In another RCT, Bernard et al. also demonstrated an improvement in 
cardiovascular effects in out-of-hospital CA patients undergoing hypothermic treatment (33°C 
for 12 hours) as compared to the normothermic control group. Of the patients undergoing 
therapeutic hypothermia 49% were discharged to home or a rehabilitation facility, whereas only 
26% of patients undergoing normothermia treatment were discharged (p  = 0.046).   
In addition to out-of-hospital adult CA patients, therapeutic hypothermia has also been 
shown to be efficacious in perinatal asphyxia (Shankaran, Laptook et al. 2005). In a RCT in 
infants with moderate or severe encephalopathy, Shankaran et al. demonstrated an improvement 
in the primary outcome measurement (death or moderate or severe disability) in infants who 
were randomly assigned to hypothermia treatment to 33.5°C for 72 hours, as compared to the 
standard-of-care normothermia control group. In the hypothermic group, death or moderate or 
severe disability occurred in 44% of the infants, in contrast to 62% in the normothermic group 
(risk ratio = 0.72; 95 percent confidence interval, 0.54 to 0.95; p=0.01).   
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To date, the two main patient populations that therapeutic hypothermia is recommended 
and used in are 1) out-of-hospital adult cardiac arrest patients and 2) neonates with hypoxic-
ischemic encephalopathy (HIE). TH has also been studied in a number of other patient 
populations including traumatic brain injury (TBI) (Clifton, Valadka et al. 2011, Georgiou and 
Manara 2013, Beca, McSharry et al. 2015, Zhang, Wang et al. 2015, Cooper, Nichol et al. 2016), 
stroke (Kollmar, Schellinger et al. 2009, Bi, Ma et al. 2011, Wan, Nie et al. 2014), and spinal 
cord injury (Levi, Green et al. 2009, Grulova, Slovinska et al. 2013). Currently, TH is not used 
for neuroprotection in TBI but it is employed to control intracranial pressure (ICP). Moreover, 
conflicting evidence has led to varying recommendations in these patient populations and in 
some cases its benefit is outweighed by its adverse drug risk (ADR). As it pertains to this 
dissertation, understanding how to successfully implement therapeutic hypothermia by 
understanding its underlying effect on drug disposition is critical. 
The use of therapeutic hypothermia as a neuroprotective treatment strategy in critically ill 
patients has shifted focus over the past decade from the initial pivotal RCTs in the early 2000s. 
Based on these initial RCTs, TH was recommended in the American Heart Association 
Guidelines for adult out-of-hospital CA patients and in neonates with hypoxic ischemic 
encephalopathy (Nolan, Morley et al. 2003). Subsequently, in the largest hypothermia RCT to 
date, no significant difference was seen in the neurological outcomes of adult CA patients who 
received therapeutic hypothermia (33°C) versus targeted temperature management (TTM) 
(36°C) (Nielsen, Wetterslev et al. 2013). These results have raised questions regarding the 
benefits of cooling to 33°C. Recently, Moler et al. (Moler, Silverstein et al. 2015) studied the 
effect of therapeutic hypothermia (33°C for 48 h) as compared to normothermia (36.8 °C) in 
children who suffered an out-of-hospital CA. A trend toward improved outcome (12 month 
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survival with favorable neurological outcome as assessed by the Vineland Adaptive Behavioral 
Scale) was seen with hypothermia versus normothermia (p=0.14) along with mortality (p=0.13). 
Given that the power of the study to detect the rather demanding target of 20% improvement in 
outcome was only 42%, some have suggested that this study supports the use of hypothermia in 
this population—until proven otherwise (Vincent and Taccone 2015). Thus, TTM at various 
levels of hypothermia, continues to be recommended for use in neonates with HIE and to treat 
out-of-hospital CA patients (Callaway, Donnino et al. 2015). As further evidence becomes 
available, the degree of which we cool patients may increase from the previous target clinical 
temperature of 32-34°C. Indeed, recent evidence indicates that even a 1°C reduction in 
temperature induces neuroprotective signaling cascades in neurons in in vitro systems (Jackson, 
Manole et al. 2015). However, studies are needed to delineate the specific patients who 
maximally benefit from hypothermia treatment based on additional considerations such as 
severity of injury, organ dysfunction following cardiac arrest, inflammation, and co-administered 
medications.   
1.1.2 Implementation of Therapeutic Hypothermia 
In a broad sense, therapeutic hypothermia is defined as a core body temperature less than 
35.0˚C. Moreover, there are different degrees of hypothermia which incur a range of 
neuroprotection and adverse physiologic effects. Hypothermia can be divided based on the 
degree of cooling and include mild hypothermia, moderate hypothermia, and severe 
hypothermia. It is generally accepted that mild hypothermia occurs when a subject is cooled to a 
temperature of 32-34˚C whereas moderate hypothermia is at a temperature range of 30 – 32˚C. 
Severe, or “deep” hypothermia, is defined as cooling to a temperature below 30˚C.  
 11 
Furthermore, therapeutic hypothermia undergoes different lengths of cooling depending 
on the patient population. Adult cardiac arrest patients typically undergo therapeutic hypothermia 
for 24-48 hours, whereas neonates with HIE are cooled for 72 hours. The AHA guidelines 
recommend that a minimum of 24 hours of cooling be achieved (Callaway, Donnino et al. 2015).  
The duration of cooling is largely based on the design of randomized control trials which 
demonstrated outcome benefits. Although these temperatures tend to be generally accepted, it is 
important to note that these categories can be arbitrary across studies and require verification of 
temperature and duration in the currently published literature. This dissertation will focus 
predominately on the effects seen within mild hypothermia (32 - 34˚C), since this is the clinically 
relevant temperature range that has been shown to afford neuroprotection without adverse 
physiologic consequences to critically ill patients in the ICU.   
In addition to the duration of cooling, the time of initiation is also an important 
consideration. Therapeutic hypothermia should be started as soon as possible following return of 
spontaneous circulation (ROSC). However, studies have demonstrated that it appears to be 
successful even if it is initiated after 4 to 6 hours (Nolan, Morley et al. 2003). For example, in 
the HACA trial, the time between ROSC and reaching the target clinical temperature ranged 
from 4 to 16 hours (Group 2002). 
There are a number of different cooling methods, such as external and internal 
techniques, which can be used to achieve target temperature (Nolan, Morley et al. 2003). 
External cooling methods consist of applying ice packs, wet towels, a cooling helmet, or a 
cooling blanket. These external methods are convenient and simple to use but often require a 
long time to achieve desired temperature. Internal methods of cooling such as intravenous 
infusion of cold saline have also been used to reach target body temperature. Moreover, careful 
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monitoring and control of temperature is essential when employing therapeutic hypothermia. 
Shivering must be controlled during cooling to prevent the body from rewarming. To control 
shivering, a neuromuscular blocking agent and sedative are employed. This is one example 
where drug-therapy interactions may occur during cooling.     
1.1.3 Guidelines for the Use of Therapeutic Hypothermia 
The recommendations for use of therapeutic hypothermia have shifted to reflect new clinical 
evidence in the field. In 2003 the International Liaison Committee on Resuscitation 
recommended 12-24 hours of cooling to 32-34°C in adult patients with spontaneous circulation 
with out-of-hospital cardiac arrest (Nolan, Morley et al. 2003). At this time, they suggested that 
such cooling may also be beneficial for in-hospital patients or for other rhythms. No 
recommendations were made for children as there was insufficient clinical data to support 
cooling in pediatric patients (Nolan, Morley et al. 2003).   
In 2010, the guidelines recommended inducing therapeutic hypothermia for V-fib cardiac 
arrest patients (Morrison, Deakin et al. 2010). A cooling duration of 12-24 hours to a degree of 
32-34°C was recommended. Most recently in 2015 the guidelines for therapeutic hypothermia 
changed drastically based on several large RCTs which investigated various target temperatures 
and durations (Callaway, Donnino et al. 2015). It was at this time that a newer term “targeted 
temperature management” was introduced to reflect the varying degrees of temperatures being 
used. Target temperature management became more commonly used to refer to both therapeutic 
hypothermia and to actively controlling temperature to any degree. These guidelines had three 
important recommendations. The first update was that TTM should be induced in comatose adult 
patients. Further, the degree of cooling was expanded to include recommendations for any 
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temperature between 32 – 36°C during TTM. Finally it was recommended that TTM be 
maintained for at least 24 hours after target temperature was achieved.     
1.1.4 Physiologic Effects of Hypothermia 
Before discussing the specific effects of therapeutic hypothermia on drug disposition and 
response, it is important to first recognize the general physiologic changes that occur in 
therapeutic hypothermia patients during the induction, maintenance, and rewarming phases. 
Figure 1 depicts the known effects of therapeutic hypothermia on drug absorption, distribution, 
metabolism, excretion and response. Additionally, the quality of the current data (preclinical 
versus clinical evidence) is described.  
1.1.4.1 Cardiovascular Effects of Hypothermia 
The effect of therapeutic hypothermia on the cardiovascular system has been divided into two 
main areas 1) hemodynamic effects and 2) electrocardiographic effects. Both of which are 
described below.  
Hemodynamic Effects 
Hypothermia has been linked to changes in myocardial function. Mild hypothermia 
induces a decrease in heart rate, but produces an overall increase in the contractility of the heart 
in sedated patients (Goldberg 1958, Suga, Goto et al. 1988, Mikane, Araki et al. 1999, Lewis, 
Al-Khalidi et al. 2002, Fischer, Cox et al. 2005, Polderman and Herold 2009). Systolic function 
will improve, but diastolic function may decrease (Polderman and Herold 2009). Some patients 
may experience an increase in blood pressure while others may see no change in blood pressure. 
Overall, cardiac output will decrease along with the heart rate. However, the subsequent 
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hypothermia-induced decrease in metabolic demand tends to equal or exceed the decrease in 
cardiac output, thus keeping the balance between supply and demand constant (Polderman 2009).  
In some cases, the heart rate may be artificially increased by drugs or external pacing. 
However, the effect of hypothermia on myocardial contractility has convoluted results under 
artificial stimulation (Mattheussen, Mubagwa et al. 1996, Mikane, Araki et al. 1999, Lewis, Al-
Khalidi et al. 2002). Two pre-clinical studies showed that under normothermic conditions an 
increase in heart rate led to an increase in cardiac output and myocardial contractility 
(Mattheussen, Mubagwa et al. 1996, Mikane, Araki et al. 1999). In contrast, when heart rate was 
increased under mild hypothermic conditions there was a decrease in myocardial contractility. 
The same results were reported in a clinical study in patients undergoing cardiac surgery (Lewis, 
Al-Khalidi et al. 2002). When heart rate was not increased artificially, mild hypothermia 
improved myocardial contractility. Thus, in most patients heart rate should be allowed to 
decrease with temperature without any serious adverse complications.  
Electrocardiographic Effects 
Mild hypothermia has also been associated with abnormal heart rhythms. During cooling, 
hypothermia causes an increase in plasma norepinephrine levels and activation of the 
sympathetic nervous system. This leads to constriction of peripheral vessels and a shift of the 
blood from small, peripheral veins to centrally located veins in the core compartment of the 
body. Ultimately, this results in an increase in venous return which leads to mild sinus 
tachycardia. As temperature continues to drop even further below 35˚C, the heart rate begins to 
slow to a below normal rate eventually leading to what is known as sinus bradycardia. The heart 
rate will continue to decrease progressively as temperature drops to 33˚C and below (Danzl and 
Pozos 1994). The mechanism behind this is a decrease in the rate of spontaneous depolarization 
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of cardiac cells in combination with prolonged duration of action potentials. These 
electrocardiogram changes usually do not require treatment and in most cases a patient’s heart 
rate should be allowed to decrease with cooling. Furthermore, some studies have linked 
hypothermia to an increased risk for arrhythmias. However, hypothermia-induced arrhythmias 
generally only apply to moderate to deep hypothermia, particularly when temperatures reach less 
than 30°C. During deep hypothermia, a patient is at higher risk to develop atrial fibrillation or 
ventricular fibrillation if temperatures reach as low as 28°C. Since temperatures are maintained 
at greater than 30°C in the ICU, few cases of hypothermia-induced arrhythmias have been 
observed in clinical trials evaluating the safety of mild therapeutic hypothermia (Polderman 
2009).   
1.1.4.2 Renal Effects of Hypothermia 
Therapeutic hypothermia also has physiologic effects on renal function. During cooling, an 
increase in urinary output, known as cold diuresis, may occur. Cold diuresis results from a 
combination of an increase in venous return, a decrease in antidiuretic hormone, tubular 
dysfunction, and decreased levels of antidiuretic hormone and renal antidiuretic hormone 
receptor levels (Morgan, Anderson et al. 1983, Allen and Gellai 1993, Polderman, Peerdeman et 
al. 2001, Polderman, Tjong Tjin Joe et al. 2002, Sun, Zhang et al. 2003, Sun 2006).  
Renal elimination can be divided into passive filtration, active tubular secretion and active 
tubular reabsorption. Passive glomerular filtration does not seem to be affected by therapeutic 
hypothermia. One clinical study investigated the effects of mild hypothermia on renal filtration 
by measuring serum creatinine levels and creatinine clearance in subjects with and without 
hypothermic treatment. The study found no change in creatinine clearance between the two 
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groups and concluded that cooling does not impair renal filtration (Zeiner, Sunder-Plassmann et 
al. 2004).   
Although passive processes of renal filtration do not seem to be significantly altered, some 
published evidence does suggest that the active processes of tubular secretion and reabsorption 
may be altered by mild hypothermia (Nishida, Okazaki et al. 2007, Liu, Borooah et al. 2009). To 
date, the effect of therapeutic hypothermia on the active process of tubular secretion has only 
been studied preclinically in rats. This study used fluorescein isothiocyanate (FITC)-dextran to 
measure glomerular filtration and phenolsulfonphthalein (PSP) to measure renal tubular secretion 
in mildly hypothermic versus normothermic rats (Nishida, Okazaki et al. 2007). The results 
showed no change in FITC-dextran clearance, but a significant change in the renal clearance of 
PSP. These results provide further evidence that the passive process of renal filtration is 
unaffected by mild hypothermia, whereas, active renal tubular secretion is decreased during 
cooling. There are, however, a limited number of studies published to date and whether or not 
these initial evaluations remain true clinically will depend on more extensive assessments of the 
effects of mild hypothermia on renal drug elimination processes. 
1.1.4.3 Electrolyte Effects of Hypothermia 
Therapeutic hypothermia also alters electrolyte levels such as magnesium, potassium, and 
phosphate. During cooling, electrolytes shift from the bloodstream to the intracellular 
compartment. The low level of electrolytes remaining in the bloodstream increases a patients risk 
for hypokalemia. During rewarming, the opposite effect is seen and potassium, as well as other 
electrolytes, is released back into the bloodstream from the intracellular compartment. If the 
patient is rewarmed too quickly, potassium levels will increase abruptly in the bloodstream and 
the patient may become hyperkalemic. To avoid hyperkalemia, a slow and consistent rewarming 
 17 
period is necessary to allow the kidneys to excrete the excess potassium. Furthermore, frequent 
lab electrolyte assessments are needed to account for shifts in systemic electrolyte 
concentrations. 
1.1.4.4 Body Metabolism & Drug Clearance Effects of Hypothermia 
Hypothermia has been shown to decrease the metabolic rate by approximately 8% per 1˚C drop 
in body temperature. A similar decrease in oxygen consumption and carbon dioxide production 
is observed. This decrease in metabolic rate arises from a global decrease in the rate of drug 
metabolism by the liver because the majority of the metabolic reactions in the liver are enzyme-
mediated. The rate of these enzyme-mediated reactions is highly temperature sensitive; thus the 
rate of these reactions is significantly slowed during hypothermia. Hypothermia-induced 
reductions in clearance have been shown for a number of commonly used ICU sedatives such as 
propofol; opiates such as fentanyl and morphine; midazolam; neuromuscular blocking agents 
such as vecuronium and rocuronium; and other drugs such as phenytoin (Polderman 2009). The 
specific alterations in drug metabolism and clearance will be further addressed in more detail in 
the subsequent sections.     
1.1.4.5 Gastrointestinal Effects of Hypothermia 
Gastrointestinal (GI) motility decreases with mild hypothermia. In some cases, decreased 
motility leads to mild ileus which typically occurs at temperatures less than 32°C (Danzl and 
Pozos 1994). Other physiological factors play a large role in the extent to which drugs and 
nutrients are absorbed across the gut wall. As with drug excretion in the kidney, drug absorption 
across the intestinal membranes depends primarily on passive diffusion with significant 
contribution by active transport mechanisms for some drugs. Also similar to the kidney, cooling 
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was shown to affect active drug transport via the ABCB1 transporter, more commonly known as 
P-glycoprotein, in vitro. However, no effect of cooling has been reported on passive diffusion, 
thereby, suggesting that passive processes are unaltered and active drug transport may be 
impaired during cooling. Further physiological factors that affect absorption include the pH of 
various biological compartments and the blood flow at the site of absorption. The 
physiochemical properties of the drug, such as its pKa and lipid solubility, in combination with 
the compartmental pH, will influence the extent of which the drug will distribute into a given 
compartment. It is expected that some drugs will have increased absorption while others may 
have decreased absorption during cooling depending on pH, lipophilicity, and primary site of GI 
absorption; however, no studies to date have thoroughly evaluated if these anticipated changes 
occur in vivo under mild hypothermic conditions.  
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Figure 1: The effects of therapeutic hypothermia on drug absorption, distribution, 
metabolism/transport, renal excretion and drug response. 
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1.2 ADVERSE DRUG EVENTS IN CRITICAL CARE  
The question of altered drug disposition and response in patients receiving therapeutic 
hypothermia is particularly important to the optimization of the wide array of drugs used in 
critically ill patients. This section briefly highlights some of the high risks associated with 
adverse drug events in critically ill patients, the commonly administered drugs in critical care, 
and the metabolic and transporter pathways associated with these medications.   
1.2.1 Critically Ill Patients are at High Risk for Adverse Drug Events 
Adverse drug events (ADE) are a significant problem among critically ill patients in the ICU 
(Kane-Gill, Rea et al. 2006, Barletta, Cooper et al. 2010, Devlin, Mallow-Corbett et al. 2010, 
Kane-Gill, Jacobi et al. 2010, Kane-Gill, Kowiatek et al. 2010, Papadopoulos and Smithburger 
2010, Kane-Gill, Kirisci et al. 2012). In the ICU, serious ADEs occur in 26% of patients as 
compared to only 11% in non-ICU patients (Cullen, Sweitzer et al. 1997). The reason for this 
high rate of ADEs is due, in part, to the plethora of medications administered to patients for 
analgesia/sedation, paralysis, control of seizure activity, blood pressure, treatment of 
arrhythmias, control of blood clotting, antibiotics, and delirium prevention, many of which are 
administered simultaneously. Table 1 provides a list of commonly administered drugs in the ICU 
organized by route of elimination. The high number of medications in combination with acute 
changes in organ function puts this vulnerable population at high risk for ADEs (Cullen, 
Sweitzer et al. 1997). Ultimately, these events may lead to extended sickness, mortality, and 
increased hospital costs (Vargas, Terleira et al. 2003).  
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Table 1:  Commonly used medications in the ICU and their elimination pathways. 
Elimination Pathway Commonly Administered Drugs in the ICU  
CYP2C9/CYP2C19 Phenytoin 
Phenobarbital 
Clopidogrel 
Pantoprazole 
Warfarin 
Omeprazole 
Lansoprazole 
CYP2D6 Metoprolol 
Propranolol 
Codeine 
Risperidone 
Tramadol 
CYP3A Midazolam 
Fentanyl 
Lidocaine 
Verapamil 
Diltiazem 
Amlodipine 
Amiodarone 
Nifedipine 
Alprazolam 
Morphine 
Carbamazepine 
Rifampin 
Diltiazem 
Dexamethasone 
Clarithromycin 
CYP2B6 Propofol 
CYP2A6 Dexmedetomidine 
Phase II 
glucuronidation/UGT 
Morphine 
Renal Filtration Gentamicin 
Sotalol 
Renal Excretion Atenolol 
Glycopeptides 
Aminoglycosides 
β-lactams 
Atracurium 
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Excreted Unchanged Bretylium 
N-acetyltransferase Procainamide 
 
 
Many of the drugs administered to critically ill patients have key pharmacokinetic 
properties such as large volumes of distributions, extensive binding to plasma proteins, and 
require hepatic metabolism as a primary mechanism of elimination. Table 2 further details the 
pharmacokinetic characteristics of these commonly administered medications. To prevent ADEs, 
the Food and Drug Administration (FDA) and Center for Drug Evaluation and Research (CDER) 
have established in vitro and in vivo guidelines to test for metabolism-based and transporter-
based drug-drug interactions (Huang, Temple et al. 2007, Services 2012). In contrast to these 
guidelines for new drugs that come to market, new pharmacological therapies are not upheld to 
the same detailed testing for potential drug-therapy interactions. Often times, a new therapy, such 
as therapeutic hypothermia, is implemented in the clinic with little to no knowledge of how it 
will impact drug pharmacokinetics. Without a better understanding of the potential alterations of 
a new pharmacological therapy, we put the patient at high risk for adverse drug events. 
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Table 2: Pharmacokinetic properties of commonly administered medications in the ICU. 
 
Primary 
Route of 
Elimination 
Pathway(s) of 
Elimination 
Volume of 
Distribution 
Protein 
Binding Half-life 
ANALGESICS/SEDATIVE      
Fentanyl Hepatic: 75%  CYP3A4 4 - 6 L/kg 80-85% 2.5-6.5 mins 
Propofol Hepatic: 90% CYP2B6/UGT 60 L/kg 95-99% 30-60 mins 
Dexmedetomidine Hepatic: 95%  CYP450 & 
glucuronidation 
118 - 152 
L/kg 
94% 2-2.67 hrs 
Remifentanil Hepatic: 90%  350 mL/kg 92% 3-10 mins 
Midazolam Hepatic: 63 - 
80%  
CYP3A4  1 - 3.1 L/kg 
 
95% 1.8-6.4 hrs 
Lorazepam Hepatic: 88%  Conjugation 1.3 L/kg 91%  9-19 hrs 
Ketamine Hepatic N-dealkylation, 
hydroxylation, 
conjugation, dehydration 
2 - 3 L/kg 47% 2-3 hrs 
Morphine Hepatic: 90% CYP2C, CYP3A; UGT 1 - 4.7 L/kg 30-40% 2-3 hrs 
PARALYTICS      
Vecuronium Hepatic: 15% 
Bile: 30 - 50% 
CYP3A4 
PGP Transporter 
0.2 - 0.4 L/kg 30% 51-80 mins 
Rocuronium Bile: extensive 
Hepatic: 33% 
CYP2D6 
Renal 
0.25 L/kg  30% 84-131 mins 
Pancuronium Hepatic: 57 - 
69% 
Bile: 11% 
Renal elimination & Bile 0.19 L/kg 77-91% 1.5-2.7 hrs 
ANTI-ARRYTHMICS      
Lidocaine Hepatic: 90% CYP1A2, CYP3A 1.5 L/kg 60-80% 1.5–2.0 hrs 
Amiodarone Bile: primary CYP2C9/19, CYP3A4 60 L/kg 33-65% 15-142 days 
Digoxin Hepatic: 57 – 
80% 
Bile: 6 - 8% 
glomerular filtration, 
PGP Transporter 
4 - 7 L/kg 25% 36-48 hrs 
Diltiazem Hepatic: 35% 
Feces:  60-
65% 
 3 - 13 L/kg 77-93% 3-6.6 hrs 
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ANTI-HYPERTENSIVE      
Verapamil Hepatic: 70% 
Feces: 9 - 16%  
CYP3A4, CYP2C9/19; 
PGP Transporter 
3.8 L/kg 90% 3-7 hrs 
Enalapril Hepatic: 61% OATP/MRP2 
Transporters  
? 50-60% 11 hrs 
Metoprolol Hepatic: 95% CYP2D6 & CYP2C9 5.6 L/kg 15% 3-7 hrs 
Valsartan Feces: 83% 
Hepatic: 7-
13% 
OATP/MRP2 
Transporters 
17 L/kg 95% 6 hrs 
Pressors and Iontropes      
Epinephrine Hepatic MAO/COMT  N/A N/A 2 mins 
Norepinephrine   N/A N/A  
Phenylephrine Hepatic: 80 - 
86% 
oxidative deamination; 
sulfation and some 
glucuronidation 
40 L/kg N/A 2-3 hrs 
Milrinone Hepatic: 80 - 
85% 
 
Active tubular secretion  0.3 - 0.47 
L/kg 
70% 1-3 hrs 
Dopamine Hepatic: 80% MAO/COMT  1.8 - 2.5 L/kg  9 mins 
Vasopressin Hepatic: 5-
10% 
 N/A N/A 10-20 mins 
ANTI-CONVULSANT      
Phenytoin Bile: Extensive 
Renal   
CYP2C9, CYP2C19; 
UGT  
0.5 - 1.0 L/kg 90% 7-42 hrs 
Phenobarbital Hepatic CYP2C9; hydroxylation 
and glucuronide 
conjugation; UGT  
 20-45% 2–7 days 
Carbamazepine Hepatic: 72% 
Feces: 28% 
CYP3A4, CYP2C9; 
PGP/UGT Transporters 
0.8 - 2 L/kg 76% 25-65 hrs 
Keppra Hepatic: 66% enzymatic hydrolysis 0.7 L/kg < 10% 6-8 hrs 
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ANTI-
PLATELET/CLOTTING 
Warfarin  Hepatic: 92% CYP2C9 0.14 L/kg 99.5% 20-60 hrs 
Heparin Hepatic  0.07 L/kg  1-2 hrs 
Dalteparin Hepatic:  
extensive 
 40 - 60 
mL/kg 
Low 3-5 hrs 
Aspirin Hepatic: 5.6 - 
35.6% 
hepatic conjugation 150 mL/kg 50-80% 15-20 mins 
4.7-9 hrs 
Clopidogrel Hepatic: 50% 
Feces: 46% 
CYP2C19  98% 6 hrs 
Rivaroxaban Hepatic: 66% 
Feces: 28% 
CYP3A4/5 & CYP2J2 50 L/kg 92-95% 5-9 hrs 
Dabigatran Hepatic: 80% esterases and 
glucuronidation  
50-70 L/kg 35% 12-17 hrs 
MISCELLANEOUS      
Quetiapine Hepatic: 70 - 
73% 
CYP3A4 6 - 14 L/kg 83% 6 hrs 
Haloperidol Hepatic: 50-
60% 
Feces: 15% 
Glucuronidation; 
CYP3A4 
9.5 - 21.7 
L/kg 
90% 18 hrs 
Gentamicin  
Hepatic: 70% 
glomerular filtration 0.2 - 0.3 L/kg <30% 1.5-3 hrs 
Piperacillin / Tazobactam Hepatic: 60-
80% 
 0.18 - 0.3 
L/kg 
16% 36-80 mins 
Vancomycin Hepatic: 40 - 
100% 
 0.2 - 1.25 
L/kg 
30-55%  
Pravastatin Hepatic: 20% 
Feces: 37% 
 0.46 L/kg 43-55% 2.6-3.2 hrs 
 
Pantoprazole 
Hepatic: 71% 
Feces: 18% 
CYP2C19/CYP3A4 11 - 24 L/kg 98% 1 hr 
Famotidine Hepatic: 25 - 
70% 
CYP450s 1 L/kg 15-20% 8-12 hrs 
Corticosteroids Hepatic CYP3A4  Varies Varies 
Abbreviations: UGT = Uridine 5'-diphospho-glucuronosyltransferase; PGP = p-glycoprotein; MAO = Monoamine 
oxidases; COMT = Catechol-O-methyltransferase; OATP = organic anion-transporting polypeptide; MRP2 = 
Multidrug resistance-associated protein 2. 
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1.3 EFFECT OF THERAPEUTIC HYPOTHERMIA ON DRUG 
PHARMACOKINETICS 
As previously discussed, therapeutic hypothermia has been shown to decrease the clearance of 
hepatically-metabolized drugs, which puts the patient at an elevated risk to reach super- or supra- 
therapeutic drug concentrations (Tortorici, Kochanek et al. 2007).  With increased 
implementation comes a growing need to understand the ramifications of therapeutic 
hypothermia on other important factors of ICU care. One such factor is drug disposition and 
efficacy changes in the hypothermic patient. Specifically, clinical practitioners have postulated 
the question, “Should drug doses be altered during or after cooling in patients receiving 
therapeutic hypothermia?” The purpose of this section is to explore this question and present the 
current understanding of the effects of therapeutic hypothermia on the processes of absorption, 
distribution, metabolism and excretion, by providing specific evidence of drugs with altered and 
unaltered pharmacokinetics. Drugs are grouped by indication. Table 3 summarizes the current 
pre-clinical and clinical studies investigating the effects of therapeutic hypothermia on drug 
pharmacokinetics. 
 
Sedatives/Anesthetics 
Midazolam.   
Midazolam is part of the benzodiazepine class of drugs and is commonly administered as 
a sedative in the ICU. Hostler et al. randomized six healthy volunteers to receive 37°C or 4°C 
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saline infusion with or without magnesium. While the lowest temperature achieved in the 
hypothermic group was 35.4°C, pharmacometric analysis predicted a 11.1% decrease in 
midazolam clearance per each degree Celsius decrease in core body temperature in healthy 
volunteers (approximately a 44.4% decrease in clearance to a target clinical temperature of 
around 33°C) (Hostler, Zhou et al. 2010).   
Bjelland et al. investigated the effects of hypothermia on the disposition of midazolam 
along with several other sedatives and anesthetics (fentanyl, morphine and propofol) in patients 
suffering from CA (Bjelland, Klepstad et al. 2013). A total of 15 CA patients who underwent 
hypothermic treatment to 33 – 34°C were enrolled in this case-control study and matched to 
critically ill patients in the ICU who did not receive hypothermia (n = 8). In contrast to Hostler et 
al., the investigators found no difference in the volume of distribution (VD), clearance (Cl), or 
elimination half-life (t1/2) of midazolam between the hypothermic patients and the normothermic 
controls. This study involved a relatively small number of subjects with significant inter-
individual variability in the midazolam time-concentration profiles in both groups. Further, the 
duration of hypothermia treatment across the 15 patients varied from 2 to 17 hours, which may 
have contributed to the large variability in the drug concentration profiles. In a follow-up 
observational study, Bjelland et al. investigated the effects of rewarming following hypothermia 
on the drug concentrations of midazolam in eight CA patients (Bjelland, Klepstad et al. 2014). In 
contrast to their previous study, they reported a 2.9% decrease in midazolam concentrations for 
every 1°C increase in temperature (11% total decrease from 33 to 37°C). One important 
difference in this study was the use of each patient as their own control which eliminated the 
high inter-individual variability seen in their previous study.    
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Bastiaans et al. reported no significant difference in the pharmacokinetics of midazolam 
between hypothermic patients (33°C) following resuscitation (n = 9) versus normothermic, non-
resuscitated patients (n = 8) (Bastiaans, Swart et al. 2013). Population PK showed no different in 
the Cl or VD of midazolam between the hypothermic and normothermic groups.   
Another clinical study, by Welzing et al., investigated the effect of hypothermia on 
midazolam PK in nine asphyxiated newborns treated with whole body hypothermia at 32 – 34°C 
for 72 hours (Welzing, Junghaenel et al. 2013). Neonates were administered a continuous 
infusion of midazolam (30 – 100 µg/kg/h). Population pharmacokinetic analysis was used to 
calculate the t1/2, VD, and Cl. In this small study, the authors report a midazolam Cl of 2.57 
ml/kg/min and t1/2 of 7.0 hours which was comparable to literature values in normothermic 
neonates. Interpretations of this study are limited by a small sample size with high inter-
individual variability in midazolam metabolism, which makes it difficult to differentiate the 
effects of hypothermia versus other covariates, such as liver impairment, on the PK of 
midazolam.       
Empey et al. demonstrated a 17.5% decrease in the systemic clearance of midazolam in 
hypothermic versus normothermic rats following CA (Empey, Miller et al. 2012). Following 
asphyxia, rats were cooled to 33°C or maintained under normothermic conditions at 37°C.  
Midazolam was administered via continuous infusion (1.5 mg/kg/h) and temperature was 
maintained over an eight-hour study duration to reach steady state. Significantly higher 
midazolam plasma concentrations were achieved in the hypothermic rats versus the 
normothermic rats. Noncompartmental analysis revealed that the increase in plasma 
concentrations was due to a 17.5% decrease in systemic clearance following CA.       
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Overall, the reported effect of TTM on the PK of midazolam varies from none to 11.1% 
decrease in systemic clearance per degree Celsius. Based on the preponderance of recent 
evidence, it is clear that the effect of TTM on midazolam PK is much less than that reported 
originally by Fukuoka et al. (Fukuoka, Aibiki et al. 2004). The difference between these studies 
may be attributed to small sample sizes (n = 8 – 15), different patient populations (neonates 
versus adults), different disease states (TBI, CA, healthy volunteers), varying duration of 
hypothermia (2 – 72 hours) and rewarming (8 hours up to 6 days) protocols, different PK 
models, and high inter-individual variability. Collectively, these results indicate that CYP3A4 
metabolism is probably due to a combination of asphyxia and/or hypothermia with the 
hypothermia effect ranging between none to 11% per degree Celsius change.       
 
Fentanyl   
Fentanyl is an analgesic agent that is commonly administered in the ICU, and is often 
used during TTM. Fentanyl is extensively metabolized by CYP3A4. However, unlike 
midazolam, it is considered a high-clearance drug in humans. Based on the well-stirred model of 
hepatic drug clearance, the elimination of a high clearance drug such as fentanyl should be 
predominately affected by changes in hepatic blood flow (Pang and Rowland 1977).     
Bjelland et al. reported a 45.5% decrease in the median total clearance of fentanyl was 
reported in 14 CA patients versus eight case-control matched critically-ill patients (36-38°C) 
[median [semi-interquartile range]:  726 [230] versus 1331 [678]; P < 0.05] (Bjelland, Klepstad 
et al. 2013). In a subsequent study, Bjelland et al. reported no change in fentanyl concentrations 
from the hypothermia to rewarming phases (Bjelland, Klepstad et al. 2014). The lack of change 
in fentanyl concentrations during rewarming, despite significant changes during hypothermia, 
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may be attributed to the long half-life of fentanyl relative to the short duration of rewarming.  
Since hepatic blood flow was not able to be measured in either of these clinical studies, it is 
difficult to mechanistically evaluate how temperature changes affected liver blood flow and 
contributed to overall changes in fentanyl PK. In conclusion, these recent studies are consistent 
with previous findings in which reduced CYP3A activity decreased fentanyl metabolism with 
potentially undefined contribution of hepatic blood flow.            
In the same pre-clinical study in which Empey et al. reported a decrease in midazolam 
clearance, they also reported a 20.5% decrease in the systemic clearance of fentanyl in 
hypothermic versus normothermic rats following CA (Empey, Miller et al. 2012). Enzyme 
kinetics revealed that the decrease in formation of the Cyp3a-dependent metabolite, norfentanyl, 
was attributed to an overall decrease in maximal velocity, Vmax, and not due to a change in 
enzyme affinity, Km.   
 
Phenobarbital. 
Phenobarbital (PB) is a barbiturate indicated for sedation and epilepsy.  Phenobarbital is 
primarily metabolized in the liver by the cytochrome P450 2C19 (CYP2C19) isoform. Three 
clinical studies have investigated the effects of hypothermia on PB PK in neonates, a population 
where PB is commonly used as a first-line agent to prevent neonatal seizures (Filippi, la Marca et 
al. 2011, van den Broek, Groenendaal et al. 2012, Shellhaas, Ng et al. 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Filippi et al. investigated PB PK at two different doses in 19 asphyxiated newborns who 
were undergoing 72 hours of mild hypothermia to 33.5°C (Filippi, la Marca et al. 2011).  
Noncompartmental analysis of steady-state PB concentrations demonstrated a higher Cavg, Cmin, 
and Cmax in the hypothermic neonates as compared to literature values reported for normothermic 
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neonates. Further, the t1/2 of PB was 32.1% longer in hypothermic neonates than the average 
literature values in normothermic neonates (t1/2 = 173.9 ± 62.5 h versus 114-118 h). Additionally, 
the Versuss was also higher than reported values and the Cl was on the lower end of reported 
values in normothermic neonates. The authors conclude that hypothermia is likely mediating the 
decrease in PB elimination but acknowledge that asphyxia may also be contributing to PK 
changes. 
In contrast to Filippi et al., a clinical study performed by van den Broek et al. reported no 
effect of hypothermia (33.5°C) for 72 hours on PB PK in asphyxiated neonates (van den Broek, 
Groenendaal et al. 2012). This retrospective study identified 31 neonates with HIE who were 
administered an intravenous loading dose of PB of 20 mg/kg with additional doses administered 
as needed in subsequent days. Phenobarbital concentration was measured in a total of 87 plasma 
samples obtained from the hypothermic phase (n = 69) and rewarming and pre-hypothermic 
phases (n = 18). Population PK analysis showed that temperature did not have a clinically 
significant effect on the Cl or VD of PB. Interestingly, van den Broek et al. noted that the 
clearance of PB in the asphyxiated neonates was reduced compared to those values reported in 
non-asphyxiated neonates. This was consistent with findings by Gal et al. who reported a 
reduction in the clearance of asphyxia neonates by over half compared to non-asphyxiated 
neonates (Gal, Toback et al. 1984). Van den Broek et al. postulated that the effect of asphyxia 
could be predominately driving changes in the PB clearance, and the effect of temperature may 
not have an additional contributing effect. Since the effect of asphyxia on PB PK was not tested 
by Filippi et al., this could be the main covariate contributing to the discrepancies in conclusions 
between these two studies.      
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Shellhaas et al. also found no effect of TTM on the clearance of PB in neonates with HIE 
(Shellhaas, Ng et al. 2013). This retrospective study included 20 neonates with HIE who were 
administered PB and TTM (33.0 – 35.0°C), and 19 neonates with HIE who were administered 
PB but did not undergo TTM. Using a population PK approach, they also found no effect of 
temperature on the Cl or VD of PB between the hypothermic and normothermic neonates. Due to 
the retrospective nature of this study, exact body temperatures and times were not available to 
include in analysis and therefore the authors were unable to compare the exact relationship 
between dose, PB PK, and body temperature. Instead, the subjects could only be grouped based 
on hypothermic or normothermic classification.    
Collectively, these studies indicate that the PK of PB may be altered in neonates with 
HIE who are undergoing TTM. However, the driving force behind that change in PK, and the 
interplay of disease versus temperature, remains to be determined. It appears that the initial 
findings reported by Filippi et al. which attribute temperature to changes in PB PK may be 
confounded by the effect of asphyxia.  More recent population PK studies have failed to show an 
effect of temperature on PB clearance or volume of distribution. It is likely that any effect of 
hypothermia on PB PK is due to a decrease in CYP2C9 activity, however the effect of asphyxia 
on PB PK is well known and any additional contributions due to a temperature-dependent change 
in CYP2C9 activity seems unlikely. Further, these studies provide evidence for neonates with 
HIE only, and whether these results extrapolate to older populations in children and adults is still 
unknown.     
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Propofol.   
Propofol is a sedative and analgesic agent commonly used in neurocritical care in the 
adult ICU. Propofol is predominately metabolized by CYP2B6 with a small amount undergoing 
glucuronidation by UDP-glucuronosyltransferase 1A9. Two recent clinical studies have 
investigated hypothermia on propofol PK. In the same study that investigated midazolam PK by 
Bjelland et al., the authors also investigated propofol PK in 14 hypothermic patients suffering 
from CA (Bjelland, Klepstad et al. 2013). Hypothermic patients had a 23.2% lower clearance of 
propofol than normothermic patients [median (semi-interquartile range):  2046 (305) versus 2665 
(223) ml/min; p-value = 0.035]. In a subsequent study, Bjelland et al. investigated the 
concentrations of propofol during rewarming in 14 CA patients (Bjelland, Klepstad et al. 2014). 
The concentration of propofol decreased 3.1% per degree Celsius increase in body temperature 
(approximately 12.4% total change in concentration from 33 – 37°C) during rewarming. 
However, no PK parameters were reported in this study. Propofol, like fentanyl, is considered a 
high clearance drug and since hepatic blood flow was not measured in either of these two clinical 
studies, it is difficult to identify the mechanism underlying the reductions in Cl. Collectively, 
these two studies indicate hypothermia may decrease propofol clearance due to a combined 
effect of hepatic blood flow and/or CYP2B6 activity leading to an increase in concentrations.          
 
Dexmedetomidine.   
Dexmedetomidine is a sedative agent which has also been shown to exhibit anti-shivering 
properties. In addition, dexmedetomidine has been associated with a lower rate of delirium 
development as compared to other sedatives in ICU patients (Li, Yang et al. 2017).  
Dexmedetomidine undergoes extensive hepatic metabolism primarily via CYP2A6 isoform and 
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direct glucuronidation. To date, one pre-clinical study in piglets has investigated the effect of 
TTM on the PK of dexmedetomidine (Ezzati, Broad et al. 2014). Nine piglets underwent 
cerebral hypoxia ischemia followed by whole-body hypothermia to 33.5°C for 72 hours. 
Population PK analysis revealed a 32.7% decrease in dexmedetomidine clearance in hypothermic 
piglets following hypoxia-ischemia. A limitation of this study is that it included only injured 
piglets undergoing TTM and therefore they could not separate out the effects of injury versus 
temperature on the PK changes of dexmedetomidine. Overall, the decrease in clearance reported 
in this study was attributed to combined effects of injury and cooling. Future clinical studies with 
larger sample size will be needed to determine the contribution of injury and temperature on the 
PK of dexmedetomidine, particularly given the recent consideration and evaluation of 
dexmedetomodine as an anti-shivering agent and reduced rates of ICU delirium (Doufas, Lin et 
al. 2003, Callaway, Elmer et al. 2015). 
 
Morphine.   
Morphine is an analgesic that is commonly administered in the ICU. In contrast to many 
of the drugs discussed so far which undergo Phase I CYP450 metabolism, morphine undergoes 
Phase II glucuronidation. Two clinical studies have demonstrated an effect of hypothermia on 
morphine concentrations and PK (Roka, Melinda et al. 2008, Bjelland, Klepstad et al. 2013). 
Roka et al. found significantly higher morphine concentrations in hypothermic neonates with 
HIE as compared to normothermic neonates with HIE (Roka, Melinda et al. 2008). In this 
observational study, 10 neonates with HIE underwent hypothermic treatment to 33 – 34°C and 6 
neonates with HIE were maintained normothermic. Mean morphine concentrations after 72 hours 
of cooling were 40.5% higher in the hypothermic group than in the normothermic group (373 ± 
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125 ng/mL versus 222 ± 73 ng/mL). Further, the hypothermic group showed a trend in higher 
morphine AUC than in the normothermic group despite no difference in the morphine infusion 
rates between groups (18608 ± 8384 ng/h/mL versus 12135 ± 3481 ng/h/mL; P = 0.051). The 
median morphine clearance was estimated from a subset of patients with samples available at 
each time point (0.69 mL/min/kg versus 0.89 mL/min/kg) however, the hypothermic group never 
reached steady-state preventing the calculation of a steady-state morphine clearance in this 
group.    
Bjelland et al. reported the median half-life of morphine was 36.8% higher in ICU 
patients undergoing hypothermia versus the normothermia group (median (semi-interquartile 
range); 266 (43) min versus 168 (11) min) (Bjelland, Klepstad et al. 2013). Further the median 
total CL decreased by 28.8% in the hypothermic versus the normothermic group (median (semi-
interquartile range); 1201 (283) ml/min versus 1687 (200) ml/min). No significant difference in 
apparent volume of distribution was seen between groups (median (semi-interquartile range); 
413 (89) l versus 435 (28) l). Collectively, these two clinical studies indicate that hypothermia 
decreases morphine clearance, which is likely due to a decrease in the Phase II metabolic 
glucuronidation pathway. However as was seen in many of the previous studies, the change in 
drug PK is most likely a combined effect of injury and temperature. The degree to which each of 
these factors contributes to changes in drug PK most likely varies across drugs.      
 
Anticonvulsants 
Phenytoin  
Phenytoin is a commonly administered anticonvulsant, which primarily undergoes 
hepatic metabolism via CYP2C9 and CYP2C19. The unique PK of phenytoin include a relatively 
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long half-life and saturable metabolism within the typical therapeutic range. We conducted a 
clinical study investigating the effects of hypothermia on phenytoin PK in children following 
TBI (Empey, de Mendizabal et al. 2013). Nineteen children with TBI in a prospective RCT were 
randomized to receive hypothermia or normothermia treatment. Using a population PK 
approach, hypothermia was shown to reduce phenytoin elimination, similar to the Iida et al. 
study. Specifically, hypothermia led to an overall decrease of approximately 50% in the Vmax of 
phenytoin. Importantly, these supra-therapeutic phenytoin concentrations remained elevated days 
after the end of cooling and rewarming and into the post-treatment period. This was a similar 
finding to Bjelland et al. who reported temperature effects on fentanyl PK long after the 
hypothermia phase. Collectively, these results are an important finding with regard to 
pharmacotherapy and TTM, namely, that drugs with long half-lives, such as phenytoin and 
fentanyl, when administered to patients undergoing TTM, should continue to be monitored even 
into the post-treatment period and subsequent dose-adjustments should be made accordingly. 
This is particularly true given that rewarming has been identified as a period of potential 
heightened hemodynamic and brain instability in brain injured patients (Hutchison, Ward et al. 
2008, Abend, Topjian et al. 2009). Furthermore, this issue is particularly important with 
sedatives such as fentanyl because this drug can mask brain activity during end-of-life 
assessment and withdrawal of support decision making after the rewarming period. 
 
Lidocaine.   
Lidocaine is an antiarrhythmic agent and is also used as a second or third-line treatment 
for neonatal seizures. Lidocaine undergoes hepatic metabolism via CYP1A2, and is classified as 
a high clearance drug therefore its hepatic clearance is predominately impacted by changes in 
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hepatic blood flow. Van den Broek et al. investigated the effects of TTM on the PK and efficacy 
of lidocaine in neonates with encephalopathy (van den Broek, Rademaker et al. 2013). A total of 
22 asphyxiated neonates underwent hypothermia to 33.5°C for 72 hours. Population PK analysis 
revealed a 24% decrease in lidocaine clearance in the hypothermic versus normothermic 
neonates. The reduction in clearance was attributed to a decrease in hepatic blood flow, which is 
a known physiologic effect of hypothermia. In conclusion, the authors recommend using the 
same dose of lidocaine with a slight decrease in the loading infusion duration by 30 minutes.      
       
Antimicrobials   
Gentamicin   
Gentamicin is an antimicrobial agent that is administered to treat infections in critically 
ill patients. Gentamicin is primarily renally-eliminated in an unchanged form via glomerular 
filtration. Since gentamicin is known to be nephrotoxic, blood concentrations are routinely 
measured in the ICU.   
Several clinical studies have investigated the effect of TTM on gentamicin PK in 
neonates (Liu, Borooah et al. 2009, Frymoyer, Meng et al. 2013, Mark, Solomon et al. 2013, 
Ting, Kwan et al. 2014). Liu et al. was the first to report no significant effect of TTM on the 
serum gentamicin concentration in neonates with HIE (Liu, Borooah et al. 2009). Trough serum 
gentamicin concentrations were not different between the hypothermic and normothermic groups 
(2.19 ± 1.7 mg/L hypothermic versus 2.30 ± 2.0 mg/L normothermic). However, neonates in 
both groups had elevated serum concentrations, which can also be explained by the strong 
correlation between acute kidney dysfunction and elevated gentamicin concentrations. Similar to 
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previous studies, this suggests a potential effect of disease over temperature on the PK of 
gentamicin. However, no PK parameters were reported in this study.       
Mark et al. also investigated the effects of hypothermia on gentamicin PK in neonates 
with HIE (Mark, Solomon et al. 2013). In this retrospective case-control study, 16 neonates with 
HIE who underwent hypothermia (33.5°C for 72 hours) and received at least 2 doses of 
gentamicin were included. Neonates with HIE (n = 7) who did not undergo hypothermia 
treatment but received at least two doses of gentamicin were included in the control group. The 
hypothermic neonates had a 40% increase in half-life (9.16 ± 2.08 hours versus 6.56 ± 1.81 
hours; P<0.01), a 25.5% decrease in Cl (0.04 ± 0.01 L/kg.h-1 versus 0.05 ± 0.01 L/kg.h-1; 
P<0.01), and a 28% decrease in the elimination rate constant ke (0.08 ± 0.02/h versus 0.11 ± 
0.03/h; P<0.01). The hypothermic neonates also had an average trough gentamicin concentration 
2.2 times higher than the normothermic neonates (1.68 ± 0.69 µg/mL versus 0.77 ± 0.53 µg/mL; 
P<0.01). These findings are consistent with those reported in our previous review by Koren et al. 
in which the half-life of gentamicin was increased by 39% in hypothermic pigs and the kel and Cl 
were decreased by 27% and 51%, respectively (Koren, Barker et al. 1985). Both the hypothermic 
study in pigs by Koren et al. and the clinical study by Mark et al. demonstrate a combined effect 
of injury and temperature on the pharmacokinetics of gentamicin. 
Frymoyer et al. further investigated the effect of hypothermia on gentamicin PK in 
neonates with HIE (Frymoyer, Meng et al. 2013). A retrospective chart review identified 29 
neonates with HIE (47 gentamicin concentrations) who underwent hypothermia and received an 
iv gentamicin dose of 5 mg/kg Q 24 hours. A population PK analysis was performed to 
determine the Cl and VD of gentamicin in this patient population and subsequent simulations 
were done to determine a dosing regimen that would achieve therapeutic concentrations.  
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Clearance in this patient population was 0.118 L/h, which was 25 – 50% lower than reported 
literature values in normothermic neonates with HIE. In contrast, the VD in the hypothermic 
neonates was similar to reported values in normothermic neonates. Simulations based off of 
these PK parameters predict a dosing regimen of gentamicin every 36 hours, instead of the 
typical 24 hours, to achieve concentrations below the recommended 2 mg/L.   
Finally, Ting et al. also investigated the effect of TTM on gentamicin PK in neonates 
with moderate to severe HIE (Ting, Kwan et al. 2014). They identified 15 neonates with HIE 
who underwent hypothermia and 19 neonates with HIE maintained normothermic. The 
hypothermic group had a 26.8% longer half-life than the normothermic group (9.57 hours versus 
7.01 hours; P = 0.007) and a high number of neonates in the hypothermic group had elevated 
gentamicin concentrations compared to those in the normothermic group.   
The majority of these studies indicate that gentamicin clearance is decreased in neonates 
with HIE treated with hypothermia. The results suggest that a decrease in the dose of gentamicin 
or an increase in the dosing interval may be beneficial when gentamicin is being administered 
during hypothermia. However, all of these studies have significant limitations: they are 
retrospective analyses with a relatively small sample size and are mostly in neonates and have a 
limited number of plasma samples based on what was previously recorded. Further, these studies 
cannot separate the combined effect of injury and hypothermia on the PK of gentamicin.   
1.3.1 Effect of Therapeutic Hypothermia on Drug Transport 
In addition to drug metabolism, drug transporters also play a key role in determining a drug’s PK 
parameters. P-gp is expressed in tissues such as the liver, kidneys, intestines, and at the blood-
brain barrier and is known to transport a number of clinically important drugs. Although less is 
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known about the effect of hypothermia on the transport of drugs, it is reasonable to postulate that 
active drug transport would be decreased similarly to active drug metabolism, since transporter 
proteins are temperature sensitive and would undergo a similar inactive response to cooling. Jin 
et al. investigated the effect of targeted temperature management on the P-glycoprotein (P-gp) 
drug transporter at 37, 32, 30, 25, and 4°C in an in vitro cell culture study (Jin, Sakaeda et al. 
2006). Radiolabeled probe drugs were used to quantify the overall flux (transport) across the cell 
monolayers of P-gp-overexpressing cells. The active transport of [
3
H]digoxin was decreased by 
~50% from 37 to 32°C whereas no change in the transport of the paracellular marker, 
[
14
C]inulin, was seen indicating a decrease in the active drug transport of P-gp. These findings 
are consistent with a previous pre-clinical study which suggests that hypothermia decreases the 
active processes of renal tubular secretion but has no effect on the passive process of renal 
filtration (Nishida, Okazaki et al. 2007). Future studies are still warranted that quantify the 
absolute change in drug transporter activity and delineate how these changes may contribute to 
overall drug PK.    
1.3.2 Interplay of Therapeutic Hypothermia and Injury on Drug Pharmacokinetics 
Based on recent studies, it is apparent that changes in drug PK are due to a combination 
of cardiac arrest and hypothermia-mediated effects, and considerations for drugs which undergo 
CYP450 elimination pathways should take both into consideration. Previously our laboratory 
investigated the interplay of therapeutic hypothermia and cardiac arrest on CYP450 pathways in 
rats (Zhou, Empey et al. 2011). In addition to its sedative use in the ICU, midazolam is also an 
established cytochrome-P450 3A (CYP3A) probe (Yuan, Madani et al. 2002, Eap, Bouchoux et 
al. 2004). Midazolam was administered with diclofenac, chlorzoxazone, and dextromethorphan 
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to probe CYP3A, CYP2C, CYP and CYP2D activity respectively. Midazolam clearance 
decreased in the CA hypothermia rats versus the normothermic shams (681.6 ± 190.0 versus 
1268.8 ± 348.9 ml/kg/h), which indicates a combined effect of injury and hypothermia. 
Similarly, CZN clearance decreased in a hypothermic rat model of CA as compared to sham 
normothermic rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml/kg/h; p < 0.05). In contrast to 
chlorzoxazone and midazolam, the clearance of diclofenac or dextromethorphan was not 
significantly different between any of the groups. Two important findings from this study are 
that 1) the CA and hypothermia-mediated changes are specific to CYP450 isoform and 2) 
ischemic injury is a significant contributor to reduced metabolism in this injury model producing 
decreased clearance of chlorzoxazone and midazolam. Future studies should investigate the 
extent of which injury versus cooling effect drug PK in clinical studies as well as the interplay of 
these effects on drug pharmacodynamics.              
1.4 EFFECT OF THERAPEUTIC HYPOTHERMIA ON DRUG 
PHARMACODYNAMICS 
In addition to an effect on a drug’s pharmacokinetics, therapeutic hypothermia can also alter a 
drug’s pharmacodynamics properties. More recently, the effects of hypothermia on the 
pharmacodynamics of anti-platelet agents has been investigated.        
   
Anti-platelets.   
Clopidogrel is a pro-drug that is used to prevent platelet aggregation. Unlike the majority 
of drugs administered in the ICU, clopidogrel is administered orally and depends on metabolic 
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activation by CYP2C19 as well as other CYP450 enzymes. Bjelland et al. investigated the effect 
of hypothermia on the clopidogrel’s efficacy to inhibit platelets (Bjelland, Hjertner et al. 2010). 
In this prospective study, 25 CA patients received hypothermia (33 - 34°C) for 24 hours. Patients 
received a loading dose of clopidogrel of 300 mg orally followed by maintenance doses of 75 
mg. Whole blood samples were collected on day 1 (n = 25) during the cooling phase and on day 
3 (n = 16). During hypothermia, the number of blood samples that had a satisfactory effect of 
clopidogrel was 0/25. One possible explanation may be a decreased metabolic conversion of 
clopidogrel to its active form during cooling, however lack of a PK analysis in this study does 
not rule out this possibility from other potential pharmacodynamics effects such as genetic 
variants or function of the gastrointestinal tract.  
 An in vitro study by Ferreiro et al. investigated the effect of hypothermia on the 
pharmacodynamics of clopidogrel and aspirin (Ferreiro, Sanchez-Salado et al. 2014). In this 
study blood samples were obtained from 20 patients who underwent percutaneous coronary 
intervention and received loading doses of aspirin and clopidogrel. Mild hypothermia to 33°C 
led to a decrease in clopidogrel-mediated platelet inhibition while having no effect on the 
pharmacodynamics response of aspirin. 
 More recently Ibrahim et al. investigated the effect of hypothermia on the 
pharmacodynamics of three anti-platelet agents clopidogrel, prasugrel, and ticagrelor in patients 
with acute coronary syndrome (Ibrahim, Christoph et al. 2014). In this study, they demonstrated 
that the platelet inhibiting effect of all three drugs was significantly decreased under hypothermic 
conditions. Clopidogrel showed the largest reduction in platelet inhibition in hypothermic versus 
normothermic groups (hypo versus normo:  66.39% ± 19.1 versus 33.36% ± 22.1; p-value < 
0.001). This study concluded that CA patients who are undergoing hypothermia versus 
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normothermia have increased rates of non-responders to P2Y12 receptor inhibitors such as 
clopidogrel, prasugrel, and ticagrelor.     
Current evidence indicates that mild hypothermia to 33°C leads to a pharmacodynamic 
change in drug-mediated platelet response. Specifically, the platelet inhibitory effect of the 
P2Y12 receptor inhibitors clopidogrel, prasugrel, and ticagrelor is decreased, with clopidogrel 
showing the most marked change in pharmacodynamics response. However, since clopidogrel 
requires conversion into its active metabolite by CYP3A and CYP2C9, the increase in 
clopidogrel non-response may be due to a combination of a decrease in metabolic conversion to 
active drug (PK change) as well as a pharmacodynamics effect. More studies are needed to 
understand how the effect of hypothermia on platelet activation versus drug metabolism is 
dictating this change in response. 
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Table 3: Effect of hypothermia on drug pharmacokinetics and response in pre-clinical and 
clinical studies.  
 
Drug Disease/Model 
Hypothermia 
Protocol 
Hypothermia PK 
Effects (versus 
Normothermia) Reference
 Ŧ
 
Clinical Studies 
Midazolam Healthy volunteers 35.4°C 
3 hours 
↓ Cl (Hostler, Zhou 
et al. 2010) 
Morphine 
Midazolam 
Fentanyl 
Propofol 
CA Patients 36 – 38°C, 
33 - 34°C  
12 – 24 hours 
↑ t1/2 and ↓ Cl of 
morphine, ↔ Vd 
↔ Cl midazolam, ↔ 
Vd, ↔ t1/2 
↓ Cltot of fentanyl 
↓ Cltot of propofol 
(Bjelland, 
Klepstad et al. 
2013) 
Remifentanyl 
Propofol 
Fentanyl 
Midazolam 
CA patients  33 - 34°C  
24 hours 
↓ concs of remifentanyl, 
propofol, and 
midazolam during 
rewarming 
↔ conc of fentanyl 
(Bjelland, 
Klepstad et al. 
2014) 
Midazolam Resuscitated 
patients 
33°C 
24 hours 
↔ Cl, V1, V2, or Q (Bastiaans, 
Swart et al. 
2013) 
Midazolam Asphyxiated 
Neonates  
32 – 34°C 
72 hours 
↔ Cl (Welzing, 
Junghaenel et 
al. 2013) 
Phenobarbital Neonates with HIE 33.5°C 
72 hours 
↑ plasma concs, ↑ t1/2 (Filippi, la 
Marca et al. 
2011) 
Phenobarbital asphyxiated 
neonates 
33.5°C 
72 hours 
↔ Cl, ↔ Vd (van den 
Broek, 
Groenendaal et 
al. 2012) 
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Phenobarbital Neonates with HIE 36 – 38°C,  
33 – 35°C 
72 hours 
↔ Cl, ↔ Vd (Shellhaas, Ng 
et al. 2013) 
Phenytoin Children with 
severe TBI 
36.5 – 37.9°C, 
32 – 33°C  
48 hours 
↓ Vmax, ↔ Km (Empey, de 
Mendizabal et 
al. 2013) 
Lidocaine Asphyxiated 
neonates 
33.5°C 
72 hours 
↓ Cl (van den 
Broek, 
Rademaker et 
al. 2013) 
Gentamicin Neonates with 
encephalopathy  
37°C, 
33 – 34.5 °C 
72 hours 
↔ serum concs, ↔ Cl (Liu, Borooah 
et al. 2009) 
Gentamicin Neonates with HIE 33.5°C 
72 hours 
↑ trough serum cons, 
↓ke,  ↑ t1/2, ↓ Cl, ↔ Vd 
(Mark, 
Solomon et al. 
2013) 
Gentamicin Neonates with HIE 33.5°C 
72 hours 
↓ Cl, ↔ Vd compared to 
previous reports 
(Frymoyer, 
Meng et al. 
2013) 
Gentamicin Neonates with HIE 37°C, 33.5°C 
72 hours 
↑ t1/2, ↓ke,  ↓ Cl, ↑ Cmax 
and Cmin, ↑ AUC 
(Ting, Kwan et 
al. 2014) 
Morphine Neonates with HIE 33 – 34°C  
72 hours 
↑ serum concs, ↑ AUC, 
↓ Cl 
(Roka, Melinda 
et al. 2008) 
Clopidogrel CA patients  33 – 34°C 
24 hours 
↓ clopidogrel-mediated 
platelet inhibition  
(Bjelland, 
Hjertner et al. 
2010) 
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Clopidogrel 
Prasugrel 
Ticagrelor 
CA patients 32 – 34°C  
12-24 hours 
↓ clopidogrel-mediated 
platelet inhibition  
↓ prasugrel-mediated 
platelet inhibition  
↓ ticagrelor-mediated 
platelet inhibition  
(Ibrahim, 
Christoph et al. 
2014) 
Pre-Clinical Studies 
Midazolam 
Fentanyl 
CA rats 32.5 – 33.5°C 
8 – 10 hours 
↑ plasma concs of 
midazolam and fentanyl 
↓ Cls of midazolam and 
fentanyl 
↔ brain to plasma ratio 
(Empey, Miller 
et al. 2012) 
Dexmedetomidine Piglets with HIE 33.5°C 
18 – 24 hours 
↑ plasma concs, ↓ Cl (Ezzati, Broad 
et al. 2014) 
Midazolam 
Diclofenac 
Dextromethorphan 
Chlorzoxazone 
CA Rats 37°C, 32.5 – 
33°C 
8 hours 
↓ Cl of midazolam and 
chlorzoxazone 
↔ Cl of diclofenac or 
dextromethorphan 
↓ V1 of midazolam and 
dextromethorphase and 
V2 for chlorzoxazone 
(Zhou, Empey 
et al. 2011) 
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Phenolsulfonphthale
in (PSP) 
Indocyanine green 
(ICG) 
Fluorescein 
isothiocyanate-
dextran (FD-4) 
Rats 37°C, 32°C, or 
28°C 
5 hours 
↑PSP plasma concs; ↓ 
PSP Cl 
↑ ICG plasma concs; ↓ 
ICG Cl 
↔ FD-4 Cl  
(Nishida, 
Okazaki et al. 
2007) 
Digoxin 
Inulin 
In vitro cell culture 37°C, 32°C, 
30°C, 25°C, and 
4°C 
 
↓ activity of ABCB1 
drug transporter  
↔ in paracellular 
transport 
(Jin, Sakaeda et 
al. 2006) 
Clopidogrel 
Aspirin 
In vitro blood 
samples from 
patients with 
myocardial 
infarction 
37°C, 33°C ↓ clopidogrel-mediated 
platelet inhibition  
↔ aspirin-mediated 
platelet inhibition 
(Ferreiro, 
Sanchez-
Salado et al. 
2014) 
Ŧ Pre-clinical and clinical studies ranging from July 2006 – October 2015 
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1.5 CONCLUSIONS 
This chapter has demonstrated that therapeutic hypothermia significantly alters drug disposition 
including drug metabolism and drug response during each of the phases of cooling, re-warming, 
and post-treatment. Specifically, the studies outlined in this Chapter indicate that during cooling, 
drug metabolism is significantly decreased. This may lead to the conclusion that the dose of 
certain drugs should be reduced in order to avoid toxicity. However, the effects of hypothermia 
on drug response are variable and less predictable. Depending on drug, a reduction in potency or 
no change in potency has been shown. Overall, the effects of hypothermia during cooling suggest 
a narrowing of the therapeutic index of multiple drugs used in the ICU. 
More recently, clinical studies have shown that drug concentrations continue to remain 
elevated after re-warming. Depending on the half-life of the drug, this effect can be seen for 
several days into the post-treatment phase. Due to the range of time dependent effects, it is 
essential that clinicians fully appreciate the potential changes in drug disposition during and after 
cooling. In some cases, this may require monitoring drug levels carefully during and after 
therapeutic hypothermia treatment. Further, the contribution of injury-mediated versus 
hypothermia-mediated effects on drug disposition will be an important area of research to help 
tailor dosing guidelines across different patient populations. 
As we further evaluate the interplay of hypothermia-mediated effects on drug disposition 
new opportunities will arise for future research to systematically evaluate these effects. 
Additional clinical trials are needed to investigate drugs which are commonly administered 
during therapeutic hypothermia and in the ICU but have not been studied yet. Furthermore, 
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therapeutic hypothermia continues to be evaluated in new disease states, such as stroke and 
epilepsy. As this research progresses, it will also be important to explore the pharmacokinetics of 
the drugs used during these studies. This will serve two primary purposes. First, it will determine 
how to safely and effectively administer drugs in these patient populations under these 
hypothermic conditions. Second, it will distinguish any potential adverse drug events from 
hypothermia treatment to determine if certain drugs are beneficial or harmful during 
hypothermia.   
The clinical studies outlined throughout this chapter can provide us with a theoretical 
time-course of hypothermia-mediated alterations on drug pharmacokinetics. As previously 
demonstrated, therapeutic hypothermia produces a significant decrease in drug metabolism 
during the period of cooling. Recent evidence has shown that this decrease in metabolism 
continues longer than initially projected. Hypothermia-mediated effects on PK can be seen into 
the rewarming phase and continue into the post-treatment phase even when core temperature is 
returned to normal body temperature. Future studies are needed in order to provide specific 
dosing recommendations for medications administered during each phase of treatment:  
hypothermia, rewarming, and post-treatment. In conclusion, research has shown that clinically 
significant hypothermia-drug interactions are a factor to be considered in the therapeutic course 
of these patients. 
The work presented throughout this dissertation aims to evaluate the effects of 
therapeutic hypothermia on drug pharmacokinetics, specifically focusing on metabolism and 
drug transport in pre-clinical and clinical studies. As discussed throughout this Chapter, 
hypothermia can affect metabolism, absorption, elimination, distribution and response of many 
drugs. We have chosen to focus this work on the effects of cooling on the CYP450-metabolism 
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of phenytoin and the ABC drug transporter pathway system. Many of the previous clinical 
studies have demonstrated that hypothermic temperatures affect drugs metabolized by CYP450’s 
during cooling. However, there are few robust pharmacokinetic studies to elucidate the 
mechanisms behind these metabolic-changes. The majority of studies describe a change in drug 
levels and a change in drug clearance. By conducting a robust pharmacokinetic analysis we are 
able to better describe the causes behind these changes. In addition we have chosen to investigate 
the effects of cooling on drug transport since little is known about how this important component 
of drug disposition is affected during cooling.  
1.6 HYPOTHESIS 
We aim to determine the effect of therapeutic hypothermia on drug disposition by expanding 
what is currently known on drug metabolism and conducting the first studies to investigate drug 
transport. We hypothesized that therapeutic hypothermia will lead to a decrease in phenytoin 
elimination due to a decrease in CYP450 metabolism in pediatrics following a cardiac arrest. We 
further hypothesized that therapeutic hypothermia will decrease the active drug transport of three 
ABC transporters (ABCB1, ABCG2, and ABCC1) but have no effect on passive transport across 
cell membranes. These studies will be the first to investigate the effects of therapeutic 
hypothermia on three ABC drug transporters. In order to evaluate these hypotheses the following 
specific aims have been proposed by chapter. 
 
Specific Aim 1:  Develop a method to quantify concentrations of phenytoin and levetiracetam in 
small volumes of pediatric serum samples. 
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Specific Aim 2:  Determine the effects of therapeutic hypothermia, and other clinical covariates, 
on the pharmacokinetics of phenytoin in pediatrics following cardiac arrest using a population 
pharmacokinetic approach. 
 
Specific Aim 3:  Evaluate the effects of therapeutic hypothermia on the ABC drug transporter 
activity of ABCB1, ABCG2, and ABCC1 by conducting permeability flux assays using an in 
vitro cell culture model. 
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2.0  ANALYTICAL METHOD DEVELOPMENT OF PHENYTOIN AND 
LEVETIRACETAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Anderson KB, Liput SL, Fink E, Kochanek PM, Empey PE, Poloyac SM. A rapid UPLC-
MS/MS method for the simultaneous measurement of phenytoin and levetiracetam in small 
volume pediatric serum samples.  Trends in Chromatography 2016, In Submission] 
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2.1 INTRODUCTION 
Following a cardiac arrest, pediatric patients are at high risk to develop seizures as a result of 
hypoxic-ischemic insult (Nishisaki, Sullivan et al. 2007, Glass, Glidden et al. 2009, Binks and 
Nolan 2010, Tress, Kochanek et al. 2010).
 
For this reason, children may receive anti-epileptic 
drugs (AED) prophylactically to prevent the onset of CA-induced seizures or to treat actual 
seizures. Multiple factors can affect drug metabolism in critically ill patients including organ 
dysfunction following cardiac arrest (McKindley, Hanes et al. 1998, Power, Forbes et al. 1998, 
Haas and Forrest 2006, Roberts, Kilgannon et al. 2013, Tujjar, Mineo et al. 2015), targeted 
temperature management (TTM) (Tortorici, Kochanek et al. 2007, Empey, Velez de Mendizabal 
et al. 2013), inflammation (Vet, de Hoog et al. 2011, Vet, de Hoog et al. 2012), and co-
administered medications (Smithburger, Kane-Gill et al. 2012).  
Previously our laboratory demonstrated an important need to monitor AEDs in children 
with traumatic brain injury particularly during the hypothermic and re-warming phases of TTM 
(Empey, Velez de Mendizabal et al. 2013). Specifically, phenytoin levels reached supra-
therapeutic concentrations both during and following hypothermic treatment due to a decrease in 
drug metabolism. The methods and results of this PK study will be further discussed in Chapter 
3. It is currently unknown how pharmacokinetics of AEDs are affected following pediatric CA. 
To address this, we aimed to develop an assay to simultaneously quantify two commonly 
administered AEDs, phenytoin (PHY) and levetiracetam (LEV), in the serum of pediatrics 
following CA. 
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To date, several methods have been developed to quantify LEV (Pucci, Bugamelli et al. 
2004, Rao, Ravi et al. 2004, Martens-Lobenhoffer and Bode-Boger 2005) or PHY (Haroon and 
Keith 1983, Kouno, Ishikura et al. 1993, Cwik, Liang et al. 1997) in human plasma using high-
performance liquid chromatography (HPLC). However, the majority of these methods require 
long run times, lack sensitivity and require large sample volumes (0.5 – 1.0 mL) which often 
cannot be obtained from children. More recently, ultra-performance liquid chromatography 
coupled with mass spectrometry (UPLC-MS/MS) has been used to quantify drug levels in 
plasma due to its improved resolution and increased sensitivity from conventional methods.  
However, few methods have been developed to quantify AEDs using UPLC-MS/MS (Blonk, van 
der Nagel et al. 2010, Shibata, Hashi et al. 2012, Karinen, Vindenes et al. 2015) and no studies 
report the simultaneous quantification of PHY and LEV in small serum volumes. Therefore, we 
aimed to develop a UPLC-MS/MS assay to quantify LEV and PHY in pediatric serum volumes 
of 20 μL.        
In the current study, we established a fully validated, sensitive, and accurate UPLC-
MS/MS method for the simultaneous quantification of LEV and PHY. This method is the first to 
report a simple one-step sample preparation method to quantify LEV and PHY in a serum 
sample volume of 20 μL. This assay was used to quantify all pediatric serum samples in this 
dissertation and is currently being used in ongoing studies evaluating LEV and PHY 
pharmacokinetics in pediatric patients following CA. 
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
HPLC-grade methanol was purchased from Fisher Scientific (Pittsburgh, PA). Formic acid was 
purchased from Sigma-Aldrich (St. Louis, MO). Other aqueous solutions were prepared using 
ultrapure (double-distilled) water. PHY and LEV were purchased from Sigma-Aldrich (St. Louis, 
MO). Phenytoin-d10  (PHY- d10) and levetiracetam-d6 (LEV- d6) were purchased from Cerilliant 
Corporation (Round Rock, Texas). Drug free serum was purchased from Golden West 
Biologicals (Temecula, CA). 
2.2.2 Patient Population and Serum Sample Collection 
The developed assay was applied to serum samples from pediatric patients following CA who 
were managed using TTM at the Children’s Hospital of Pittsburgh. The Institutional Review 
Board of the Children’s Hospital of Pittsburgh approved the protocol. Informed consent was 
obtained from parents before enrolling the child in the study. At Children’s Hospital of 
Pittsburgh, LEV and PHY are the two first-line therapies administered to children following CA 
for prophylaxis and treatment of seizures. Since the use of both LEV and PHY are non-
protocolized, the choice of therapy and/or dose was at the discretion of the treating physician. In 
some cases, both LEV and PHY were administered. Blood samples were drawn two times per 
day on the first four days following cardiac arrest and once on day 7. After centrifugation, serum 
was stored at -80°C until analysis. Serum levels of LEV and PHY were measured in 20 μL 
samples according to the assay described in this chapter.       
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2.2.3 Preparation of Calibration Standards and Quality Control Samples 
Two separate stock solutions were prepared for LEV and PHY in methanol at a concentration of 
1 mg/mL. These concentrations were spiked into serum to produce stock concentrations 
containing both LEV and PHY at 0.5, 1, 5, 10, 25, 50 and 75 μg/mL. Standard working solutions 
were stored in -80°C freezer until use. LEV-d6 and PHY-d10 were used as internal standard (IS). 
A stock solution containing both internal standards with a final concentration of 1 mg/mL was 
prepared and stored in -80°C until use. A working solution of IS was prepared fresh from stock 
solution on day of assay.   
For the internal quality control (QC) samples, a separate stock solution was prepared in 
methanol at a concentration of 2.5 mg/mL. QCs were prepared in serum at three concentrations:  
3 μg/mL (low level), 30 μg/mL (medium level), and 60 μg/mL (high level) and stored at -80°C 
until further use. 
To 20 μL of serum, 20 μL of IS working solution (50 ng/mL) was added to an eppendorf 
tube. For protein precipitation, 200 μL of methanol was added. The sample was vortexed 
rigorously for 30 seconds and then centrifuged at 13,500 rpm for 8 minutes. Following 
centrifugation, 20 μL of supernatant was removed and transferred to a new eppendorf tube and 
then diluted with 200 μL of 50:50 methanol:water. Sample was vortexed for 30 seconds and then 
100 μL was transferred to a glass autosampler vial of which 7.5 μL was injected into the UPLC-
MS/MS.       
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2.2.4 Chromatographic and Mass Spectrometric Conditions 
The UPLC-MS/MS system consisted of a Waters Acquity Ultra Performance LC coupled to a 
TSQ Quantum Ultra triple quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, 
CA). Separation of analytical compounds was achieved on a UPLC BEH C18, 1.7 μm (2.1 × 
100mm) reversed-phase column (Waters, Milford, MA). The mobile phase consisted of a 
gradient of solution A (95% water, 5% methanol with 0.05% formic acid) and solution B (10% 
water, 90% methanol with 0.05% formic acid) with an initial composition of 100% A. Mobile 
phase composition changed from 100% A to 20% A/80% B at 3 minutes and returned to 100% A 
at 5 minutes. Total run time was 5 minutes. The flow rate was 0.3 mL/min with a column 
temperature of 50°C and an injection volume of 7.5 μL.   
Analytes were detected via MS/MS with an electrospray ionization source under positive 
mode with a collision gas pressure of 1.3 mTorr. Mass transitions of LEV (m/z 171→ 125.9), 
LEV-d6 (m/z 177→132), PHY (m/z 253.2→182) and PHY-d10 (m/z 263.2→192) were 
optimized. LEV conditions included a spray voltage of 4000 V; collision energy of 13 V; and 
vaporizer and capillary temperatures of 311°C and 300°C, respectively. PHY conditions included 
a spray voltage of 3000 V; collision energy of 18 V; and vaporizer and capillary temperatures 
were both 300°C. Data were acquired and analyzed using XCalibur software version 2.0.6. 
2.2.5 Validation Procedures 
Validation of the assay in human serum was performed. Seven serum calibration standards 
ranging in concentration from 0.5 – 75 µg/mL were prepared and analyzed in duplicate in 3 
analytical runs on 3 consecutive days. The lower limit of quantification (LLOQ) was determined 
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by the minimum value with an accuracy and precision within ±15% of the nominal value. The 
lower limit of detection (LLOD) was determined by the minimum value with a signal-to-noise 
ratio greater than 3:1.      
Accuracy and precision were determined by analyzing QC samples. LEV and PHY were 
spiked into serum to yield low, medium, and high QCs that corresponded to 3 μg/mL, 30 μg/mL, 
and 60 μg/mL, respectively. Six samples of each QC were analyzed on days one, two and three 
of validation and 12 samples of each QC were analyzed on day four of validation. Accuracy was 
defined as the deviation of the calculated value (E) from that of its true value (T) and expressed 
as a percentage. This accuracy, or relative standard error (RE%), was calculated using the 
equation RE% = (E-T)/T*100. This was performed by calculating QC samples on a freshly 
prepared standard curve. Precision was calculated as the percent coefficient of variance (%CV) 
where %CV = standard deviation/mean x 100. A deviation and precision within ±15% of the 
nominal value is considered acceptable.   
Stability of the analytes was tested for 6 hours at room temperature and compared with 
freshly spiked serum. Long-term stability was evaluated using low, medium, and high QCs that 
had been stored at -20°C and -80°C for 1 month and 3 months. 
2.2.6 Evaluation of Matrix Effects and Recovery Efficiency 
Matrix effects were evaluated using 0.5 mL volume of the same serum that was used to process 
calibration curves. Matrices were protein precipitated using 200 μL methanol via the same 
method described above. Neat samples containing the same concentration of PHY, LEV, PHY-
d10 and LEV-d6 were prepared in 50:50 methanol:deionized water. Samples were analyzed using 
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UPLC-MS/MS as described above. The internal standard normalized matrix factor (IS-
normalized MF) for each sample was calculated based on the area ratio (analyte/internal 
standard) of the post-extraction spiked samples to the neat samples as described by  Matuszeki et 
al. IS-normalized MF results are expressed as average percentage ± coefficient of variation (CV) 
(n=5). Values less than 100% indicate ion suppression and values greater than 100% indicate ion 
enhancement. Recovery efficiency was calculated as the average peak areas spiked after 
precipitation to before precipitation and expressed as percentage.     
2.2.7 Comparison of Published and Modified Quantitation Methods 
To date, several methods have been developed to quantify LEV (Pucci, Bugamelli et al. 2004, 
Rao, Ravi et al. 2004, Martens-Lobenhoffer and Bode-Boger 2005) or PHY (Haroon and Keith 
1983, Kouno, Ishikura et al. 1993, Cwik, Liang et al. 1997) via HPLC. However, these methods 
require larger sample volumes and longer run times.  
More recently, several studies have reported the quantification of single or multiple 
AEDs via UPLC-MS/MS (Blonk, van der Nagel et al. 2010, Shibata, Hashi et al. 2012, Karinen, 
Vindenes et al. 2015). Blonk et al. developed a sensitive and fast UPLC-MS/MS method to 
quantify only LEV in pediatric sample volumes of 50 μL. While this method is highly sensitive 
and specific for LEV, it is only able to quantify a single drug and would not be applicable to 
pediatric patients who receive combination therapy. Shibata et al. developed a method to 
quantify LEV and PHY, among many other AEDs, in 50 μL plasma samples using UPLC-
MS/MS. To the best of our knowledge, this is the smallest sample volume which quantifies 
AEDs via UPLC-MS/MS. However, the total run time for this assay was 10 minutes per sample 
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and no internal standards were used in this development or processing with this assay. Therefore, 
we aimed to expand on these current methods to develop an assay with greater sensitivity (20 μL 
per sample) and a shorter run time (< 5 mins per sample).     
 
  
2.2.8 Statistical Analysis 
Statistical analysis was completed using GraphPad Prism software, version 4.03 (GraphPad 
Software, La Jolla, CA). In the matrix effects studies, IS-normalized MF values were compared 
using unpaired t-test (2 tailed). For all statistical tests, a p<0.05 was considered significant. 
2.3 RESULTS 
The following section reports the results of the development, linearity, accuracy, precision and 
validation of the UPLC-MS/MS assay. 
2.3.1 Development of UPLC-MS/MS Method 
Mass spectrometer parameters were optimized to achieve complete fragmentation (Table 
4) and chromatographic conditions were optimized to achieve short run time and optimal 
peak shape. The optimal mobile phase consisted of solution A (95% water, 5% methanol 
with 0.05% formic acid) and solution B (10% water, 90% methanol with 0.05% formic 
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acid). A representative chromatogram of LEV (25 μg/ml), PHY (25 μg/ml), LEV-d6 (50 
ng/mL) and PHY-d10 (50 ng/mL) is depicted in  
Figure 2. The elution sequence was as follows:  LEV (2.35 mins), LEV-d6 (2.34 mins), PHY 
(3.80 mins), and PHY-d10 (3.78 mins).   
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Table 4: UPLC-MS/MS conditions for the quantification of LEV and PHY. 
Parameter LEV Setting PHY Setting 
Run duration (min) 4 4 
Vaporizer temperature (°C) 311 300 
Capillary temperature (°C) 300 300 
Spray voltage (V) 4000 3000 
   
 LEV LEV-d6 PHY PHY-d10 
Q1 (m/z) 171.0 177.0 253.2 263.2 
Q3 (m/z) 125.9 132.0 182.0 192.0 
Collision energy (V) 13 13 18 18 
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Figure 2: Chromatograms of drug analytes and internal standards.  
 
(A) spiked human serum at the 50 μg/ml standard. Levetiracetam (50 μg/ml), levetiracetam-d6 (50 ng/ml), 
phenytoin (50 μg/ml), and phenytoin-d10 (50 ng/ml) and (B) spiked human serum at the LOQ. 
Levetiracetam (5 μg/ml), levetiracetam-d6 (50 ng/ml), phenytoin (5 μg/ml), and phenytoin-d10 (50 ng/ml).   
 A
 B
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2.3.2 Linearity, Accuracy, and Precision 
We performed a validation of the calibration curves which provide a reliable and linear range for 
both LEV (0.5 to 75 μg/mL) and PHY (0.5 to 75 μg/mL). Figure 3 shows the calibration curves 
for both drugs. The correlation coefficients of the 1/y-weighted calibration curves were in the 
range of 0.9975 – 0.9991 and 0.9975 – 0.9991 for PHY and LEV, respectively. The lower limit 
of quantification in this assay was 0.5 μg/ml for levetiracetam and phenytoin. Even with the very 
low serum volumes, we were still able to achieve adequate sensitivity with an estimated LOD of 
0.02 μg/mL for both PHY and LEV, which is well below the LLOQ at 0.5 μg/mL.   
 
 
Figure 3: Validated calibration curves for PHY and LEV. 
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The intra-day and inter-day precision and accuracy of the assay was less than 11.9% at 
each QC level. Results of the assay validation are presented in Table 5. Intra- and inter- assay 
precision and accuracy were within the acceptable range of 15% for both LEV and PHY. 
 
Table 5: Accuracy and precision of assay.  
 Levetiracetam Phenytoin 
Nominal 
concentration 
(μg/mL) 
Mean 
calculated 
conc (μg/mL) 
Accuracy 
(% deviation) 
Precision 
(%CV) 
Mean 
calculated 
conc (μg/mL) 
Accuracy 
(% 
deviation) 
Precision 
(%CV) 
Intra-assay
a
       
3 3.04 1.25 10.42 3.27 9.16 7.95 
30 31.51 5.03 7.59 33.48 11.60 2.01 
60 56.23 -6.28 3.76 59.82 -0.30 7.83 
       
Inter-assay
b
       
3 2.83 -5.71 10.92 3.03 0.88 11.90 
30 29.04 -3.20 10.54 31.02 3.39 10.20 
60 61.72 2.87 9.53 63.48 5.80 7.99 
a 
n = 12 (one run) 
b
 n = 24 (three different runs of n=6 performed on separate days) 
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The bench-top and long-term stability studies demonstrated that the analytes were stable 
for up to 6 hours at room temperature and for 1 month and 3 months at -20°C and -80°C. The 
average percent change of peak areas were less than 4.8%. 
2.3.3 Assay Validation 
This assay was successfully applied to 30 serum samples from twelve pediatric patients 
following cardiac arrest who were being managed using therapeutic hypothermia and receiving 
LEV and/or PHY. The dose administered ranged from 5 - 38 mg/kg for levetiracetam (n = 6 
patients) and 2.5 – 20 mg/kg for phenytoin (n = 6 patients). PHY and LEV concentrations from 
these varying doses ranged from 11.38 – 27.09 μg/ml and 0.66 – 89.53 μg/ml, respectively. All 
serum samples fell above our LLOQ thus confirming the suitability of the assay range for this 
patient population (Figure 4).   
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Figure 4: Quantitation of PHY and LEV in serum of pediatric patients following CA. 
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2.3.4 Analysis of Matrix Effects 
The matrix effect in serum was between 106.0 - 109.4% and 107.4 – 109.2% for LEV and PHY, 
respectively at all 3 QC levels. This demonstrates minimal matrix effects of serum on the 
reproducibility and reliability of the assay. The recovery in serum ranged from 98.6 – 99.8% and 
98.6 – 99.2% for LEV and PHY, respectively. Table 6 shows the results of the matrix effect and 
recovery efficiency.   
 
Table 6: Evaluation of matrix effects and recovery efficiency.   
 
 LEV LEV-d6 PHY PHY-d10 
 3 μg/mL 30 μg/mL 60 μg/mL 50 ng/mL 3 μg/mL 30 μg/mL 60 μg/mL 50 ng/mL 
ME % 
(%CV) 
106.0 ± 2.8 108.1 ± 1.8 109.4 ± 2.2 101.2 ± 2.1 108.9 ± 3.3 109.2 ± 3.5 107.4 ± 
2.4 
102.1 ± 1.8 
RE % 
(%CV) 
99.8 ± 2.6 99.4 ± 2.2 98.6 ± 2.7 106.2 ± 3.2 98.6 ± 2.5 99.2 ± 1.7 98.7 ± 2.7 104.2 ± 2.9 
 
2.4 CONCLUSIONS 
A protein precipitation sample preparation combined with a UPLC-MS/MS method was 
validated and successfully applied for simultaneous determination of PHY and LEV. This 
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method was optimized from previous reports to achieve high sensitivity for the detection of these 
two drugs in small serum volumes of 20 μL. A linear calibration curve was validated from 0.5-
75μg/ml. This method was successfully used to measure PHY and LEV in pediatric serum 
samples that fell above the LLOQ. This method is the first to report a quick and easy method to 
quantify both PHY and LEV in small serum volumes as low as 20 μL. Further, this assay method 
was successful applied on samples obtained from patients in a realistic clinical setting where one 
or both of the drugs were being administered and where therapeutic hypothermia and critical care 
therapies were being applied.  
2.5 DISCUSSION 
In this study we demonstrated that this method is useful in simultaneously measuring phenytoin 
and levetiracetam in low volumes of serum samples. Both AEDs, and their respective IS, were 
simultaneously detected, identified, and quantified using a validated UPLC-MS/MS method. 
Furthermore, we determined that these two drugs are generally stable for 24 hours at room 
temperature. Collectively, these results suggest that UPLC-MS/MS is an accurate and sensitive 
method for quantification of phenytoin and levetiracetam in serum samples of 20 µL.  
More specifically, this chapter describes the validation of linear calibration curves 
ranging from 0.5 – 75 µg/mL. The inter-day and intra-day variance was less than 15% at all 
concentrations with a recovery efficiency of greater than 98%. Additionally, we demonstrated 
that the matrix effect of serum did not significantly affect the reliability and reproducibility of 
the assay, for both compounds measured.  
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Our results also demonstrate that phenytoin and levetiracetam are stable at room 
temperature in serum for up to 6 hours. Further, both phenytoin and levetiracetam were stable 
under -20°C and -80°C for 1 month and up to 3 months.  Collectively, these results suggest that 
serum samples stored in -80°C freezer and then analyzed at room temperature for less than 6 
hours are appropriate for quantification of phenytoin and levetiracetam.  
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3.0  POPULATION PHARMACOKINETICS OF PHENYTOIN IN PEDIATRICS 
FOLLOWING CARDIAC ARREST 
  
 72 
3.1 INTRODUCTION  
As discussed in Chapter 2, pediatric patients are at high risk to develop seizures as a result of 
brain insult following CA. For this reason, pediatrics typically receive AEDs prophylactically to 
prevent the onset of CA-induced seizures. Multiple factors can affect drug metabolism in 
critically ill patients including ischemia during cardiac arrest, targeted temperature management, 
inflammation, and co-administered medications, to name a few. Previously our laboratory 
demonstrated an important need to monitor AEDs in pediatrics following TBI, particularly 
during the hypothermic and re-warming phases of therapeutic hypothermia. The results of this 
population pharmacokinetic (PopPK) analysis are discussed in the subsequent section.  
3.2 BACKGROUND ON POPULATION PHARMACOKINETIC ANALYSIS IN 
CHILDREN WITH TBI 
In this prospective clinical trial, children with severe TBI (less than 18 years of age) were 
randomized to receive 48 hours of therapeutic hypothermia (n = 10) or normothermia standard-
of-care treatment (n = 9) (Empey, Velez de Mendizabal et al. 2013). Pediatric patients were 
enrolled as part of a clinical trial to determine the effect of induced moderate hypothermia (32-33 
°C) on outcomes in children after severe TBI (“Cool Kids Trial,” Clinicaltrials.gov: 
NCT00222742). Phenytoin is a commonly administered AED in children undergoing therapeutic 
hypothermia, however little is known about its pharmacokinetics during cooling. Thus, a 
population pharmacokinetic analysis was performed to describe phenytoin disposition during 
cooling using nonlinear mixed-effects modeling (NONMEM).  
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The pharmacokinetics of phenytoin in this study was best described using a 1-
compartment Michaelis-Menten model with parameter estimates for the Michaelis-Menten 
elimination rate constant (Km) and maximum velocity of metabolism (Vmax). Results of the 
population pharmacokinetic modeling showed that therapeutic hypothermia decreased the Vmax 
of phenytoin elimination by as much as 49.5%. An important finding of this study was that 
hypothermia-mediated effects on phenytoin PK continued well past the cooling period and into 
the rewarming and post-treatment phases of treatment. Collectively, these results demonstrated 
that therapeutic hypothermia led to an increase in phenytoin levels during the cooling and 
rewarming phases due to an overall decrease in phenytoin elimination in children with TBI 
(Empey, Velez de Mendizabal et al. 2013). This study is the first to use a robust PopPK approach 
to quantify the effect of hypothermia on phenytoin metabolism. We aimed to expand on these 
results in children with severe TBI to another patient population, pediatrics with CA, of which 
therapeutic hypothermia is recommended and commonly used as a neuroprotective therapy 
(Bernard, Gray et al. 2002, Shankaran, Laptook et al. 2005).  
3.3 AIMS AND HYPOTHESIS OF STUDY 
We aimed to investigate the effects of therapeutic hypothermia on the pharmacokinetics of 
phenytoin in pediatrics following a cardiac arrest using a PopPK analysis. We hypothesized that 
therapeutic hypothermia would lead to an increase in phenytoin levels due to a decrease in 
overall phenytoin elimination, as was seen in children with TBI. However, as discussed in 
Chapter 1, the extent of injury-mediated versus hypothermia-mediated effects on PK is still 
largely unknown, and thus the degree of hypothermia effects on phenytoin elimination may be 
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vastly different across patient populations. The following sections describe the clinical study 
methods and the population pharmacokinetic analysis performed to investigate therapeutic 
hypothermia in pediatrics with CA.  
3.4 SUBJECTS AND METHODS 
Patients were recruited and enrolled under an IRB approved protocol as part of multiple clinical 
studies investigating therapeutic hypothermia in pediatrics with CA. Pediatric patients were 
pooled from a study which aimed to investigate the optimal duration of hypothermia for brain 
protection in children following cardiac arrest (K23 IRB #PRO07080349, Title: What is the 
optimal duration of hypothermia for brain protection in children following cardiac arrest?). In 
this study, patients (ages 2 days - 18 years) suffering a CA requiring chest compressions for at 
least 2 minutes with ROSC were randomized to receive normothermia or hypothermia (33°C) 
treatment for 24 or 72 hours.  
Additionally, patients were pooled from a clinical trial which aimed to evaluate the effect 
of therapeutic hypothermia on clinical outcomes in pediatrics with CA. Furthermore, a number 
of patients were enrolled through a separate study which aimed to investigate biomarkers in 
pediatric CA patients. All serum samples were obtained from one of these three clinical studies 
and under IRB approval. Following serum collection, an IRB exemption was granted to achieve 
additional demographic and covariate information for these subjects.   
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3.4.1 Drug administration 
Anti-epileptic drugs are often used as prophylactic therapy in children following CA to prevent 
the onset of seizures. At our institution, the two most commonly administered AEDs in pediatrics 
with CA are phenytoin and levetiracetam, of which the selection of AED is non-protocolized. In 
some cases, pediatrics received either phenytoin or leveitracetam, while in other cases pediatrics 
received a combination of one followed by the other, depending on seizure activity and response 
to treatment. In other cases, pediatrics were administered one of the AEDs not as prophylaxis but 
in response to seizure activity. Fosphenytoin is administered as an intravenous loading dose of 
10-20 mg/kg followed by maintenance therapy. Clinical data collection included amount and 
time of fosphenytoin and levetiracetam doses, and any concurrent medications.      
3.4.2 Serum Sampling, Therapeutic Drug Monitoring, and Data Collection 
Serum sampling times for PK analysis were designed prospectively. Serum PK samples were 
taken twice a day on Days 1-4 and on Day 7 following cardiac arrest. Sampling times on Days 1-
4 were designed to capture the cooling and rewarming phases of hypothermia treatment while 
Day 7 was chosen to capture the post-treatment phase. The exact date and time when each serum 
sample was drawn was recorded. 
In addition to serum PK samples, blood samples were collected for routine therapeutic 
drug monitoring (TDM) as part of clinical care. Concentrations were measured at the Children’s 
Hospital of University of Pittsburgh Medical Center using a particle-enhanced turbidimetric 
inhibition immunoassay (Beckman-Coulter, Brea, CA) with or without initial sample 
ultrafiltration. Both total and free phenytoin levels were measured as part of TDM, and used to 
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guide dosing of fosphenytoin to maintain therapeutic ranges. The date and time of each TDM 
measurement was recorded. Further, all study times were reported from time of injury.   
Demographic and covariate information was also collected via chart review. 
Demographic information included age, sex, height, and weight. Covariate information included 
extensive temperature data (hourly or more frequent); co-administered medications (fentanyl and 
levetiracetam); indices of organ function including albumin (ALBL), hepatic albumin (ALBH), 
blood urea nitrogen (BUNH), corticotropin-releasing hormone (CRH), bilirubin (BILIH), alanine 
aminotransferase (ALTH), and aspartate aminotransferase (ASTH); extra-corporeal membrane 
oxygenation (ECMO) treatment; and length of cardiac arrest was used as a measure of disease 
severity. 
3.4.3 Hypothermia Protocol 
Children were cooled for a duration of 24, 48 or 72 hours. In some cases, children came into the 
ICU already cooled and in some cases children died before finishing hypothermia treatment. 
Temperature was monitored using a rectal temperature probe to measure core body temperature. 
A cooling blanket and/or cold intravenous saline were used to achieve and maintain core body 
temperature. Following the cooling duration, patients were slowly rewarmed over a 24 – 48 hour 
period until normal body temperature was achieved.   
Since cooling duration varied among patients and to maintain consistency across studies, 
the following treatment periods were designated based on length of cooling and initial time of 
administration. For children who underwent 24 hours of cooling, the cooling phase was 
designated between 10-34 hours; the rewarming phase was designated between 34-72 hours; and 
the post-treatment phase was designated after 72 hours. For children who underwent 72 hours of 
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cooling, the cooling phase was designated as 12-84 hours; the re-warming phase was designated 
as 84-104 hours; and the post-treatment phase was designated after 104 hours.  
 
 
Figure 5 and Figure 6 show the compiled temperatures across the children who were 
cooled for 24 or 72 hours, respectively. These treatment periods were used for initial exploratory 
data analysis. The differences in hypothermia treatment across patients is another reason why 
using a robust PopPK approach is necessary since this allows for temperature to be included as 
both a continuous and categorical covariate. Individual temperature profiles for all patients are 
included in Appendix A.1. 
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Figure 5: Temperature profiles of patients who were cooled for 24 hours.  
 
Protocol timing is organized into three designated shaded areas: hypothermia; rewarming; and 
post-treatment. Rectal temperature designates the success of the study protocol in achieving 24 
hours of hypothermia treatment. Straight lines represent the 95% confidence intervals. 
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Figure 6: Temperature profiles of children who were cooled for 72 hours.  
 
Protocol timing is organized into three designated shaded areas: hypothermia; rewarming; and 
post-treatment. Rectal temperature designates the success of the study protocol in achieving 72 
hours of hypothermia treatment. Straight lines represent the 95% confidence intervals. 
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3.5 DATA COMPILATION 
A NONMEM input file (Appendix B.1.) for the population PK analysis was constructed to 
contain the full dosing records and PK observation records. Phenytoin levels measured as part of 
routine TDM in the clinic and from levels quantified via UPLC-MS/MS were both included. 
Relevant covariates for each individual were also included. An explanation of each variable in 
the NONMEM input data file and its description is described in Appendix B.2. 
3.6 DATA REVIEW 
Serum phenytoin level measurements excluded from the analysis were retained in the dataset and 
commented out (C = C). Missing phenytoin levels or doses were not imputed or accounted for in 
the analysis. All serum phenytoin levels which were below the limit of quantification (BLQ) 
were excluded from the analysis. Missing covariate information was denoted as missing in the 
dataset.  
3.7 POPULATION PHARMACOKINETIC METHODS 
NONMEM® program Version 7.3 was used in this analysis (ICON Development Solutions, 
Ellicott City, Maryland, USA) [Error! Reference source not found. Users Guides, 2009]. 
irana (version 2.9.4) was used as the NONMEM interface. PK parameters were estimated using 
the First-Order Conditional Estimation Method with Interaction (FOCEI) method. Perl-speaks-
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NONMEM (PsN, version 4.6.0) was used for NONMEM execution and VPC. R (version 3.2.3; 
http://r-project.org), R Studio (version 0.98.1091; https://www.rstudio.com/) and Prism (version 
5.0) were used for post-processing and plotting of results. 
3.7.1 Population Pharmacokinetic Analysis 
Prior knowledge of the compartmental disposition of serum phenytoin derived from the previous 
PopPK analysis in children with TBI (3.2) suggested that a 1-compartmental Michaelis-Menten 
model with a time-variant maximum velocity term provides an adequate description of phenytoin 
concentration-time data. Therefore, this model served as a starting point for the present analysis, 
and was tested during development of the structural model. The disposition parameters were 
expressed in terms of volume of distribution (V1), time varying Michaelis-Menten parameter at 
baseline (Vmax0), Michaelis-Menten elimination rate constant (Km), maximum velocity of 
metabolism (Vmax), and proportionality constant between bound and unbound drug (θprop).  
In addition to the 1-compartment Michaelis-Menten model, a linear 1-compartment and 
2-compartment model were also tested as previous population pharmacokinetic analysis have 
used these models to describe phenytoin PK (Tanaka, Kasai et al. 2013, Hennig, Norris et al. 
2015). Previous modeling has indicated that it may be advantageous to use log-transformed data; 
hence both log-transformed and untransformed phenytoin serum levels were explored. 
3.7.2 Pharmacostatistical Model 
Distributions of individual parameters (Pi) were assumed to be log-normal and were described by 
an exponential error model: 
 82 
  
)exp(ˆ Pii PP   
where: Pi  is the parameter value for individual i, Pˆ  is the typical population value of the 
parameter (when eta=0), and Pi are individual-specific inter-individual random effects for 
individual i and parameter P that are assumed to be normally distributed (~N(0, 2)) with 
covariance’s defined by the inter-individual covariance matrix Ω.  
Initial model building was performed using diagonal covariance matrix of inter-
individual random effects. For the final model, attempts were made to define a full block 
covariance matrix for the inter-individual random effects (Ω). If the resulting model was not 
numerically stable and the goodness of fit criteria demonstrated no clear difference, then the 
preference was given to models with on-diagonal elements. 
For PK observations in this analysis, the residual error model was a combined additive 
and proportional error model: 
aijpijijij CC   )1(
ˆ   
where Cij is the jth measured observation in individual i, ijCˆ  is the jth model predicted value in 
individual i, and pij and aij are proportional and additive residual random errors, respectively, 
for individual i and measurement j. They were assumed to be independently and identically 
distributed: x~NID (0,x
2).   
 83 
3.7.3 Covariate Model 
After the development and selection of the best structural model, covariate modeling was 
performed for phenytoin levels on Vmax and Km only. The final model was then used to model 
phenytoin levels.   
The following continuous covariates were considered: body weight (WT), age, length of 
cardiac arrest, and temperature. 
The following categorical covariates were considered:  age (< 1 year versus  ≥ 1 year), 
gender, co-administered drugs (fentanyl and levetiracetam), temperature (hypothermic versus 
normothermic). 
The full model with backward deletion approach was utilized for covariate modeling. An 
initial exploratory assessment of covariate effects versus predicted etas from the base model was 
performed as part of covariate screening. A full model was then developed with all covariates of 
interest. Backward deletion was carried out at the p < 0.001 (increased objective function value 
(OFV) less than 10.83 points, d.f. = 1) significance level where the relative influence of each 
covariate on the model was re-evaluated by deleting it from the semi-full model on an individual 
basis. Backward deletion was carried out until all remaining covariates in the model were 
significant at p < 0.001.  
Continuous covariates (COV) were centered at their typical values (TVCOV) and typical 
population value (TVP) expressed as: 
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where TVP and TVCOV are as defined above, P is the estimated parameter representing the typical 
value of model parameter P when the individual covariate (COVi) is equal to TVCOV and COV,P is 
the estimated parameter representing the influence of covariate COV on model parameter P. 
Categorical covariates (CAT) were tested and incorporated in the model as a series of 
index variables taking on values of zero or one (e.g., CAT1, CAT2, …, CATn-1 representing the n-
1 levels of CAT). Index variables were included in the model as follows: 
 



1
1
,
n
i
CAT
CATpp
i
Pi
TV   
 
where TVP is as previously defined, P is the estimated parameter representing the typical value 
of model parameter P for a reference category when all the individual categorical covariate index 
variables (CATi) are equal to zero and 
PiCAT ,
 is the estimated parameter representing the relative 
influence of a categorical covariate index variable on model parameter P when CATi is equal to 
one. 
3.8 MODEL EVALUATION AND DISCRIMINATION 
3.8.1 Goodness of Fit 
The goodness-of-fit (GoF) for a model was assessed by a variety of plots and computed metrics:   
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 Observed versus population and individual predicted concentration plots; 
 Conditional weighted residuals (CWRES) versus population predicted concentrations and 
versus time plots; 
 Histograms of individual random effects to ensure they were centered at zero without 
obvious bias; 
 Scatter plots of individual random effects versus modeled covariates;   
 Relative standard errors (RSE) of the parameter estimates; 
 Shrinkage estimates for each η and ; 
 Successful minimization and execution of a covariance step; 
 The minimum objective function value (OFV).   
The difference in the objective function value (OFV) between models was considered 
proportional to minus twice the log-likelihood of the model fit to the data and was used to 
compare competing hierarchical models. Models were considered hierarchical if the more 
complex model could be reduced to the less complex model by removal of one or more model 
parameters. This OFV was asymptomatically 2 distributed with degrees of freedom (d.f.) equal 
to the difference in number of estimated parameters between the two models. A OFV with a 2 
probability less than or equal to 0.01 (6.64 points of OFV, d.f. = 1) would favor the model with 
the lower OFV. Backward elimination during covariate evaluation used a more stringent criterion 
at a significance level of less than or equal to 0.001 (10.83 points of OFV, d.f. =1).   
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3.8.2 Visual Predictive Checks 
The final phenytoin population PK model was also evaluated by performing a prediction 
corrected (pc) VPC (Error! Reference source not found. et al., 2011) to assess how closely 
odel simulations replicated both the central tendency and the variability in the observed data. As 
such, the predicted median, 5th, and 95th percentiles of the concentration time courses following 
1000 simulations were superimposed with the observed data. 
3.8.3 Simulations 
Using results of the final PopPK model of phenytoin, simulations were performed to determine 
phenytoin elimination under clinically relevant conditions. A 1000 pediatrics receiving a 
standard loading dose of fosphenytoin (20mg/kg) followed by maintenance doses and cooled to 
33°C for 24 or 72 hours was simulated. A population median and 90% confidence interval was 
determined. 
3.9 RESULTS 
3.9.1 Dataset Analyzed 
A total of 36 pediatrics with cardiac arrest were included in the analysis dataset. Of the 36 
patients, two subjects were undergoing ECMO treatment; three subjects were cooled previous to 
start of study; and eight subjects died before the end of hypothermia treatment.  
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3.9.2 Phenytoin Concentrations  
Of the phenytoin concentrations measured as part of TDM (total PHY: n = 178; free PHY: n = 
162), one level was excluded because it fell well above a normal phenytoin level (55 µg/mL). 
Figure 7 depicts the total phenytoin levels from TDM measurements against time after first dose 
(TAFD). Overall, the phenytoin levels remain fairly consistent following first dose; however it is 
difficult to tease out treatment phases since dosing began at different phases across all patients. 
Each patient had an average of 7 serum samples (range: 4 – 10 samples per patient). 
Further, of the phenytoin concentrations measured via UPLC-MS/MS, all samples post-
dose were quantifiable via UPLC-MS/MS with respect to phenytoin concentrations. However, 
8% of pre-infusion samples were BLQ. A total of 29 serum samples were quantified from 4 
subjects who received only phenytoin and a total of 77 serum samples were quantified from 10 
subjects who received both phenytoin and levetiracetam. 
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Figure 7: Total phenytoin concentration (µg/mL) versus time after first dose (hours) as 
measured by routine therapeutic drug monitoring. 
 
3.9.3 Demographics and Covariates 
Table 7 presents the basic distribution of covariates. Demographic data were expressed as mean 
± standard deviation (SD) unless the data were not normally distributed, in which case median 
and range were reported. 
One subject was a neonate (age = 0.04 years; 14.2 days old); ten subjects were infants 
(between 0.07 to 1 year old); and the remaining twenty-two subjects were children (between 1-
18 year old). Three subjects did not have a recorded age in their medical charts. 
Of the 36 patients administered phenytoin, 27 (75.0%) of them also received fentanyl. 
Additionally of the patients receiving phenytoin, 13 (36.1%) also received levetiracetam. In 
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some cases, levetiracetam was administered simultaneously with phenytoin and in other cases 
levetiracetam was administered prior or following treatment with phenytoin.  
In this study, length of cardiac arrest, defined as time from collapse to return of 
spontaneous circulation, was used as a measure of injury severity. Studies have demonstrated 
that a cardiac arrest longer than 25 minutes is generally associated with poor outcomes 
(Hayakawa, Tasaki et al. 2011). The median length of cardiac arrest in this study was 27 minutes 
(range: 3 – 70 minutes). Sixteen subjects had a cardiac arrest longer than 25 minutes. Fifteen 
subjects had a cardiac arrest 25 minutes or less. Five subjects did not have a recorded length of 
cardiac arrest. 
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Table 7:  Subject characteristics and demographics. 
   
Male – n (%) 12 (33.3%) 
Height (cm) - mean (SD) 99.91 (38.41) 
Weight (kg) - mean (SD) 23.54 (21.42) 
Age (yr) - median (range) 2.44 (0.04) 
CPR (mins) – median (range) 27 (3 – 70) 
Albumin  
 Day 1 - mean (SD) 2.71 (0.74) 
    Day 2 - mean (SD) 3.11 (0.60) 
 Day 3 - mean (SD) 2.83 (0.77) 
 Day 7 - mean (SD) 3.43 (0.54) 
AST - median (range) 104 (29 – 4191) 
ALT - median (range) 61 (1 – 3624) 
CRH – median (range) 0.3 (0.07 – 10) 
BUNH – median (range) 13 (2 – 93)  
Co-Administered Drugs 
 
Fentanyl – n (%)  27 (77.1%) 
Levetiracetam 13 (37.1%) 
Footnote: BUNH: blood urea nitrogen; CRH: corticotropin-releasing hormone; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase. 
3.9.4 Phenytoin Population Pharmacokinetic Model Development 
A summary of the phenytoin population PK model development is presented in Table 8. A one-
compartment Michael-Menten model provided a good description of the phenytoin 
concentration-time data. The phenytoin doses were administered as a short IV injection and 
hence dosing events were coded as infusions in the NONMEM dataset.    
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3.9.4.1 Base Model Results 
As listed below in the following table, the final base model was a one-compartment Michaelis-
Menten model with parameters for the elimination rate constant (Km) and maximum velocity 
(Vmax). A subset of the base models tested are listed in Table 8. 
 
 
Table 8: Summary of models run when development structural PopPK model of phenytoin.  
Run  
Number 
(in 
Pirana) 
Description of Model OFV Comment 
2 1-cmpt model -43.823  
11 1-cmpt Michaelis Menten Model -363.853  
12 Added time-variant Vmax parameter -391.062  
18 Added generalized additive model 
(GAM) 
-482.937 GAM decreased 
overall OFV 
19 Added omega block -481.883  
22 2-cmpt model -98.475  
29 Proportional Error Model -326.843   
30 Combined Error Model -371.912  
78 Combined TBI and CA patient 
populations 
-906.091   
81 Combined CA patients with 
normothermic TBI patients  
-595.893   
Final base model highlighted in bold. 
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The 1-compartment Michaelis-Menten model to describe phenytoin PK was built as follows: 
 
Equation 1:   
𝒅𝑼𝒏𝒃
𝒅𝒕
=  - 𝑽𝒎𝒂𝒙 *
𝑼𝒏𝒃
𝑽𝟏
⁄
𝒌𝒎+
𝑼𝒏𝒃
𝑽𝟏
⁄
 
 
Equation 2:  𝑩𝒐𝒖 =  𝜽𝒑𝒓𝒐𝒑 ∗ 𝑼𝒏𝒃  
 
Equation 3:  𝑻𝒐𝒕𝒂𝒍𝒅𝒓𝒖𝒈 = 𝑼𝒏𝒃 + 𝑩𝒐𝒖 
 
Equation 4:  𝑽𝒎𝒂𝒙(𝒕) = 𝑽𝒎𝒂𝒙𝟎 + 𝑽 ∗ (𝟏 − 𝒆
−𝒌𝒊𝒏𝒅∗ 𝒕) 
 
where Unb is the amount of free phenytoin; Bou is the amount of boud phenytoin; Vmax is the 
maximum velocity of metabolism; km is the Michaelis-Menten elimination constant; V1 is the 
volume of distribution in liters; kind is the rate constant describing induction; θprop is the 
proportionality constant between the bound and unbound drug; Vmax0 is the time invariant 
maximum velocity of metabolism at baseline; Vmaxt is the time variant maximum velocity of 
metabolism; Vmaxi is the portion of velocity impacted by induction and described by kind. 
Error! Reference source not found. describes the 1-compartment Michaelis-Menten 
odel that was fit to the unbound phenytoin concentration. Error! Reference source not found. 
describes the relationship of total and free phenytoin in the model where θprop is the 
proportionality between bound and unbound phenytoin. Total phenytoin was the sum of bound 
and unbound phenytoin (Error! Reference source not found.). Additionally, a time variant 
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aximum velocity term was incorporated into the final model (Error! Reference source not 
found.). This equation makes the assumption that Vmax varies as a function of time. 
GoF plots for the base model demonstrate good agreement between the predicted and 
observed data. There appears to be a deviation in the population prediction activity versus 
observed activity plot at higher concentrations, which indicates the need to account for 
covariates.    
Correlations between covariates were assessed prior to inclusion in the model and are 
displayed in Figure 8. Due to the inclusion of neonates and infants in the dataset, the relationship 
between age and weight is also presented in Figure 9. As expected, there was a strong 
correlation between body weight and age in the pediatric population (R2 = 0.88). Based on this, 
age was tested as a continuous and categorical covariate in the full model (age < 1 years versus 
age ≥ 1 years). 
Based on these exploratory plots as well as on previous phenytoin PopPK modeling and 
clinical rationale, the following covariates were tested in the full model on the PK parameters:  
age, weight, height, gender, temperature and length of cardiac arrest. The inclusion of these 
covariates constituted the “full model” as discussed below. 
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Figure 8:  Comparison between weight and age in males versus females (top).  
Scatterplot of length of cardiac arrest versus age (bottom).  
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Figure 9: Correlation between age (years) and body weight (kg) of pediatrics.  
 
Figure on the left includes all patients in this study. Figure on the right includes patients <2 
years. 
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3.9.4.2 Full Model Results (Inclusion of Covariates) 
The key analysis steps of the backward elimination process for covariate testing are provided in 
Table 9. Model 88 represented the full model with inclusion of all covariates on Vmax. Each 
covariate was subsequently removed and the change in OFV was assessed for each analysis run.  
The final model was reached after 5 rounds of backward elimination, with weight and 
temperature as the significant covariates on volume.     
 
Table 9: A subset of PopPK models run during final model building of phenytoin. 
Final model highlighted in bold. 
 
The final phenytoin population PK model equation for Vmax is as follows: 
 
Equation 5:         𝑽𝟏  =  
𝒘𝒆𝒊𝒈𝒉𝒕
𝟐𝟓
𝜸𝒘𝒕𝟏
∗ 𝜽𝑽𝟏 ∗ 𝒆𝒙𝒑(𝜼𝑽𝟏 ) 
Round Run 
Number 
Description OFV Comment 
1 88 all covariates of interest 
added 
-1797.654 Full covariate model 
2 93 remove height on volume  -1797.28 Not significant 
3 97 remove age on volume -1793.076 Not significant 
4 104 remove gender on volume  -1786.220 Not significant 
5 112 Remove length of cardiac 
arrest on volume 
-1776.309 Not significant  
5 110 =104, Remove weight   Significant, cannot delete 
this covariate 
5 111 =104, Remove temperature   Significant, cannot delete 
this covariate 
5 104_1 =104 -1704.167 Final model 
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Equation 6: 𝑽𝒎𝒂𝒙𝟎  =  𝜽𝑽𝒎𝒂𝒙𝟎 ∗ 𝒆𝒙𝒑(𝜼𝑽𝒎𝒂𝒙𝟎 + (𝒘𝒆𝒊𝒈𝒉𝒕 − 𝟐𝟓) ∗ 𝒘𝒕𝟐) 
 
Equation 7:  𝑽 =  𝜽𝑽 ∗ 𝒆𝒙𝒑 (𝜼𝑽 + (𝑻 − 𝟑𝟕) ∗ 𝒕𝟏) 
where Vmax is the maximum velocity of metabolism; V1 is the volume of distribution in liters; θ 
is the fixed effects parameter; η is the random effects parameter; Vmax0 is the time invariant 
maximum velocity of metabolism at baseline; γwt1 is the weight effect parameter on volume; wt2 
is the weight effect parameter on Vmax; t is temperature and t1 is the temperature effect on Vmaxi 
parameter.   
The parameters of the final phenytoin population PK model are presented in Table 10.   
 
Table 10: Parameter Estimates of Phenytoin Population PK Final Model  
Parameter (Units)   
 Point Estimate %RSE 
WT 1.05 6.2 
WT2 0.029 4.3 
V
1 (L) 360 14.3 
V
max0
 9.17 15.6 
k
m (mg/L) 3.17 18.2 
V
max
 induced (mg/hr) 12.2 20.5 
   
   
Inter-individual   
2V1 0.23 12.1 
2Km 0 FIX  
   
Residual variability   
2add  0.0333 13 
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Footnote: %RSE: percent relative standard error of the estimate = SE/parameter estimate * 100, V1 = apparent 
volume of distribution; Vmax0 = time-invariant maximum velocity of metabolism at baseline; WT = weight effect 
parameter on V1; WT2 = weight effect parameter on Vmax0; Vmaxi = time-dependent velocity defined by the rate 
constant kind and time t; km = Michaelis-Menten elimination rate constant.  
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Figure 10: Goodness-of-fit and diagnostic plots for final phenytoin population PK model. 
 
IPRED: Individual predicted; PRED: Population predicted; IWRES: individual weighted 
residual.  
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Circles represent individual data points.  The lines represent the local regression (Loess) smoothing lines. 
 
 
3.9.5 Phenytoin Model Evaluation 
3.9.5.1 VPC 
A prediction corrected visual predicted check (pcVPC) for the final model of phenytoin data was 
also analyzed. The pcVPC confirmed that the final phenytoin population PK model provided a 
good description of the data.  
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3.9.5.2 Bootstrap Analysis 
A bootstrap analysis was performed to compare the estimates generated from 500 simulated 
subjects to the estimates generated in the NONMEM analysis. Median and 90% CI were 
comparable between the bootstrap analysis and parameters generated. Appendix B.3. includes 
comparison between bootstrap and generated PK parameters. 
3.9.5.3 Simulations 
The final PopPK model of Phenytoin was used to simulate phenytoin concentrations at different 
degrees of cooling and under clinically relevant conditions. Cooling for 24 or 72 hours 
demonstrated a decrease in phenytoin elimination, which led to elevated phenytoin 
concentrations (above the therapeutic range of 2 mg/L).  
3.9.5.4 Phenytoin Disposition in Children with CA versus TBI 
The current population PK model describing phenytoin disposition in children with CA was 
compared with the previous PopPK model describing phenytoin PK in children with TBI. 
Overall, a 1-compartment Michaelis-Menten model best described the PK of phenytoin in both 
patient populations. Parameters differed between the two populations (Vmax: 9.17 versus 6.73; 
Km 3.17 versus 0.483). Several differences between the two population PK studies may 
contribute to differences in parameters between patient populations. The previous study in 
children with TBI consisted of 19 subjects, which is smaller than the current study, however 
more extensive phenytoin sampling across each subject (121 total and 114 free phenytoin levels) 
was collected. Importantly, the previous study included both normothermic and hypothermia 
subjects, unlike the study described here which only includes hypothermic subjects. 
Additionally, the previous study in pediatric TBI consisted of a hypothermia protocol of 48 
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hours, as compared to the current study which included hypothermia durations of 24, 48, and 72 
hours.  
To further compare the PopPK analysis in children with CA versus TBI, the datasets 
were combined and the final model was re-run (  
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Table 11). The final population PK model described in Section 3.7 was run on the 
following four datasets 1) pediatric CA patients only, 2) pediatric TBI patients only 
(normothermic and hypothermic), 3) critically ill patient dataset comprised of pediatric CA and 
TBI patients, and 4) compiled pediatric CA patients and normothermic patients from the TBI 
study.  
Overall, the Vmax and Km were slightly higher in the pediatric CA patient population 
(dataset #1) than in the children with TBI population (dataset #2). Interestingly, when both 
patient populations were combined (dataset #3, “Critically ill patients”), the overall OFV value 
decreased significantly and the Vmax and Km parameters fell between the two patient populations. 
Further, when the pediatric CA population was compiled with the normothermic patients from 
the TBI study (dataset #4), a significant decrease in OFV was seen and the Vmax and Km 
parameters decreased slightly from the pediatric CA population alone. 
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Table 11: Comparison of phenytoin PK parameters from PopPK analysis in children with CA 
and TBI. A PopPK analysis was run on 4 different datasets to compare final PK parameters 
across populations. 
 Pediatric CA 
 
(Ref.) 
Pediatric TBI Critically Ill Pts 
(TBI + CA) 
Ped CA Pts and 
Normotherms from 
TBI Pt Population 
Dataset # 1 2 3 4 
∆OFV from Ref.  +5.2 -423.154 -112.956 
WT 1.05 0.809 1.04 1.04 
WT2 0.029 0.0299 0.030 0.034 
T1  0.381 0.0705 0.118 
T2 0 FIX 0 FIX 0 FIX 0 FIX 
V
1
 360 433 394 370 
V
max
 9.17 6.73 7.17 8.47 
K
m
 3.17 0.483 1.11 1.54 
V
max
 induced 12.2 11.6 12.3 13.1 
Omegas     
V
1
 0.23 0.0108 (31%) 0.166 (6%) 0.181 (5%) 
K
m
 0 FIX 0 FIX 0 FIX 0 FIX 
V
max
  0.619 (30%) 0.302 (10%) 0.467 (20%) 0.442 (26%) 
Additive Error 0.0333 (13%) 0.0372 (7%) 0.0353 (11%) 0.0421 (12%) 
Footnote: OFV = objective function value; WT = weight effect parameter on V1; WT2 = weight effect 
parameter on Vmax0; T = temperature; V1 = apparent volume of distribution; Vmaxi = time-dependent 
velocity defined by the rate constant kind and time t; km = Michaelis-Menten elimination rate constant; 
Vmax0 = time-invariant maximum velocity of metabolism at baseline.  
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3.10 CONCLUSIONS 
In summary, a 1-compartment Michaelis-Menten model best described phenytoin levels in 
pediatrics with CA, which included PK parameters for the elimination rate constant (Km) and the 
maximum velocity (Vmax). This model incorporated a time-varying term for Vmax, which assumes 
that the Vmax of phenytoin is varying over time. Following covariate model building, weight was 
found to be a significant covariate on the volume of distribution of phenytoin. Temperature was 
also found to be a significant covariate on phenytoin PK. Collectively, these PopPK results 
demonstrate that therapeutic hypothermia to 33°C decreased the phenytoin metabolism in this 
patient population. This decrease in phenytoin metabolism was consistent with findings from a 
previous PopPK analysis, which demonstrated hypothermia-mediated effects on phenytoin PK in 
children with TBI. Moreover, simulations indicate that the extent of hypothermia-mediated 
affects is specific to cooling duration (24 versus 72 hours). Future analysis should investigate 
these results in a larger patient population, which constitutes both hypothermia and 
normothermia patients.    
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3.11 DISCUSSION 
The objectives of this study were to characterize the population PK of phenytoin in pediatrics 
following CA and to identify variability and potential determinants (demographic and clinical 
covariates) of phenytoin PK during treatment with therapeutic hypothermia. We found that 
therapeutic hypothermia when applied to pediatrics following a CA decreases the metabolism of 
phenytoin.   
 Results of this study are consistent with our previous study (children with TBI), which 
demonstrated that therapeutic hypothermia decreased phenytoin elimination in children 
following traumatic brain injury. Despite differences in study population (CA versus TBI) and 
cooling duration (24, 48, and 72 hrs), an overall decrease in phenytoin elimination was seen 
during therapeutic hypothermia in both of these studies. Overall, a 1-compartment Michaelis-
Menten model best described the PK of phenytoin in both patient populations. Parameters 
differed between the two populations (Vmax: 9.17 versus 6.73; Km 3.17 versus 0.483). Several 
differences between the two population PK studies may contribute to differences in parameters 
between patient populations. The previous study in children with TBI consisted of 19 subjects, 
which is smaller than the current study, however more extensive phenytoin sampling across each 
subject (121 total and 114 free phenytoin levels) was collected. Importantly, the previous study 
included both normothermic and hypothermia subjects, unlike the study described here which 
only includes hypothermic subjects. Additionally, the previous study in pediatric TBI consisted 
of a hypothermia protocol of 48 hours, as compared to the current study which included 
hypothermia durations of 24, 48, and 72 hours.  
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Hypothermia-mediated effects on drug elimination is particularly important with drugs, 
such as phenytoin, that have a long half-life (t1/2 = 20.7 ± 11.6 hours in neonates) (Donovan, 
Griffin et al. 2016). It is important for clinician’s to recognize that the effects of therapeutic 
hypothermia may be seen long past the cooling and rewarming phases into the post-treatment 
phase when drugs with long half-lives are administered. This creates an extended time period of 
potentially unexpected drug responses after the active cooling period in which clinicians should 
continue to monitor drug levels. 
 In this study, age was not found to be a significant covariate on phenytoin PK. However, 
previous studies report an effect of age on phenytoin PK due to an age-dependent decrease in the 
metabolic rate (Battino, Estienne et al. 1995). The half-life of phenytoin is generally longer in 
neonates, of which it decreases following the first postnatal month and then increases with age. 
In this study, patients were on average 5.7 years old, with 4 patients being less than 2 months, 11 
patients between 2 months and 2 years old, 11 patients between 2 and 11 years old, and 6 patients 
between 11 and 18 years old. The remaining patients in the study did not have a recorded age. 
While this dataset did not support age as a significant covariate on phenytoin PK, weight was 
found to be a significant covariate, which was highly correlated with age. One possible 
explanation that age was not identified as a significant covariate on phenytoin PK is the small 
number of neonates included in this study.   
Other studies have used various compartmental models to describe the population 
pharmacokinetics of phenytoin (Odani, Hashimoto et al. 1996, Ahn, Cloyd et al. 2008, Tanaka, 
Kasai et al. 2013). Tanaka et al. described phenytoin using a linear 2-compartment model. This 
study consisted of pooled Phase 1/2 trials following an intravenous administration of 
fosphenytoin sodium (Tanaka, Kasai et al. 2013). This study included numerous plasma samples 
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following each fosphenytoin dose (n = 923 plasma samples from 24 healthy volunteers) and 
therefore was able to capture the conversion of fosphenytoin to phenytoin in the model. Given 
the sparse sampling of phenytoin in our clinical study, the conversion of fosphenytoin to 
phenytoin was unable to be characterized in our model. 
Another study by Odani et al. performed a population pharmacokinetic analysis on 
phenytoin serum concentrations at steady-state (n = 531) from 116 epileptic patients (Odani, 
Hashimoto et al. 1996). This study used a 1-compartment model with Michaelis-Menten 
elimination to best describe the PK of phenytoin in this patient population. This study reported a 
Vmax of 9.80 mg/d/kg and a Km of 9.19 micrograms/ml. Weight and a co-administered drug, 
zonisamide, were included in the model. The inclusion of zonisamide was based on an 
observation during TDM, which indicated higher phenytoin concentrations when co-
administered with zonisamide. A number of patients were taking other anticonvulsants including 
carbamazepine, valproic acid, phenobarbital, and “others”. None of these were included in the 
model. In the present study, we tested the effect of two co-administered medications 
(levetiracetam and fentanyl) on phenytoin PK. Neither was found to be a significant covariate on 
phenytoin PK in this population. This is consistent with previous studies which have found no 
significant DDI between fentanyl and phenytoin. Levetiracetam, which is predominately renally-
eliminated was not anticipated to affect phenytoin elimination; however, it’s important to note 
that this analysis included only a small number of patients who were co-administered 
levetiracetam and phenytoin.  
Another study by Ahn et al. used a population PK approach to describe the effects of age 
and sex on phenytoin in adult patients with epilepsy (Ahn, Cloyd et al. 2008). In this study, a 
linear 1-compartment model with a drug depot compartment for fosphenytoin best described the 
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data. Of the 63 subjects included in this study, there was no difference in the clearance, volume 
of distribution, or half-life of phenytoin between elderly versus adult subjects nor between male 
versus females. While this study was conducted in a different population (adults with epilepsy) 
as compared to the present analysis (pediatrics with CA), we also found no significant difference 
in phenytoin PK between age or sex. 
In all three of the studies described above, phenytoin PK parameters were correlated with 
body weight in the final model, which is consistent with what we found. A few differences can 
be seen between the PopPK analysis in our study versus the ones described above. First, the 
patient populations vary between studies. Tanaka et al. included pediatric patients, as well as 
adult and healthy volunteers. The population studied by Ahn et al. and Odani et al. both 
consisted of adult patients with epilepsy. The different patient populations (both disease state and 
age) and study designs (dosing and sampling frequency/duration) likely explains the difference 
in PK models which were used to describe phenytoin PK. Additionally, Ahn et al. and Tanaka et 
al. consisted of a single IV dose of phenytoin with numerous PK samples whereas our study 
consists of sparse PK sampling (approximately 7 per subject across 7-9 days).    
 The main limitations of this study are 1) lack of normothermic subjects; 2) small number 
of serum samples per subject and 3) lack of free phenytoin levels for samples quantified by 
UPLC-MS/MS. The lack of a comparator (normothermic) group in this study prevented 
associations of phenytoin levels with clinical covariates between the two groups. However, given 
the extensive temperature and sample collection throughout this study, the effect of temperature 
across different treatment phases (hypothermic, rewarming, and post-treatment) served as an 
internal control for patients. Additionally, we were able to compare phenytoin PK in pediatrics 
with CA with our previous analysis in children with TBI, which included a normothermic group. 
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While disease-mediated affects (cardiac arrest versus traumatic brain injury) are also a possible 
contributor of phenytoin PK variability, the combined study populations (pediatric CA and TBI) 
reduced overall variability in the model. Further, disease severity was tested as a covariate in 
pediatrics with CA (length of cardiac arrest) and in pediatrics with TBI (Glasgow Coma Score 
and Injury Severity Score), but neither were found to be significant contributors of PK variability 
in these small sub-populations. Future studies should investigate hypothermia-mediated effects 
on phenytoin PK in cooled versus non-cooled children following CA.   
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4.0  EFFECT OF TEMPERATURE ON ABC DRUG TRANSPORT ACTIVITY IN VITRO  
  
 110 
 
4.1 INTRODUCTION 
As demonstrated in previous Chapters, therapeutic hypothermia has been shown to decrease drug 
metabolism via CYP450 metabolic pathways leading to an increase in drug concentrations 
(Tortorici, Mu et al. 2009, Hostler, Zhou et al. 2010, Zhou, Empey et al. 2011, Empey, Miller et 
al. 2012). To date, pharmacokinetic studies investigating the effects of therapeutic hypothermia 
on drug disposition are almost exclusively focused on hepatic drug metabolism. Evidence is 
limited supporting other important components of pharmacokinetics such as drug absorption and 
distribution. Specifically, drug transporters play a role in drug distribution and pharmacokinetics. 
Of the multitude of drugs administered to critically ill patients, many of them undergo 
transporter pathways in addition to metabolic pathways (Table 12). Despite this, there is 
minimal evidence investigating clinically relevant temperature-mediated effects on drug 
transporters. The following sections describe the important role of drug transporters in drug 
disposition, the current evidence of hypothermia-mediated effects on drug transport, and the aims 
and hypothesis of the studies described in this Chapter.   
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Table 12: Drugs administered in the ICU and their transporter pathways. 
Drug Transporter(s) Pathway 
Antiarrythmics 
Digoxin ABCB1 
Quinidine ABCB1 
Antibiotics 
Ciprofloxacin SLC22A8 
Antihypertensives 
Enalapril ABCG2, SLCOs 
Prazosin ABCG2 
Valsartan ABCG2, SLCOs 
Statins  ABCG2, SLCOs 
Opioids ABCB1 
Miscellaneous 
Cimetidine ABCG2 
Dipyradamole ABCG2 
Vecuronium ABCB1 
Protease Inhibitors ABCG2, ABCB1 
Fluoroquinolones ABCG2 
Verapamil ABCB1 
Diltiazem ABCB1 
Phenytoin ABCB1 
Vecuronium ABCB1 
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4.2 ROLE OF DRUG TRANSPORTERS IN DRUG DISPOSITION 
Drug transporters have been increasingly recognized for their important role in drug 
pharmacokinetics (Schinkel and Jonker 2003, Sai 2005, 2010, Tweedie, Polli et al. 2013). To 
date, a number of studies have demonstrated that transporters, along with drug metabolizing 
enzymes, play a role in therapeutic efficacy, drug safety, and ADEs (2008, Huang, Strong et al. 
2008, 2010). Specifically, two main transporter superfamilies, the solute carrier (SLC) and ATP-
binding cassette (ABC), account for over 400 transporters that are widely distributed throughout 
the body (Giacomini, Huang et al. 2010). Clinically observed drug-drug interactions with drug 
transporters have been reported for a number of drugs (König, Müller et al. 2013) such as 
inhibition of P-gp mediated digoxin transport by quinidine (Ochs, Bodem et al. 1981, Schenck-
Gustafsson and Dahlqvist 1981, Fenster, Comess et al. 1982, Fenster, Hager et al. 1984); 
inhibition of OCT2 and MATE-mediated transport of methotrexate by probenecid (Aherne 
1978); and inhibition of BCRP-mediated transport of elacridar by topotecan (Kruijtzer, Beijnen 
et al. 2002), to name a few. However, as was previously discussed in Chapter 1 (1.2.1), drug-
therapy interactions do not undergo the same degree of testing as drug-drug interactions. 
Consequently, little is understood as to the role of drug transporters during drug-therapy 
interactions, such as therapeutic hypothermia. The subsequent section describes the current in 
vitro evidence that has investigated therapeutic hypothermia on drug transport to date.   
 
 
 113 
4.3 EVIDENCE THAT THERAPEUTIC HYPOTHERMIA EFFECTS ABCB1 DRUG 
TRANSPORT ACTIVITY 
To date, only one study has investigated therapeutic hypothermia on drug transporter activity. 
This study investigated the effect of therapeutic hypothermia on one of the ABC drug 
transporters, ABCB1 (P-gp). Jin et al. reported a decrease in active transport of ABCB1 during 
cooling, but no change was seen in passive diffusion (Jin, Sakaeda et al. 2006). In this study, 
LLC-PK1 cell lines transfected with human MDR1 and their respective wild-type cells were 
treated with 3 hours of hypothermia (32˚C) or normothermia (37˚C). Two radiolabeled probes 
were used to measure ABCB1 transport across cell membranes, [
3
H]digoxin and [
3
H]quinidine. 
The results demonstrate that active ABCB1 transport of the radiolabeled probe substrate 
[
3
H]digoxin was decreased by 50% under mild hypothermic conditions (32˚C). The transport of 
[
3
H]digoxin continued to significantly decrease below therapeutic hypothermia temperatures 
down to as low as 4˚C. In addition, the effects of cooling on the other ABCB1 probe substrate, 
[
3
H]quinidine, was also investigated in this cell line. Interestingly, quinidine transport only 
decreased at a temperature of 4˚C, but not at temperatures of 32°C or 25°C. The authors suggest 
that a possible explanation for the selective effect of cooling on [
3
H]digoxin versus [
3
H]quinidine 
transport could be due to the fact that quinidine is also a substrate for the organic cation 
transporter (OCT), which is expressed in the LLC-PK1 cell line used in this study.        
Additionally, Jin et al. measured paracellular transport using a specific radiolabeled 
marker, [methoxy-
14
C]inulin. No effect of cooling was seen on paracellular transport down to 
25°C. Further, [
3
H]tetracycline, a non-Pgp substrate, was used as a control. Overall, the net 
transport (B to A/A to B) was not altered at lower temperatures, however the unidirectional 
transport (B to A and A to B) was decreased at lower temperatures in both directions. The 
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authors suggest that this may be due to a change in transcellular transport mediated by passive 
diffusion.  
Results of this study demonstrate an effect of therapeutic hypothermia on ABCB1 drug 
transport by as much as 50% in vitro. In addition to ABCB1, other drug transporters play an 
important role in drug disposition, of which the impact of temperature-mediated changes is 
largely unknown. Therefore, we aimed to expand on what’s currently known to include 
additional ABC drug transporters. Additionally, we aimed to focus on clinically meaningful 
temperatures to investigate how drug transporters may be affected under different temperatures 
(including both hyper- and hypo- thermic conditions).      
 
 
4.4 AIMS AND HYPOTHESIS OF STUDY 
We aimed to investigate the effects of clinically relevant temperatures (therapeutic hypothermia 
and hyperthermia) on the active drug transport of three ABC transporters:  ABCB1, ABCG2, and 
ABCC1. We hypothesize that therapeutic hypothermia will lead to a decrease in the active drug 
transport of all three ABC drug transporters, while having no effect on the passive transport 
across cell membranes. Further, we anticipate that the magnitude of these effects will likely be 
different between transporters since transporter function is dependent on specific drug-transport 
interactions. 
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4.5 METHODS 
4.5.1 Materials and Chemicals 
[
3
H]digoxin and [
14
C]sucrose were purchased from PerkinElmer (Waltham, MA).  
[
3
H]cimetidine and [
3
H]estradiol-17-β-D-glucuronide were purchased from American 
Radiolabeled Chemicals (St. Louis, MO). Gibco MEM Optimem cell culture media was 
purchased from Invitrogen (#41090-101). Additional reagents were purchased from the 
following: FBS, Optima, heat-inactivated (Atlanta Biologicals #S12450H), Pen/strep (Fisher 
(Cellgro) #MT-30-002-C), Genecitin (Fisher (Cellgro) #MT-30-234-C).     
4.5.2 Cell Lines 
The Madin-Darby canine kidney-II (MDCKII)-ABCG2 cell line was developed in the laboratory 
of Dr. McNamara (University of Kentucky, Lexington, Kentucky) (Wang, Leggas et al. 2012). 
The MDCKII-ABCB1 and ABCC1 cell lines were obtained from Dr Piet Borst (Netherlands 
Cancer Institute, Amsterdam, The Netherlands). MDCKII-ABCG2 cells were cultured in Gibco 
Minimum Essential Media (MEM), Earle’s salts, with glutamax (Invitrogen #41090-101) with 
5% FBS, Optima,, heat-inactivated (Atlanta Biologicals #S12450H) and 800 ng/mL genecitin 
(Fisher(Cellgro) #MT-30-234-C). MDCKII-ABCB1 cells were cultured in Gibco Minimum 
Essential Media (MEM), Earle’s salts, with glutamax (Invitrogen #41090-101) with 10% FBS 
and 800 ng/mL genecitin. MDCKII-ABCC1 cells were cultured in DMEM, High Glucose, 
GlutaMAX™ (Invitrogen # 10566024) with 1mM Sodium Pyruvate (Invitrogen # 11360070 
Lot# 1227460), 10% FBS Optima, heat-inactivated (Atlanta Biologicals #S12450H) and 1% 
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Pen/strep (Fisher(Cellgro) #MT-30-002-C). All cell lines were grown in incubators at 37°C in a 
humidified atmosphere of 5% CO2. 
4.5.3 Transepithelial Drug Transport Assay 
Cells were initially grown at a density of 2 × 10
6
 cells per 24.5 mm well on transwell 
polycarbonate filters with a 3.0 μm pore size (Corning Inc., Corning, NY). Cells were seeded 
onto polycarbonate filters to form monolayers.  
The MDCK-II cell line is a polarized cell line derived from the kidney of canines. When 
grown to form monolayers, the apical membranes face up while the basal membranes are 
attached to the microporous polycarbonate filter. In MDCKII cells overexpressing-ABCB1, 
ABCB1 is highly expressed on the apical membrane and acts as an efflux transporter. Thus, 
transport from the basal to the apical side (B→A) is increased and transport from the apical to 
the basal side (A→B) is decreased for specific ABCB1 probes in the over-expressed cell line as 
compared to the empty (control) cell line (Figure 11). Therefore, ABCB1-mediated transport can 
be assessed in these cell lines using specific probe substrates. Similarly, ABCG2 and ABCC1 
can be assessed in the same fashion in MDCKII-overexpressed versus control cells.     
 
 
Figure 11: Illustration of drug transporter expression across cell membranes. 
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Following seeding to transwells, cells were cultured for 4-6 days with media changed 
once every two to three days. To confirm the quality of cell monolayers, transepithelial electrical 
resistance (TEER) was measured with an epithelial voltohmmeter (World Precision Instruments, 
Sarasota, FL). Cell monolayers with TEER values lower than 100 Ω were not used for flux 
assay. Immediately prior to the start of experiment, old media was removed, and cells were 
washed once and then replaced with OptiMEM (2 mL in each basolateral and apical side of 
transwell). The transport across the cell monolayer was conducted by adding the following 
specific transporter probes to each of the over-expressed cell line:  [
3
H]cimetidine for ABCG2 
cell line; [
3
H]digoxin for ABCB1 cell line; [
3
H]estradiol-17-β-D-glucuronide for ABCC1 cell 
line. In addition, [
14
C]sucrose was added with probes to assess the degree of tight junction 
formation. Probes and sucrose were added to either the apical or basolateral side of the 
monolayer to measure transport in both directions across the member (basal to apical, B→A and 
apical to basal, A→B). Transwells were stored in incubators until sampling. Samples (50 μL) 
were taken from the opposite side of the cell monolayer at 0, 30, 60, 120 and 240 minutes. 
Radioactivity was then measured using a liquid scintillation counter. 
4.5.4 Apparent Permeability and Efflux Ratio Calculations 
Following radioactivity measurements, the observed permeability (Papp) of probe substrates or 
paracellular (sucrose) marker were determined by calculating its initial transfer rate across the 
cell monolayer and dividing by the surface area of the membrane filter and the initial 
concentration in the donor chamber (Equation 8) where dQ/dt is the permeability rate of the 
probe substrate, A is the surface area of the monolayer and Co is the initial concentration in the 
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donor compartment. The overall flux of each probe substrate was determined by best fit line 
through the linear region of the graph of the cumulative pmol transferred versus time. Linear 
regression was performed using GraphPad Prism version 4.03 (San Diego, CA). A paracellular 
leakage of less than 1% per hour is considered negligible (Pavek, Merino et al. 2005). Therefore, 
monolayer integrity was considered acceptable and flux was calculated as long as paracellular 
marker did not exceed 1% per hour.     
   
Equation 8:  𝑷𝐚𝐩𝐩 =  
𝟏
𝐀 ∗  𝑪𝒐 
∗ (
𝒅𝑸
𝒅𝒕
)  
 
The efflux ratio (ERα) was calculated by dividing the transepithelial drug efflux rate of (B→A) 
by (A→B) to evaluate drug transporter-mediated directional efflux (Equation 9). Data was 
expressed as mean ± S.D.   
 
Equation 9:  𝑬𝑹𝜶 =  
𝑷𝒂𝒑𝒑𝑩→𝑨
𝑷𝒂𝒑𝒑𝑨→𝑩
 
4.5.5 Statistical Analysis 
Data are expressed as mean ± S.D. from two to three observations for transwell assays. Statistical 
significance was evaluated by the Student’s t-test (unpaired, two-tailed, α = 0.05) and by a two-
way ANOVA followed by the Bonferroni post-t-test (α = 0.05). All statistical analyses were 
performed using GraphPad Prism version 4.03 (San Diego, CA) with a p-value<0.05 considered 
significant. 
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4.6 CONTROL EXPERIMENTS 
4.6.1 Temperature Control Experiments 
It is critical in these studies that we achieve and maintain consistent temperatures throughout 
these experiments in order to accurately quantify a temperature effect and eliminate any potential 
noise in this data. Therefore, we began by conducting a series of control experiments to measure 
the temperature within 1) cell culture media prior to distributing into transwells, 2) incubators, 
and 3) cell culture media post dispensing into transwells.     
4.6.1.1 Temperature of Cell Culture Media Prior to Distribution to Transwells 
At the start of flux experiments, the cell culture media in transwells is rinsed and replaced with 
OptiMEM. The OptiMEM is stored in a refrigerator until time of experiment. Prior to 
experiments, OptiMEM is warmed in a water bath (set to 37°C) and then dispensed into 
transwells. In this control experiment, we aimed to record the temperature of OptiMEM while in 
the water bath in order to determine the optimal pre-incubation time necessary to achieve target 
temperature. A mercury thermometer was used to measure the temperature of the OptiMEM and 
ensure it achieved appropriate temperature before it was distributed into transwell plates.   
 During experiment, OptiMEM was removed from the fridge and placed in a 37°C water 
bath. Temperature was measured over 15 minute increments up until the desired temperature was 
achieved in the media (Figure 12). After 2 hours in the water bath, the OptiMEM achieved close 
to the desired temperature (36.5°C). Next, we removed the OptiMEM from the water bath, 
transferred to the hood, and measured how quickly the temperature decreased. After 15 minutes, 
the temperature of the OptiMEM was at 31.5°C. Based on these results and the highly variable 
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and quick changes in temperature, we conducted a series of additional control experiments 
(subsequent sections) to further determine how to maintain consistent and accurate temperatures 
throughout experiments.  
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Figure 12: Temperature of cell culture media when warmed in water bath prior to experiment. 
4.6.1.2 Temperature within Incubators 
The objective of this control experiment was to determine the temperature within incubators by 
measuring 1) how consistent incubators maintained temperature and 2) recovery time of 
temperature in incubators under experimental conditions. Incubators were set to 40°C, 37°C, 
33°C and 30°C. Figure 13 and Figure 14 depict the temperature of the incubators set to 37°C and 
33°C, respectively, during simulated experimental conditions. Sharp drops in temperature can be 
seen when the incubator door was open. Based on incubator output, incubators take ~1-2 minutes 
to achieve target temperature and ~5-8 minutes to completely restore to set temperature after the 
door is open and closed. Therefore, we concluded that 1) the incubators maintain consistent 
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temperature under experimental conditions over the duration of the study and 2) are able to 
recover quickly from drops in temperature when the door is open and closed.  
In addition to temperature, the stability of the atmospheric pressure inside the incubators 
was also evaluated. During a simulated experiment, incubators take approximately 2-3 minutes 
to restore the %CO2 to set level (5.0%) after the door is open and closed (Figure 15). Therefore, 
we concluded that 1) atmospheric pressure in the incubators was consistent throughout the study 
and 2) atmospheric pressure recovered quickly from changes under experimental conditions. 
 
 
Figure 13: Temperature stability of incubators (37°C).  
 
The incubator door was open at the following sampling timepoints: 0, 30, 60, 120, and 290 
minutes. 
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Figure 14: Temperature stability of incubators (33°C).  
 
The incubator door was open prior to the following sampling timepoints: 0, 30, 85 and 95 
minutes.  
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Figure 15: Atmospheric stability of incubators (5.0% CO2).  
 
The incubator door was open prior to the following time points: 0, 30, 85 and 95 minutes. 
4.6.1.3 Temperature of Media within Transwells 
Based on the output from the incubator study, we concluded that temperature was achieved and 
maintained in the incubators throughout the duration of the study. However, the results of the 
OptiMEM study demonstrated sharp declines in temperature once removed from the water bath. 
Therefore, the next question we asked was if the target temperature was achieved in the 
transwells and maintained during the study duration. To answer this question we used a 
temperature probe, which was inserted into the media in the transwell, and recorded the 
temperature reading during a simulated experiment. The following describes the results of this 
study. 
In these experiments, incubators were set to 40°C, 37°C, 33°C and 30°C. Temperature 
was recorded from the incubator output and from the probe within the media in the transwell. 
Figure 16 depicts the incubator and probe temperatures over the course of the experiment when 
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the incubator was set to 33°C. Incubator temperature was within 33 ± 0.7 °C while transwell 
temperature ranged from 28.6 - 33.2°C and was within 33±1°C during 35.4% of the experiment. 
Figure 17 depicts the incubator and probe temperatures over the course of the experiment when 
the incubator was set to 37°C. Incubator temperature was within 37 ± 0.8 °C while transwell 
temperature ranged from 31.8 – 36.5°C and was within 37±1°C during 31.2% of the experiment. 
Figure 18 depicts the incubator and probe temperatures over the course of the experiment when 
the incubator was set to 40°C. Incubator temperature was within 40 ± 1.0 °C while transwell 
temperature ranged from 31.5 - 39.6°C and was within 40±1°C during 47.9% of the experiment. 
Based on these results, we concluded that temperature was highly inconsistent between the 
incubator temperature and the media temperature and highly variable throughout the study.  
 
 
Figure 16: Temperature within transwells (33°C). 
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Figure 17: Temperature within transwells (37°C). 
 
 
Figure 18: Temperature within transwells (40°C). 
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To address these temperature discrepancies, we added a heating pad inside the cell 
culture hood. Transwell plates were transferred directly from incubators into the hood and placed 
on the heating pad to preserve temperature. This prevented significant loss of heat during 
sampling time in the hood. Additionally, the length of time to warm the media was extended in 
order to ensure that media reached desired temperature before being dispensed into transwells. 
Further, aliquots of OptiMEM were removed from the bottle to achieve target temperature faster. 
Additionally, aliquots of OptiMEM were transferred from the water bath to a beaker of water in 
the hood on a hot plate. This helped to preserve the temperature of OptiMEM while being 
transferred to transwells. Temperature control experiments were repeated under revised 
conditions and results are discussed in subsequent section (4.6.1.4).   
 
4.6.1.4 Revised Methods to Maintain Temperature in Transwells 
Temperature experiments were repeated, as described in previous section, under revised 
experimental conditions with the intent of achieving more consistent and accurate target 
temperatures during the course of the experiment. When incubator was set to 30°C, transwell 
temperature ranged from 29.4 - 30.3°C and was within 30.0±0.9°C for 100% of the experiment 
(Figure 19). When incubator was set to 33°C, transwell temperature ranged from 32.0 - 33.2°C 
and was within 33.0±1.0°C during 100% of the experiment (Figure 20). When incubator was set 
to 37°C, transwell temperature ranged from 35.3 - 37.1°C and was within 37.0±1.0°C during 
95.8% of the experiment (Figure 21). When incubator was set to 40°C, transwell temperature 
ranged from 35.6 - 39.4°C and was within 40.0±1.0°C during 47.1% of the experiment (Figure 
22). Results demonstrated that with the revised heating methods, temperature was consistent 
 127 
during the study duration. Therefore, we concluded that temperature-mediated effects could be 
accurately quantified under experimental conditions.   
 
Figure 19: Temperature of media versus incubator temperature (30°C). 
 
 
Figure 20: Temperature of media versus incubator temperature (33°C). 
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Figure 21: Temperature of media versus incubator temperature (37°C). 
 
 
 
Figure 22: Temperature of media versus incubator temperature (40°C). 
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4.6.2 Concentration Control Experiments 
After controlling for the temperature throughout the study, we next aimed to conduct 
concentration assays in order to determine the linearity of transport for each probe and their drug 
transporter. Concentration assays were conducted to select the probe concentration to use in 
permeability flux assays. The following sections describe the results of the probe concentration 
versus flux for ABCB1-, ABCG2-, and ABCC1- overexpressed cells. 
4.6.2.1 ABCB1-Overexpressed Cell Line 
[
3
H]digoxin, an established probe substrate for ABCB1, was selected for flux assays. The flux of 
[
3
H]digoxin (pmol transferred) across the over-expressed cell monolayers was measured at 1, 
2.5, 5, and 10 μM. Results demonstrated linear flux of digoxin from 1-10 μM (Figure 23). Based 
on these results, the concentration of drug added to the donor compartment for permeability flux 
assays was selected to be 5.0 μM. 
 
Figure 23: Flux of digoxin across ABCB1-overexpressed cell monolayers. 
 130 
4.6.2.2 ABCG2-Overexpressed Cell Line 
[
3
H]cimetidine, an established probe substrate for ABCG2, was selected for flux assays. The flux 
of [
3
H]cimetidine at 1, 2.5, 5, and 10 μM was measured across ABCG2-overexpressed cell 
monolayers. Cimetidine flux was linear across ABCG2-overexpressed cell monolayers from 1-
10 μM (Figure 24). The concentration of drug added to donor compartment in permeability flux 
assays was selected to be 5.0 μM.  
 
 
Figure 24: Flux of cimetidine across ABCG2-overexpressed cell monolayers. 
4.6.2.3 ABCC1-Overexpressed Cell Line 
[
3
H]estradiol-17-β-D-glucuronide, an established probe for ABCC1, was selected as the probe 
substrate. The flux of [
3
H]estradiol-17-β-D-glucuronide at 1, 2.5, 5, and 10 μM concentration 
was measured. Flux was linear from 1-10 μM (Figure 25). The concentration of drug added to 
donor compartment was selected to be 5.0 μM.  
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Figure 25: Flux of estradiol-17-β-D-glucuronide concentration across ABCC1-overexpressed 
cell monolayers. 
4.6.3 Time Course Experiments 
A time course study was performed to measure the transepithelial transport of [
3
H]digoxin, 
[
3
H]cimetidine, and [
3
H]estradiol-17-β-D-glucuronide in ABCB1-, ABCG2-, and ABCC1- 
overexpressing cell monolayers, respectively. The following sections describe the results of these 
time course experiments in each cell line. 
4.6.3.1 ABCB1-Overexpressed Cell Line 
The transepithelial transport of [
3
H]digoxin across the cell monolayers of ABCB1-
overexpressing cells was time dependent from 0.5 – 6 hours at 37°C (Figure 26), confirming the 
linearity of digoxin flux up to six hours. Each point represents the mean ± standard deviation 
from three separate experiments. Based on these results, we selected a 4 hour study duration to 
perform permeability flux assays.  
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Figure 26: Transepithelial transport of digoxin in ABCB1-overexpressing cells. 
 
Transport was linear from 0.5 – 6 hours at 37°C. Each point represents mean ± standard 
deviation from three separate experiments. 
4.6.3.2 ABCG2-Overexpressed Cell Line 
The transepithelial transport of [
3
H]cimetidine across the cell monolayers of ABCB1-
overexpressing cells was time dependent at 37°C and 33°C (Figure 27). Each point represents 
the mean ± standard deviation from three separate experiments. Based on these results which 
demonstrate the linearity of cimetidine flux up to six hours, we selected a time duration of 4 
hours to conduct flux assays.  
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Figure 27: Transepithelial transport of cimetidine in ABCG2-overexpressing cells. 
 
Transport was linear from 0.5 – 6 hours at 37°C. Each point represents mean ± standard 
deviation from three separate experiments. 
 
4.6.3.3 ABCC1-Overexpressed Cell Line 
The transepithelial transport of [
3
H]estradiol-17-β-D-glucuronide across the cell monolayers of 
ABCC1-overexpressing cells was time dependent at 37°C (Figure 28). Each point represents the 
mean ± standard deviation from three separate experiments. Based on these results and the 
linearity of estradiol-17-β-D-glucuronide flux up to six hours, we selected a time duration of 4 
hours to conduct flux assays.  
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Figure 28: Transepithelial transport of estradiol in ABCC1-overexpressing cells.  
 
Transport was linear from 0.5 – 6 hours at 37°C. Each point represents mean ± standard 
deviation from three separate experiments. 
 
4.6.4 Confirmation of Overexpressed Cell Lines 
In these studies, the flux of [
3
H]digoxin, [
3
H]cimetidine, and [
3
H]e estradiol-17-β-D-glucuronide 
was measured in ABCB1-, ABCG2-, and ABCC1- overexpressing cell monolayers, respectively, 
and their respective wild-type cell lines. Flux in both the apical to basolateral and basolateral to 
apical direction across cell membranes was measured. The transport of probe drug across both 
directions of the cell monolayer was compared between each over-expressed cell line and their 
respective wildtype cell line to confirm over-expression of drug transporter. The following 
sections describe the results of these experiments in each cell line. 
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4.6.4.1 ABCB1-Overexpressed Cell Line 
The basal to apical transport of [
3
H]digoxin across ABCB1-overexpressed cells was significantly 
higher than the apical to basolateral transfer. Further, the basal to apical transport was higher and 
the apical to basolateral transport was lower in the ABCB1-overexpressed cells compared to 
empty cells (Figure 29). This confirms the over-expression of the ABCB1-overexpressed cell 
line and ensures that it can be used to measure flux. 
One interesting observation with the ABCB1-overexpressed cell line is that the apical to 
basolateral flux was similar to the flux observed in the wildtype cell line. Previous studies also 
report seeing a higher flux of digoxin in wildtype cells due to endogenous ABCB1 (Kuteykin-
Teplyakov, Luna-Tortos et al. 2010).   
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Figure 29: Flux of digoxin across ABCB1-overexpressed and empty- MDCKII cells. 
4.6.4.2 ABCG2-Overexpressed Cell Line 
The basal to apical transport of [
3
H]cimetidine across ABCG2-overexpressed cells was 
significantly higher than the apical to basolateral transfer. Further, the basal to apical transport 
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was higher and the apical to basolateral transport was lower in the ABCG2-overexpressed cells 
compared to empty cells (Figure 30). This confirms the over-expression of the ABCG2-
overexpressed cell line and ensures that it can be used to measure flux. 
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Figure 30: Flux of cimetidine across ABCG2-overexpressed and empty- MDCKII cells. 
4.6.4.3 ABCC1-Overexpressed Cell Line 
The basal to apical transport of [
3
H]estradiol-17-D-glucuronide across ABCC1-overexpressed 
cells was significantly higher than the apical to basolateral transfer. Further, the basal to apical 
transport was higher and the apical to basolateral transport was lower in the ABCC1-
overexpressed cells (Figure 31). This confirms the over-expression of the ABCC1-
overexpressed cell line and ensures that it can be used to measure flux. 
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Figure 31: Flux of [
3
H]estradiol-17-D-glucuronide across ABCC1-overexpressed and empty- 
MDCKII cells. 
4.7 RESULTS OF PERMEABILITY FLUX ASSAYS 
4.7.1 ABCB1 Flux Assays 
4.7.1.1 Transepithelial Electrical Resistance 
Transepithelial electrical resistance (TEER) measurements were taken on Days 1 – 4 of flux 
assay experiments. The TEER measurements ranged from 280 – 619 (Figure 32). 
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Figure 32: Transepithelial electrical measurements of ABCB1 cell monolayers. 
4.7.1.2 Paracellular Transport 
Paracellular transport across cell monolayers in ABCB1-overexpressed and wildtype cell lines at 
40, 37, 33, and 30°C is shown in Error! Reference source not found.. A radiolabeled [
14
C]sucrose 
ompound was used as a paracellular marker. Negligible [
14
C]sucrose transport occurred across 
the entire four hour study duration. Less than 2% of the total [
14
C]sucrose added crossed the cell 
membrane during the experiment.  
4.7.1.3 ABCB1 Flux Across Cell Monolayers 
The B to A transport and A to B transport of digoxin decreased with lower temperature, which 
indicates that ABCB1 activity was reduced at 33°C and lower (Figure 33).  
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Figure 33: Digoxin flux across ABCB1-overexpressed cell monolayers at 37° versus 33°C. 
 
4.7.2 ABCG2 Flux Assays 
4.7.2.1 Transepithelial Electrical Resistance 
Transepithelial electrical resistance measurements were taken on Days 1-4 of flux assay 
experiments. The TEER measurements ranged from 180 – 481 (Figure 34). 
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Figure 34: Transepithelial electrical resistance of ABCG2 cell monolayers. 
 
4.7.2.2 Paracellular Transport 
Paracellular transport across cell monolayers in ABCG2-overexpressed and wildtype cell lines at 
40°, 37°, 33°, and 30°C is shown in Figure 35. A radiolabeled [
14
C]sucrose compound was used 
as a paracellular marker. Negligible transport of [
14
C]sucrose occurred across the entire four hour 
study duration. Less than 2% of the total [
14
C]sucrose added crossed the cell membrane during 
the experiment.  
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Figure 35: Transport of [
14
C]sucrose across cell monolayers in ABCG2-overexpressed and 
wildtype cell lines at 40°, 37°, 33°, and 30°C. 
 
4.7.2.3 ABCG2 Flux Across Cell Monolayers 
The B to A transport and A to B transport of cimetidine decreased with lower temperature, which 
indicates that ABCG2 activity was reduced at 33°C and lower (Figure 36). 
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Figure 36: Cimetidine flux across ABCG1-overexpressed cell monolayers at 37° versus 33°C. 
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4.7.3 ABCC1 Flux Assays 
4.7.3.1 Transepithelial Electrical Resistance 
Transepithelial electrical resistance measurements were taken on Days 1-4 of flux assay 
experiments. The TEER measurements ranged from 204 – 462 (Figure 37). 
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Figure 37: Transepithelial electrical resistance of ABCC1 cell monolayers. 
 
4.7.3.2 Paracellular Transport 
Paracellular transport across cell monolayers in ABCC1-overexpressed and wildtype cell lines at 
40, 37, 33, and 30°C is shown in Figure 38. A radiolabeled [
14
C]sucrose compound was used as 
a paracellular marker. Negligible transport of [
14
C]sucrose occurred across the entire four hour 
study duration. Less than 2% of the total [
14
C]sucrose added crossed the cell membrane during 
the experiment. 
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Figure 38: Transport of [
14
C]sucrose across cell monolayers in ABCC1-overexpressed. 
 
4.7.3.3 ABCC1 Flux Across Cell Monolayers 
The B to A transport and A to B transport of [
3
H]estradiol-17-D-glucuronide decreased with 
lower temperature, which indicates that ABCC1 activity was reduced at 33°C (Figure 39). 
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Figure 39: Estradiol-17-D-glucuronide flux across ABCC1-overexpressed cell monolayers at 
37°C versus 33°C. 
4.7.4 Efflux Ratios  
The efflux ratio (Equation 9) was calculated for each over-expressed and control cell line across 
all temperatures. Figure 40 demonstrates a significant decrease in the efflux ratio from 37° to 
30°C in all over-expressed cell lines, which indicates a decrease in the active drug transport of 
these three ABC transporters. The efflux ratio decreased by 28, 32, and 26% from 37° to 33°C in 
ABCB1, ABCG2, and ABCC1 –overexpressed cells. No significant change in the paracellular 
marker, [
14
C]sucrose, was seen in any of the cell lines or between any temperatures.    
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Figure 40: Efflux ratios of each probe in over-expressed and wild type cell lines at 30°, 33°, 37°, 
and 40°C. 
 
Efflux ratios are measured from [
3
H]digoxin in ABCB1-overexpressed cells, [
3
H]cimetidine in 
ABCG2-overexpressed cells, and [
3
H]estradiol-17-β-D-glucuronide in ABCC1-overexpressed 
cells. Two-way analysis of variance was performed (** p-value < 0.05; *** p-value < 0.01). 
4.8 CONCLUSIONS 
In summary, therapeutic hypothermia to 33°C decreased the active drug transport of ABCB1, 
ABCG2, and ABCC1, while having no significant effect on the passive transport across the cell 
monolayers. This decrease in active drug transport continues down to 30°C in all of the cell 
lines. Further, under hyperthermic conditions of 40°C active drug transport also decreased to a 
varying degree in each of the over-expressed ABC cell lines. 
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4.9 DISCUSSION 
Therapeutic hypothermia has been shown to effect drug metabolism by decreasing 
cytochrome-P450 activity in an isoform specific manner. The aim of this study was to 
evaluate the effect of hypothermia and hyperthermic temperatures on the active drug 
transport of three ABC drug transporters (ABCB1, ABCG2, and ABCC1) at 40°C, 37°C, 
33°C and 30°C. A temperature of 37°C was considered the optimal condition (normal body 
temperature) and significant reductions were seen in active drug transport at 33°C and 30°C. 
Overall, we report a decrease of 28, 32, and 26% in the active drug transport of ABCB1, 
ABCG2 and ABCC1, when temperature was lowered from 37°C to a mild hypothermia 
temperature of 33°C. No change was seen in passive transport from 37° to 33°C in any of the 
cell lines. 
 To date, there is only one in vitro study that has reported the effect of mild hypothermia 
on the active drug transport of ABCB1 (Jin, Sakaeda et al. 2006). In this study, Jin et al. 
investigated the effects of hypothermia on ABCB1 activity at 37°, 33°, 30°, and 4°C. The 
authors report a decrease in the active transport of digoxin, a specific ABCB1 probe, from 
37° to 33°C (clinical target temperature), which continues to decrease down to 4°C. The 
authors report a decrease in active transport of 50% from 37° to 33°C, which is 
approximately twice as high as the decrease in transport activity we observed. One possible 
explanation for the difference in magnitude of transport activity is the different cell lines used 
in these studies. Jin et al. used a porcine cell line (LLC-PK1), while we used a MDCKII cell 
line; Literature provides evidence of differences in endogenous levels of ABCB1 between 
these two cell lines (Kuteykin-Teplyakov, Luna-Tortós et al. 2010).       
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 In addition to hypothermia-mediated alterations on drug transport, we also investigated 
the effect of hyperthermia (40°C) on the active drug transport of ABCB1, ABCG2, and 
ABCC1. Critically ill patients are at high risk for whole-body hyperthermia, since a fever is a 
normal host response to infection or acute injury (Kluger 1991). During therapeutic 
hypothermia the subject’s body temperature is actively maintained below normal body 
temperature, thus preventing hyperthermic conditions. However, many of the subjects 
present with temperatures above normal body temperature and in some cases, spikes in body 
temperature can be seen even throughout phases of hypothermia treatment. Thus, 
hyperthermia-mediated effects on drug transport activity are important to understand PK 
changes in these patients. Under fever conditions, the core body temperature may range from 
37° to 41°C (Kregel, Wall et al. 1988, Erten, Saka et al. 2005). Thus, we chose to investigate 
drug transport activity at 40°C. We found a temperature increase from 37°C to 40°C led to a 
significant decrease in the active drug transport of ABCB1 and ABCG2 (19.1% and 21.8%), 
but a non-significant decrease in ABCC1 (2.5%). This implies that the optimal drug transport 
activity occurs at 37°C with reductions in transport activity under either hypothermia or 
hyperthermic conditions.  
The influence of heat on drug transport activity is of considerable interest, but many of 
the underlying mechanisms are yet to be fully understood. While we report changes in drug 
transporter activity in these studies, a number of other cellular mechanisms may also be 
impacted by temperature, of which may contribute to overall changes in transporter-mediated 
drug. We discuss here literature that has investigated the effects of heat on gene expression; 
on the phosphorylation of drug transporter proteins; and on the permeability of epithelial 
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tight junctions. Many of these studies describe effects on ABCB1 (P-gp), but these changes 
may also be seen to a varying extent across other drug transporter proteins.   
In addition to hyperthermia-mediated effects on transporter activity, the effect of 
hyperthermia-mediated effects on gene expression must also be taken into consideration. 
Hyperthermia has the potential to induce or enhance the MDR phenotype, however the effect 
of hyperthermia on the expression of MDR genes has not been clearly delineated. Stein et al. 
reported a strong up-regulation of P-gp and MRP1 protein levels following hyperthermia  
(Stein, Jurchott et al. 2001). Furthermore, hyperthermia led to an increase in the transcription 
of MDR1 and MRP1, which led to elevated levels of the corresponding proteins as well as an 
increase in efflux pump activity. The influence of hyperthermia on gene expression, such as 
MDR genes, is another factor that may contribute to overall effects of hyperthermia on drug 
transporter activity. The extent and degree of affect may vary depending on the length and 
depth of hypo- /hyper- thermia achieved.  In the current study, cell lines were exposed to 4 
hours under hyper- and hypo- thermic conditions to assess transport activity. While 
transcriptional alterations were not assessed in this study, future studies can expand on our 
assessment of transport activity to investigate changes in functional expression.  
In addition to potential changes in gene expression, the phosphorylation of drug 
transporter proteins may also be modified with changes in temperature. A pre-clinical study 
by Yang et al. investigated the effect of heat shock on the activation of P-glycoprotein 
phosphorylation (Yang, Chin et al. 1995). Yang et al. reported that heat shock increased the 
phosphorylation of P-gp in MDR human breast cancer cells. They further suggest that an 
increase in phosphorylation of P-gp may result in an increase in its transport function. In 
support of this claim, several other studies demonstrated that heat shock led to an increase in 
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resistance of certain chemotherapeutic drugs which are substrates of P-gp in human kidney 
carcinoma cells and breast cancer cells (Chin, Tanaka et al. 1990, Ciocca, Fuqua et al. 1992). 
These results indicate that an increase in temperature may lead to an increase in transporter 
activity by increasing the phosphorylation of P-gp. Moreover, it’s unknown how the 
mechanism by which the phosphorylation of P-gp is initiated. However, this interplay can 
further contribute to the overall effects of temperature, specifically hyperthermia, on 
transporter activity.     
We observed no change in passive transport across any of the temperatures (30°, 33°, 
37° and 40°C) and within any of the cell lines. Several studies have investigated the 
epithelial tight junction permeability under physiological relevant temperatures (Shapiro, 
Alkan et al. 1986, Lambert, Gisolfi et al. 2002, Dokladny, Moseley et al. 2006). Dokladny et 
al. investigated the effect of temperature changes (37° to 41°C) on intestinal epithelial tight 
junction permeability in vitro using Caco-2 intestinal epithelial monolayers (Dokladny, 
Moseley et al. 2006). Results showed that an increase in temperature from 37° to 41°C led to 
a significant disturbance in intestinal epithelial tight junction barrier. Further, results 
demonstrate that expression of heat-shock protein plays an important protective role in 
preventing disruption of the intestinal TJ barrier when under heat-induced stress. Another in 
vitro study investigated the effect of temperature (heat only) on epithelial permeability, using 
a radiolabeled mannitol probe (paracellular marker), in MDCK cells (Moseley, Gapen et al. 
1994). At temperatures above 37°C, a temperature-dependent increase in epithelial 
permeability was observed. Furthermore, hyperthermia leads to a number of cellular effects 
which may contribute to altering epithelial permeability such as changes in membrane 
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fluidity, phospholipase C (PLC) activation, and alterations in cytoskeletal microfilaments 
(Laszlo 1992).  
In addition to the affects described above, hyperthermia may lead to a number of 
other physiologic and mechanistic effects, similarly to what was described for hypothermia 
in Chapter 1. Whole body hyperthermia causes a reduction in blood flow to the GI tract 
(Kregel, Wall et al. 1988), which allows for a greater cardiac output to reach the periphery 
for heat dissipation (Rowell 1974). Additional hyperthermia-mediated affects include 
hypoxia (Hall, Baumgardner et al. 1999), free radical production (Hall, Buettner et al. 1994, 
Hall, Buettner et al. 2001), ATP depletion, and cellular dysfunction (Gisolfi 2000). 
Collectively, these results demonstrate the intricate interplay of temperature-mediated affects 
at the cellular level, which may contribute to different affects seen in vivo than in vitro.     
 There are several limitations to this study. First, this is an in vitro analysis to investigate 
changes in drug transport, and while it allows for absolute quantification of each independent 
drug transporter, the magnitude of hypothermia-mediated decreases in drug transport may not 
directly correspond to clinical changes. Additionally, these results describe the magnitude of 
change of each independent transporter. However, clinical changes will constitute a variety 
of other covariate effects that may affect drug transport activity. Many of the temperature 
effects both mechanistically and physiologically will contribute to varying extents in vivo. 
Further, injury is also known to affect drug transport activity and may further affect 
magnitude of change seen in patients. 
 In addition to temperature-mediated effects on active drug transport, there is also a 
potential for injury-mediated affects. Zhou et al. investigated the effect of therapeutic 
hypothermia and disease on CYP450 pathways in a rat model of cardiac arrest. In this pre-
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clinical study, cardiac arrest was shown to have an effect on drug metabolism via CYP450 
pathways as demonstrated by several different probe drugs (Zhou, Empey et al. 2011). Future 
analysis is warranted to determine if these injury related affects carry over to drug transporter 
pathways as well. 
Injury-mediated effects on drug transporter activity have also been described following 
brain injury, such as ischemic, hemorrhagic, or traumatic (Chodobski, Zink et al. 2011). 
Following brain injury, changes in blood-brain barrier permeability may occur, in addition to 
other pathophysiological factors, which in combination may be attributed to an overall post-
traumatic dysfunction of the blood-brain barrier. The activity of efflux transporters at the 
BBB is one important factor which controls whether neuroprotective drugs can reach the 
brain (Loscher and Potschka 2005). Many of the molecular mechanisms that contribute to the 
regulation transporter activity are not fully understood, however some factors have been 
identified, such as proinflammatory mediators and ROS, which play a role in this regulation 
(Loscher and Potschka 2005, Potschka 2010). In a mouse model of cerebral ischemia, 
ischemic brain injury was associated with an upregulation of ABCB1 expression (Spudich, 
Kilic et al. 2006). While evidence on blood-brain barrier disruption following cardiac arrest 
is more limited, pre-clinical evidence demonstrates that under hypoxic-ischemic conditions 
disruption of the BBB occurs (Kaur and Ling 2008). Moreover, injury-mediated changes are 
expected in addition to temperature-mediated changes. The combination of disease and 
hypothermia may lead to different effects on drug transport. Future studies should investigate 
how injury-mediated versus hypothermia-mediated effects play a role on drug transport. 
Additionally, a focus on post-cardiac arrest effects on drug transport at the blood brain 
barrier is a future area of study. 
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In addition to ABCB1, ABCG2, and ABCC1, various other drug transporters, both of the 
ABC and SLC superfamilies, can play a role in drug disposition in vivo. Further studies 
should investigate the combination of other drug transporters. In particular, other transporters 
that are known to have emerging clinical important such as ABCC2, ABCC3, and ABCC4 
would be important to evaluate (Giacomini, Huang et al. 2010). In addition, the interplay of 
therapeutic hypothermia and injury-mediated effects on drug pharmacokinetics, both from a 
metabolic and transporter-mediated pathway, should be further investigated to understand 
how each plays a role in overall drug disposition. Overall, we report a decrease in the active 
drug transport of ABCB1, ABCG2, and ABCC1 from 37°C to 33°C and 30°C. Determining 
the translation of theses affects from an in vitro to an in vivo system will be an important next 
step.    
  
4.10 CLINICAL RELEVANCE 
While therapeutic hypothermia has been shown to effect drug metabolism, the effects on other 
components of drug pharmacokinetics such as drug transporters are still largely unknown. Drug 
transporters play a significant role in drug disposition. The International Transporter Consortium 
has provided recommendations for which drug transporters are clinically important and which 
methods are best for studying these drug interactions (Giacomini, Huang et al. 2010, Hillgren, 
Keppler et al. 2013). The following sections discuss the clinical relevance of each of the three 
ABC drug transporters (ABCB1, ABCG2, and ABCC1) discussed in this Chapter. 
 153 
4.10.1 ABCB1 
ABCB1 (more commonly known as P-glycoprotein or P-gp) is an ATP-dependent drug 
transporter within the ABC superfamily of drug transporters. ABCB1 is expressed in a number 
of tissues including the luminal membrane of the small intestine and blood-brain barrier; the 
apical membranes of excretory cells such as hepatocytes; and kidney proximal tubule epithelia. 
ABCB1is known to play an important role in regulating the entry of xenobiotics into the central 
nervous system (Choudhuri and Klaassen 2006, Raub 2006, Chinn and Kroetz 2007, Kimura, 
Morita et al. 2007, Miller, Bauer et al. 2008, Zhou 2008, Giacomini, Huang et al. 2010). 
 The International Transporter Consortium lists the following P-gp-mediated drug-drug 
interactions:  quinidine-digoxin; ritonavir-digoxin; dronedarone-digoxin; and ranolazine-digoxin 
(Giacomini, Huang et al. 2010). Currently the majority of the data surrounding P-gp-mediated 
drug-drug interactions is pre-clinical. Clinical evidence is limited for these drug-interactions and 
inconsistent as to whether inhibition of P-gp at the blood brain barrier leads to adverse events. 
Furthermore, studies on ABCB1 polymorphisms on P-gp substrates also demonstrate conflicting 
results, which makes it unclear if polymorphisms in ABCB1 may also contribute to drug-drug 
interactions.    
4.10.2 ABCG2 
ABCG2 (more commonly known as the breast cancer resistance protein, or BCRP) is considered 
a half ABC drug transporter (Wakabayashi, Tamura et al. 2006, Giacomini, Huang et al. 2010). 
ABCG2 is expressed in many tissues within the body including the gastrointestinal tract, liver, 
kidney, brain endothelium, mammary tissue, testis and placenta. Like ABCB1, ABCG2 plays a 
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role in regulating transport across the blood-brain barrier, as well as transport across the blood-
testis barrier and the maternal-fetal barrier (van Herwaarden and Schinkel 2006, Vlaming, Lagas 
et al. 2009). Additionally, ABCG2 plays a role in absorption by limiting oral bioavailability.   
The International Transporter Consortium suggests a potential ABCG2-mediated drug-
drug interaction between GF120918 and Topotecan (Giacomini, Huang et al. 2010). 
Additionally, clinical studies have demonstrated that a decrease in ABCG2 activity may lead to 
altered pharmacokinetics of diflomotecan, irinotecan, rosuvastatin, sulphasalazine, 9-
aminocamptothecin and topotecan (Cusatis, Gregorc et al. 2006, Zhang, Yu et al. 2006, Cusatis 
and Sparreboom 2008, Polgar, Robey et al. 2008, Yamasaki, Ieiri et al. 2008, Keskitalo, Zolk et 
al. 2009). While evidence is still very limited, changes in BCRP activity and function could 
potentially lead to changes in drug absorption, exposure and distribution for drugs that are 
substrates of ABCG2. 
4.10.3 ABCC1 
ABCC1 (more commonly known as the multidrug resistance protein 1 or MRP1) is a full ABC 
drug transporter located ubiquitously in tissues with highest expression in testis, lung, kidney, 
cardiomyocytes, placenta, prostate and lower expressions in small intestine, colon, and brain 
(Rosenberg, Mao et al. 2001, Zhang, Schuetz et al. 2004, Bakos and Homolya 2007). ABCC1 is 
known to play a role in multi-drug resistance in various types of cancer. Currently there are no 
significant evidence of a role in drug metabolism or absorption; however it may play a role in 
chemotherapeutic agents and drug distribution. It has been shown to affect drug distribution in 
tissue and it is believed to play a role in the lack of response from chemotherapeutic drugs 
(Wijnholds, Evers et al. 1997, Mueller, Widder et al. 2005). 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 CONCLUSIONS 
5.1.1 Key Research Findings 
The purpose of this research was to investigate the effects of therapeutic hypothermia on drug 
metabolism and ABC-drug transport. In order to assess drug metabolism, an analytical method 
was first developed to quantify phenytoin and levetiracetam concentrations in serum. 
Furthermore, this method was applied to a clinical study to quantify serum samples for 
pharmacokinetic analysis. Additionally, a population pharmacokinetic analysis was developed to 
evaluate the effect of therapeutic hypothermia on phenytoin elimination in pediatrics following 
cardiac arrest. In order to begin to systematically investigate the effects of therapeutic 
hypothermia on drug transport, an in vitro cell culture model was utilized to examine these 
effects on ABCB1, ABCG2, and ABCC1. Specifically, MDCKII cells were utilized to examine 
the effect of hypo- and hyper- thermia (30, 33, 37, 40°C) on active and passive transport across 
cell monolayers. 
Results from Chapter 2 demonstrate that a sensitive and specific method was successfully 
developed to quantify low volume serum samples. This method is the first to report 
quantification of both phenytoin and levetiracetam in serum volumes as low as 20 µL.  From this 
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analytical method, we accurately quantified serum samples from pediatrics (n = 36) receiving 
anti-epileptic drug and simultaneously undergoing therapeutic hypothermia. 
Chapter 3 extends the method developed in Chapter 2 by investing the effect of 
therapeutic hypothermia on the metabolism of phenytoin in pediatrics following cardiac arrest.  
This chapter describes the population pharmacokinetic model that was developed to best describe 
phenytoin levels in this patient population consisting of pediatrics after cardiac arrest. A 1-
compartment Michaelis-Menten model best described phenytoin concentration in this population, 
which is consistent with previous models of phenytoin pharmacokinetics. Following covariate 
model building, weight and temperature were found to be significant on the maximum velocity 
of phenytoin. Visual predictive checks confirmed that the predicted model concentrations well 
described the observed data. 
In order to expand what’s known about hypothermia-mediated effects on drug 
disposition, we performed permeability flux assays in MDCKII-cell line overexpressing specific 
drug transporters. Chapter 4 describes the development of assay and experimental conditions to 
investigate how temperature (clinically applicable hyperthermic and hypothermic conditions) 
effect drug transporters in a cell culture model.  Interestingly, both hypothermic and 
hyperthermic conditions decreased overall active transport activity in all three drug transporters, 
ABCB1. ABCG2, and ABCC1, but did not significantly change the passive transport across the 
cell membranes. Collectively, these findings demonstrate that in addition to drug metabolism, 
therapeutic hypothermia decreases active drug transport activity in vitro and may contribute to 
changes in drug disposition in vivo. 
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5.2 FUTURE DIRECTIONS 
5.2.1 Future Studies and Potential Areas for Discovery 
The implementation of therapeutic hypothermia has continued to evolve over the past decade as 
we have learned more about how to safely and effectively administer this intervention. As a 
result, new recommendations for the application of therapeutic hypothermia have been advised 
as we learn more about the benefits and risks of cooling patients and the expanding 
sophistication of PK evaluations in critical care. In the initial implementation of therapeutic 
hypothermia, the depth of cooling varied considerably across pre-clinical and clinical studies (28 
– 34°C). Many initial clinical and pre-clinical studies cooled to temperatures well below the 
current optimal target clinical range, to concentrations more likely to be associated with adverse 
events. In addition, the majority of the patient population was brain-injured patients or healthy 
volunteers, instead of the patient populations recommended for therapeutic hypothermia, CA 
patients and neonates with HIE. Further, over the past ten years the need for more robust 
population PK analysis approaches (pharmacometrics) has been recognized and applied (Poloyac 
and Empey 2013). Initial studies reported mostly surveys of drug concentrations. However, more 
recent studies have conducted true PK evaluations and a number of clinical studies have used 
more robust pharmacometric approaches to investigate the effect of temperature versus other 
covariates on PK parameters.             
Recent studies suggest that the magnitude of change during hypothermia is impacted by 
the fact that ischemic insults, or changes in physiology such as blood flow, also reduce drug 
metabolism. As outlined in Chapter 1, therapeutic hypothermia decreases Phase I drug 
metabolism of the CYP450 enzymatic pathways leading to an increase in the blood 
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concentrations of many of these drugs. However, the change in drug PK may be attributed to a 
combined effect of injury and hypothermia. Previously our laboratory demonstrated that 
chloroxazone and midazolam clearance decreased in a hypothermic rat model of CA as 
compared to sham normothermic rats (Zhou, Empey et al. 2011). Population pharmacokinetic 
modeling demonstrated that an interaction between hypothermia and cardiac arrest led to an even 
greater effect on metabolism than in the presence of either covariate alone. In addition many 
clinical studies, such as Filippi et al., speculated that asphyxia was contributing to PK changes in 
addition to hypothermia. Some studies, such as van den Broek et al., found no effect of 
temperature on drug PK but did find changes in clearance parameters in asphyxia neonates when 
compared to non-asphyxia neonates in the literature.     
Based on recent evidence evaluating rewarming and post-treatment phases, the 
theoretical time course of hypothermia-mediated effects on drug disposition should be revised. 
We previously described a decrease in CYP450 activity during cooling followed by a return to 
basal activity following the rewarming phase. However, newer data clearly demonstrate that 
consequences of metabolic effects may persist even after the rewarming phase and into the post-
treatment period. This was seen in the study by Empey et al. demonstrating prolonged effects of 
reduced phenytoin elimination well into the post-treatment period. Additionally Bjelland et al. 
saw no change in fentanyl concentration during the rewarming phase and attributed it to a 
possible delay in metabolic changes due to its long half-life. Shellhaas et al. also speculated that 
PB’s long half-life may attribute to changes even after rewarming. Heightened awareness and 
increased monitoring of hypothermia effects should thus be taken into consideration even after 
cooling is stopped and during the rewarming and post-treatment phases, particularly for drugs 
with long half-lives. 
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In conclusion, recent data confirm that hypothermia, such as that employed during 
therapeutic hypothermia, alters PK and elevates drug concentrations for several medications 
commonly used in the intensive care unit. In contrast to early studies, recent clinical 
investigations have 1) incorporated robust PK methods such as pharmacometrics and 2) 
conducted experiments using recommended clinical protocols (degree of cooling and duration of 
cooling/rewarming) and 3) incorporated appropriate comparator/control groups. The current data 
demonstrates a combined effect of injury and hypothermia on drug PK and response. Clinical 
studies are on-going to evaluate specific dosing regimens in critically ill patients undergoing 
therapeutic hypothermia across various levels of hypothermia (clinicaltrials.gov; NCT01560338, 
NCT02546947, NCT02529202, NCT02621944, NCT02252848). The effects of hypothermia and 
injury on drug disposition continue to be an important consideration when dosing and monitoring 
patients undergoing targeted therapeutic hypothermia. Finally, additional well-designed studies 
evaluating the impact of hypothermia on drug transport and pharmacodynamics are needed.   
5.2.2 Targeted Temperature Management versus Therapeutic Hypothermia 
In the largest randomized control trial of TTM to date, Nielson et al. reported that cooling 
to 36 versus 33°C does not have a significant difference on the outcome of out-of-hospital CA 
patients (Nielsen, Wetterslev et al. 2013). These results suggest that the degree to which adult 
CA patients are cooled may lessen, which could potentially diminish the effects of cooling on 
drug disposition. However, as seen in the findings and interpretation of the recent pediatric out-
of-hospital CA study, currently, many centers continue to cool adult and pediatric CA patients to 
33-34°C and therapeutic hypothermia remains standard of care in term neonatal HIE patients.   
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5.2.3 Expected Trends and Research Focused on Therapeutic Hypothermia 
The initial effects on hepatic drug elimination approximated an 11% decrease in systemic 
clearance for 1°C change in body temperature. Recent clinical and preclinical studies have 
verified these findings in mild hypothermia, although earlier investigations had suggested a 
much greater change. A discrepancy in the results of hypothermia-mediated effects can largely 
be attributed to changes in the hypothermia protocols. Many initial estimates were based on 
studies that cooled patients well below the clinically optimal temperature range and for much 
longer or shorter cooling periods. As guidelines have evolved to reflect the optimal benefit-to-
risk ratio for active cooling, pharmacometric analysis has become more robust, using a 
population pharmacokinetic approach to evaluate the impact of temperature versus other 
potential covariates (e.g., disease severity) contributing to changes in drug disposition. 
 
Future studies should investigate the extent of which injury versus cooling effect drug PK 
in clinical studies as well as the interplay of these effects on drug pharmacodynamics.  Another 
important observation in these studies is the effect of critical care injuries on metabolism. Studies 
have demonstrated that critical care injuries lead to alterations in drug metabolism and 
disposition. Preclinical work in our lab has further demonstrated a combined effect of injury and 
hypothermia on drug pharmacokinetics and, in some cases, injury may be the predominant driver 
in pharmacokinetic changes. Evidence of a combined injury and temperature effect on drug 
pharmacokinetics can be seen in a number of clinical studies where pharmacometric analysis 
failed to demonstrate a temperature-mediated change on drug clearance, but a decrease in 
clearance was still seen when results were compared to those in uninjured subjects. For example, 
pharmacometric analysis could not identify any (clinically relevant) effect of moderate 
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therapeutic hypothermia on the pharmacokinetics of phenobarbital in asphyxiated neonates; 
however, a decrease in clearance was observed when results were compared to literature values 
of non-asphyxiated neonates. Most hypothermia studies demonstrate a combined effect of injury 
and cooling on drug pharmacokinetics; therefore, future studies should focus on determining 
which factor is predominately driving changes in pharmacokinetics. 
             Furthermore, the implementation of therapeutic hypothermia in various other patient 
populations should be a future area of research. To date, therapeutic hypothermia has been 
studied in a number of patient populations. However, it has only been shown to be efficacious in 
two main patient populations:  adult CA patients and neonates with HIE. One reason for the lack 
of beneficial effects in various other populations may be due to adverse events that occur during 
treatment. As implementation of therapeutic hypothermia continues to evolve it is important that 
we continue to evaluate hypothermia treatment in various populations 
Current data suggest that both liver ischemia and targeted temperature management 
decrease hepatic metabolism in a cytochrome P-450 isoform-specific/drug-specific manner. The 
magnitude of the change in metabolism will likely be most important for drugs with long half-
lives and narrow therapeutic windows. In particular, the prolonged duration of action of 
sedatives and hypnotics should be considered when evaluating neurological function after insult. 
Furthermore, specific drugs that require enzymatic activation (such as clopidogrel) and other 
pharmacokinetic processes (such as drug transport) are important areas for study. 
5.2.4 Clinical and Translational Implications 
The results of the work performed throughout this dissertation could have important clinical 
implications. Reductions in drug metabolism have been shown to lead to super-therapeutic drug 
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levels, which ultimately could lead to drug toxicity and adverse events in patients treated with 
therapeutic hypothermia. Several recent clinical studies have begun to provide dosing 
recommendations during hypothermia therapy, based on the results of pharmacokinetic and/or 
pharmacometric analyses. In order to continue to provide dosing recommendations, more 
research is warranted in order to optimize patient care. 
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APPENDIX A:  EXPERIMENTAL DATA FROM THERAPEUTIC HYPOTHERMIA IN 
PEDIATRIC CARDIAC ARREST STUDY 
A.1. TEMPERATURE PROFILES OF INDIVIDUAL PEDIATRIC PATIENTS  
The following figures depict the temperature profiles (degrees Celsius) of each pediatric patient 
enrolled in the study and receiving phenytoin (n = 35). Therapeutic hypothermia was 
administered at cooling durations of 24, 48, or 72 hours. Each dot represents an individual 
temperature measurement. In some cases, the patient died before the end of therapeutic 
hypothermia treatment. 
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A.2. FREE PHENYTOIN CONCENTRATIONS IN INDIVIDUAL PATIENTS
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APPENDIX B:  INPUT DATA FOR POPULATION PHARMACOKINETIC ANALYSIS 
B.1. NONMEM INPUT DATA FILE FOR PHENYTOIN LEVELS IN PEDIATRICS 
WITH CARDIAC ARREST 
The following data depicts the formatted input file for running nonlinear mixed effect modeling 
(NONMEM) on this data set.  
 178 
C ID TIME DOSE AMT LI_DV MDV TOTALCONC TEMP FLG_1 WT GENDER HT FLG_CM LIDV AGE DV 
. 14 0.1 18.9 680 0 1 0 36 4 36 0 129.5 1 0 8.88 0 
. 14 2.3 0 0 3.6 0 30.8 33.4 4 36 0 129.5 1 3.6 8.88 1.280934 
. 14 2.3 0 0 30.8 0 30.8 33.4 4 36 0 129.5 2 30.8 8.88 3.427515 
. 14 9.8 0 0 2.2 0 14.1 37.5 4 36 0 129.5 1 2.2 8.88 0.788457 
. 14 9.8 0 0 14.1 0 14.1 37.5 4 36 0 129.5 2 14.1 8.88 2.646175 
. 14 16.4 0 0 1.9 0 12.1 36.2 4 36 0 129.5 1 1.9 8.88 0.641854 
. 14 16.4 0 0 12.1 0 12.1 36.2 4 36 0 129.5 2 12.1 8.88 2.493205 
. 14 34.2 0 0 2.2 0 13.4 36.8 4 36 0 129.5 1 2.2 8.88 0.788457 
. 14 34.2 0 0 13.4 0 13.4 36.8 4 36 0 129.5 2 13.4 8.88 2.595255 
. 14 46.3 0 0 2.4 0 13.4 35.5 4 36 0 129.5 1 2.4 8.88 0.875469 
. 14 46.3 0 0 13.4 0 13.4 35.5 4 36 0 129.5 2 13.4 8.88 2.595255 
. 14 57.6 0 0 1.9 0 13.9 36.6 4 36 0 129.5 1 1.9 8.88 0.641854 
. 14 57.6 0 0 13.9 0 13.9 36.6 4 36 0 129.5 2 13.9 8.88 2.631889 
. 14 66.2 2.5 90 0 1 0 36.6 4 36 0 129.5 1 0 8.88 0 
. 14 77.5 2.5 90 0 1 0 36.6 4 36 0 129.5 1 0 8.88 0 
. 14 82.2 0 0 2 0 13.4 37 4 36 0 129.5 1 2 8.88 0.693147 
. 14 82.2 0 0 13.4 0 13.4 37 4 36 0 129.5 2 13.4 8.88 2.595255 
. 14 89.9 2.5 90 0 1 0 37.3 4 36 0 129.5 1 0 8.88 0 
. 14 102.4 2.5 90 0 1 0 36.6 4 36 0 129.5 1 0 8.88 0 
. 14 105.9 0 0 1.8 0 14.9 36.3 4 36 0 129.5 1 1.8 8.88 0.587787 
. 14 105.9 0 0 14.9 0 14.9 36.3 4 36 0 129.5 2 14.9 8.88 2.701361 
. 14 113.8 2.5 90 0 1 0 36.8 4 36 0 129.5 1 0 8.88 0 
. 14 127.3 2.5 90 0 1 0 36.6 4 36 0 129.5 1 0 8.88 0 
. 14 130 0 0 1.8 0 11.7 36.2 4 36 0 129.5 1 1.8 8.88 0.587787 
. 14 130 0 0 11.7 0 11.7 36.2 4 36 0 129.5 2 11.7 8.88 2.459589 
. 14 138.5 2.5 90 0 1 0 36.2 4 36 0 129.5 1 0 8.88 0 
. 14 149.7 2.5 90 0 1 0 35.6 4 36 0 129.5 1 0 8.88 0 
. 15 0.4 20 240 0 1 0 36 1 12 1 . 1 0 8.88 0 
. 15 3.1 0 0 20.8 0 20.8 34.1 1 12 1 . 2 20.8 8.88 3.034953 
. 15 5 0 0 1.7 0 16.9 30 1 12 1 . 1 1.7 8.88 0.530628 
. 15 5 0 0 16.9 0 16.9 30 1 12 1 . 2 16.9 8.88 2.827314 
. 15 12.1 2.5 30 0 1 0 33.3 1 12 1 . 1 0 8.88 0 
. 15 23.4 2.5 30 0 1 0 32.6 1 12 1 . 1 0 8.88 0 
. 15 30.9 0 0 1 0 10 34.5 1 12 1 . 1 1 8.88 0 
 179 
. 15 30.9 0 0 10 0 10 34.5 1 12 1 . 2 10 8.88 2.302585 
. 15 35.5 2.5 30 0 1 0 33.4 1 12 1 . 1 0 8.88 0 
. 15 48 2.5 30 0 1 0 32 1 12 1 . 1 0 8.88 0 
. 15 54.9 0 0 1.1 0 8.4 35.1 1 12 1 . 1 1.1 8.88 0.09531 
. 15 54.9 0 0 8.4 0 8.4 35.1 1 12 1 . 2 8.4 8.88 2.128232 
. 15 59.3 2.5 30 0 1 0 34.9 1 12 1 . 1 0 8.88 0 
. 15 72.7 2.5 30 0 1 0 36.1 1 12 1 . 1 0 8.88 0 
. 15 79.1 0 0 0.9 0 7.1 37 1 12 1 . 1 0.9 8.88 -0.10536 
. 15 79.1 0 0 7.1 0 7.1 37 1 12 1 . 2 7.1 8.88 1.960095 
. 15 83.7 2.5 30 0 1 0 37.4 1 12 1 . 1 0 8.88 0 
. 15 94.9 2.5 30 0 1 0 37 1 12 1 . 1 0 8.88 0 
. 15 107.5 2.5 30 0 1 0 37.3 1 12 1 . 1 0 8.88 0 
. 15 119.7 2.5 30 0 1 0 36.6 1 12 1 . 1 0 8.88 0 
C 15 127.4 0 0 0 0 -99 36 1 12 1 . 1 0 8.88 0 
. 15 131.2 2.5 30 0 1 0 36.6 1 12 1 . 1 0 8.88 0 
. 16 6.8 20 80 0 1 0 34.9 4 4 0 50 1 0 0.14 0 
. 16 10.8 0 0 1.9 0 14.7 35.9 4 4 0 50 1 1.9 0.14 0.641854 
. 16 10.8 0 0 14.7 0 14.7 35.9 4 4 0 50 2 14.7 0.14 2.687847 
. 16 34.8 0 0 1.9 0 6.4 36.5 4 4 0 50 1 1.9 0.14 0.641854 
. 16 34.8 0 0 6.4 0 6.4 36.5 4 4 0 50 2 6.4 0.14 1.856298 
. 16 50 20 80 0 1 0 36.6 4 4 0 50 1 0 0.14 0 
. 16 50.8 0 0 3.1 0 16.7 36.7 4 4 0 50 1 3.1 0.14 1.131402 
. 16 50.8 0 0 16.7 0 16.7 36.7 4 4 0 50 2 16.7 0.14 2.815409 
. 16 58.6 0 0 2.5 0 19.7 36. 3 4 4 0 50 1 2.5 0.14 0.916291 
. 16 58.6 0 0 19.7 0 19.7 36. 4 4 4 0 50 2 19.7 0.14 2.980619 
. 16 68.1 0 0 2 0 14.4 36.6 4 4 0 50 1 2 0.14 0.693147 
. 16 68.1 0 0 14.4 0 14.4 36.6 4 4 0 50 2 14.4 0.14 2.667228 
. 16 71.9 2.5 10 0 1 0 36.6 4 4 0 50 1 0 0.14 0 
. 16 109.3 0 0 9.4 0 9.4 36.6 4 4 0 50 2 9.4 0.14 2.24071 
C 22 -0.6 20 140 0 1 0 32.4 2 7 . 72 1 0 . 0 
. 22 10.6 3 21 0 1 0 32.4 2 7 . 72 1 0 . 0 
. 22 12 0 0 1.3 0 10.7 33 2 7 . 72 1 1.3 . 0.262364 
. 22 12 0 0 10.7 0 10.7 33 2 7 . 72 2 10.7 . 2.370244 
. 22 22.7 3 21 0 1 0 32.3 2 7 . 72 1 0 . 0 
 180 
. 22 34.3 3 21 0 1 0 32.5 2 7 . 72 1 0 . 0 
. 22 35.3 0 0 1.1 0 0 32.4 2 7 . 72 1 1.1 . 0.09531 
. 22 35.3 0 0 9.6 0 0 32.4 2 7 . 72 2 9.6 . 2.261763 
. 22 45 3 21 0 1 0 32.3 2 7 . 72 1 0 . 0 
. 22 58.3 3 21 0 1 0 33.1 2 7 . 72 1 0 . 0 
. 22 60 0 0 1.1 0 8.8 32.8 2 7 . 72 1 1.1 . 0.09531 
. 22 60 0 0 8.8 0 8.8 32.8 2 7 . 72 2 8.8 . 2.174752 
. 22 70 3 21 0 1 0 34.8 2 7 . 72 1 0 . 0 
. 22 82 3 21 0 1 0 36 2 7 . 72 1 0 . 0 
. 22 85.2 0 0 0.8 0 7 35.6 2 7 . 72 1 0.8 . -0.22314 
. 22 85.2 0 0 7 0 7 35.6 2 7 . 72 2 7 . 1.94591 
. 22 95.3 3 21 0 1 0 36 2 7 . 72 1 0 . 0 
. 22 107.4 3 21 0 1 0 36.6 2 7 . 72 1 0 . 0 
. 22 108.4 0 0 1 0 10.1 36.5 2 7 . 72 1 1 . 0 
. 22 108.4 0 0 10.1 0 10.1 36.5 2 7 . 72 2 10.1 . 2.312535 
. 22 119.3 3 21 0 1 0 36.6 2 7 . 72 1 0 . 0 
. 22 131.5 3 21 0 1 0 35.6 2 7 . 72 1 0 . 0 
. 22 132.5 0 0 0.8 0 6.5 35.9 2 7 . 72 1 0.8 . -0.22314 
. 22 132.5 0 0 6.5 0 6.5 35.9 2 7 . 72 2 6.5 . 1.871802 
. 22 144.3 3 21 0 1 0 34.9 2 7 . 72 1 0 . 0 
. 23 2.2 20.6 330 0 1 0 32.3 5 16 0 87.5 1 0 3.93 0 
. 23 5.4 0 0 2.6 0 20.3 36.2 5 16 0 87.5 1 2.6 3.93 0.955511 
. 23 5.4 0 0 20.3 0 20.3 36.2 5 16 0 87.5 2 20.3 3.93 3.010621 
. 23 7.2 2.6 42 0 1 0 36.7 5 16 0 87.5 1 0 3.93 0 
. 23 9 0 0 2.6 0 15.6 36 5 16 0 87.5 1 2.6 3.93 0.955511 
. 23 9 0 0 15.6 0 15.6 36 5 16 0 87.5 2 15.6 3.93 2.747271 
. 23 16.8 2.6 42 0 1 0 37.6 5 16 0 87.5 1 0 3.93 0 
. 23 36.7 0 0 1.6 0 13.1 36.8 5 16 0 87.5 1 1.6 3.93 0.470004 
. 23 36.7 0 0 13.1 0 13.1 36.8 5 16 0 87.5 2 13.1 3.93 2.572612 
. 23 61 0 0 1.3 0 0 36 5 16 0 87.5 1 1.3 3.93 0.262364 
. 23 61 0 0 11.7 0 0 36 5 16 0 87.5 2 11.7 3.93 2.459589 
. 24 1.3 21.3 700 0 1 0 34.2 2 32.8 0 . 1 0 3.93 0 
. 24 12.5 0 0 1.5 0 10.7 32.9 2 32.8 0 . 1 1.5 3.93 0.405465 
. 24 12.5 0 0 10.7 0 10.7 32.9 2 32.8 0 . 2 10.7 3.93 2.370244 
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. 24 14 3 105 0 1 0 30.6 2 32.8 0 . 1 0 3.93 0 
. 24 25.8 2.9 105 0 1 0 30.4 2 32.8 0 . 1 0 3.93 0 
. 24 37 2.9 105 0 1 0 33.4 2 32.8 0 . 1 0 3.93 0 
. 24 37 0 0 1.8 0 10.9 33.4 2 32.8 0 . 1 1.8 3.93 0.587787 
. 24 37 0 0 10.9 0 10.9 33.4 2 32.8 0 . 2 10.9 3.93 2.388763 
. 24 49.3 2.8 105 0 1 0 31.7 2 32.8 0 . 1 0 3.93 0 
. 25 0 19.2 300 0 1 0 38.9 5 15.6 0 85 1 0 3.37 0 
. 25 11.3 0 0 1.2 0 12.6 37.8 5 15.6 0 85 1 1.2 3.37 0.182322 
. 25 11.3 0 0 12.6 0 12.6 37.8 5 15.6 0 85 2 12.6 3.37 2.533697 
. 25 12.6 2.4 37 0 1 0 37.6 5 15.6 0 85 1 0 3.37 0 
. 25 24 2.4 37 0 1 0 37.4 5 15.6 0 85 1 0 3.37 0 
. 25 35 0 0 1.7 0 13 36.9 5 15.6 0 85 1 1.7 3.37 0.530628 
. 25 35 0 0 13 0 13 36.9 5 15.6 0 85 2 13 3.37 2.564949 
. 25 36.8 2.4 37 0 1 0 36.9 5 15.6 0 85 1 0 3.37 0 
. 25 49 2.4 37 0 1 0 36.6 5 15.6 0 85 1 0 3.37 0 
. 25 55 0 0 1.9 0 12.5 35.8 5 15.6 0 85 1 1.9 3.37 0.641854 
. 25 55 0 0 12.5 0 12.5 35.8 5 15.6 0 85 2 12.5 3.37 2.525729 
. 25 61.9 2.4 37 0 1 0 37.1 5 15.6 0 85 1 0 3.37 0 
. 25 74.2 2.4 37 0 1 0 36.3 5 15.6 0 85 1 0 3.37 0 
. 25 79 0 0 1.2 0 8.4 36.4 5 15.6 0 85 1 1.2 3.37 0.182322 
. 25 79 0 0 8.4 0 8.4 36.4 5 15.6 0 85 2 8.4 3.37 2.128232 
. 25 86.2 2.4 37 0 1 0 36.3 5 15.6 0 85 1 0 3.37 0 
. 25 97.7 2.4 37 0 1 0 36.9 5 15.6 0 85 1 0 3.37 0 
. 25 102.8 0 0 0.4 0 3.7 36.4 5 15.6 0 85 1 0.4 3.37 -0.91629 
. 25 102.8 0 0 3.7 0 3.7 36.4 5 15.6 0 85 2 3.7 3.37 1.308333 
. 25 109.9 2.6 40 0 1 0 37.1 5 15.6 0 85 1 0 3.37 0 
. 25 122.3 2.6 40 0 1 0 37 5 15.6 0 85 1 0 3.37 0 
. 25 131.3 0 0 0.5 0 2.7 36.5 5 15.6 0 85 1 0.5 3.37 -0.69315 
. 25 131.3 0 0 2.7 0 2.7 36.5 5 15.6 0 85 2 2.7 3.37 0.993252 
. 25 134.3 2.6 40 0 1 0 37.7 5 15.6 0 85 1 0 3.37 0 
. 25 145.4 2.6 40 0 1 0 37.5 5 15.6 0 85 1 0 3.37 0 
. 26 6.2 17.1 300 0 1 0 31 2 17.5 . 102 1 0 2.31 0 
. 26 9.9 0 0 2.3 0 15.5 33 2 17.5 . 102 1 2.3 2.31 0.832909 
. 26 9.9 0 0 15.5 0 15.5 33 2 17.5 . 102 2 15.5 2.31 2.74084 
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. 26 13.8 0 0 2.1 0 16.1 32.6 2 17.5 . 102 1 2.1 2.31 0.741937 
. 26 13.8 0 0 16.1 0 16.1 32.6 2 17.5 . 102 2 16.1 2.31 2.778819 
. 26 18 0 0 17.4 0 17.4 33.4 2 17.5 . 102 2 17.4 2.31 2.85647 
. 26 31.3 2.3 40 0 1 0 33.3 2 17.5 . 102 1 0 2.31 0 
. 26 39.2 0 0 1.6 0 0 33.3 2 17.5 . 102 1 1.6 2.31 0.470004 
. 26 39.2 0 0 14.9 0 0 33.3 2 17.5 . 102 2 14.9 2.31 2.701361 
. 26 42 2.3 40 0 1 0 33.1 2 17.5 . 102 1 0 2.31 0 
. 26 56.4 2.3 40 0 1 0 33.3 2 17.5 . 102 1 0 2.31 0 
. 26 66.3 0 0 1.7 0 16 34.6 2 17.5 . 102 1 1.7 2.31 0.530628 
. 26 66.3 0 0 16 0 16 34.6 2 17.5 . 102 2 16 2.31 2.772589 
. 26 67.8 2.3 40 0 1 0 35.1 2 17.5 . 102 1 0 2.31 0 
. 26 80.7 2.3 40 0 1 0 37.1 2 17.5 . 102 1 0 2.31 0 
. 26 108.3 0 0 17.1 0 17.1 36.8 2 17.5 . 102 2 17.1 2.31 2.839078 
C 17 . 2.1 20 0 1 0 37.6 4 9.6 0 74 1 0 0.95 0 
. 17 5 0 0 1.7 0 12.5 37.6 4 9.6 0 74 1 1.7 0.95 0.530628 
. 17 5 0 0 12.5 0 12.5 37.6 4 9.6 0 74 2 12.5 0.95 2.525729 
. 17 8.5 3.1 30 0 1 0 37.9 4 9.6 0 74 1 0 0.95 0 
. 17 10 0 0 1.9 0 18.5 37.4 4 9.6 0 74 1 1.9 0.95 0.641854 
. 17 10 0 0 18.5 0 18.5 37.4 4 9.6 0 74 2 18.5 0.95 2.917771 
. 17 18.5 3.1 30 0 1 0 37.5 4 9.6 0 74 1 0 0.95 0 
C 18 -0.3 0 240 0 1 0 32.4 . 13 0 89 1 0 3.53 0 
. 18 1.8 0 0 4.3 0 8.5 32.1 . 13 0 89 1 4.3 3.53 1.458615 
. 18 1.8 0 0 8.5 0 8.5 32.1 . 13 0 89 2 8.5 3.53 2.140066 
. 18 10.9 0 0 8.4 0 8.4 35.8 . 13 0 89 2 8.4 3.53 2.128232 
. 20 93 20 360 0 1 0 38 4 18 0 105 1 0 7.79 0 
. 20 94 0 0 3.1 0 23.9 38 4 18 0 105 1 3.1 7.79 1.131402 
. 20 94 0 0 23.9 0 23.9 38 4 18 0 105 2 23.9 7.79 3.173878 
. 20 111 0 0 1.5 0 10 37.8 4 18 0 105 1 1.5 7.79 0.405465 
. 20 111 0 0 10 0 10 37.8 4 18 0 105 2 10 7.79 2.302585 
. 20 121 0 0 0.9 0 5.7 37.2 4 18 0 105 1 0.9 7.79 -0.10536 
. 20 121 0 0 5.7 0 5.7 37.2 4 18 0 105 2 5.7 7.79 1.740466 
. 20 123 5 90 0 1 0 37.6 4 18 0 105 1 0 7.79 0 
. 20 126 5 90 0 1 0 37.6 4 18 0 105 1 0 7.79 0 
. 20 130 0 0 2 0 13.8 37.6 4 18 0 105 1 2 7.79 0.693147 
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. 20 130 0 0 13.8 0 13.8 37.6 4 18 0 105 2 13.8 7.79 2.624669 
. 20 133 0 0 1.7 0 11.3 37.6 4 18 0 105 1 1.7 7.79 0.530628 
. 20 133 0 0 11.3 0 11.3 37.6 4 18 0 105 2 11.3 7.79 2.424803 
. 20 134 3.3 60 0 1 0 37.8 4 18 0 105 1 0 7.79 0 
. 20 147 3.3 60 0 1 0 37.2 4 18 0 105 1 0 7.79 0 
. 20 147 0 0 0.8 0 6.1 37.2 4 18 0 105 1 0.8 7.79 -0.22314 
. 20 147 0 0 6.1 0 6.1 37.2 4 18 0 105 2 6.1 7.79 1.808289 
. 20 149 10 180 0 1 0 37.6 4 18 0 105 1 0 7.79 0 
. 20 150 0 0 2.6 0 16.9 37.2 4 18 0 105 1 2.6 7.79 0.955511 
. 20 150 0 0 16.9 0 16.9 37.2 4 18 0 105 2 16.9 7.79 2.827314 
. 20 157 0 0 11.7 0 11.7 37.4 4 18 0 105 2 11.7 7.79 2.459589 
. 20 157.7 0 0 11.7 0 11.7 37.4 4 18 0 105 2 11.7 7.79 2.459589 
. 20 159 0 0 1.4 0 9.4 36.8 4 18 0 105 1 1.4 7.79 0.336472 
. 20 159 0 0 9.4 0 9.4 36.8 4 18 0 105 2 9.4 7.79 2.24071 
. 20 162 3.7 66 0 1 0 37.2 4 18 0 105 1 0 7.79 0 
. 20 174 3.7 66 0 1 0 36.8 4 18 0 105 1 0 7.79 0 
. 27 1.1 2.5 150 0 1 0 35 3 60 1 170.2 1 0 16.63 0 
. 27 1.3 20 1200 0 1 0 35.1 3 60 1 170.2 1 0 16.63 0 
. 27 13.5 2.5 150 0 1 0 32.2 3 60 1 170.2 1 0 16.63 0 
. 27 15 0 0 2.4 0 23.1 33 3 60 1 170.2 1 2.4 16.63 0.875469 
. 27 15 0 0 23.1 0 23.1 33 3 60 1 170.2 2 23.1 16.63 3.139833 
. 27 24.2 0 0 2.3 0 22.2 33.2 3 60 1 170.2 1 2.3 16.63 0.832909 
. 27 24.2 0 0 22.2 0 22.2 33.2 3 60 1 170.2 2 22.2 16.63 3.100092 
. 27 24.9 2.5 150 0 1 0 33.9 3 60 1 170.2 1 0 16.63 0 
. 27 35.3 0 0 2.4 0 24.4 34.3 3 60 1 170.2 1 2.4 16.63 0.875469 
. 27 35.3 0 0 24.4 0 24.4 34.3 3 60 1 170.2 2 24.4 16.63 3.194583 
. 27 44.5 0 0 2.3 0 23.9 35.4 3 60 1 170.2 1 2.3 16.63 0.832909 
. 27 44.5 0 0 23.9 0 23.9 35.4 3 60 1 170.2 2 23.9 16.63 3.173878 
. 27 64.4 0 0 2.1 0 19.9 37.4 3 60 1 170.2 1 2.1 16.63 0.741937 
. 27 64.4 0 0 19.9 0 19.9 37.4 3 60 1 170.2 2 19.9 16.63 2.99072 
. 27 87.3 0 0 2 0 17.7 37.8 3 60 1 170.2 1 2 16.63 0.693147 
. 27 87.3 0 0 17.7 0 17.7 37.8 3 60 1 170.2 2 17.7 16.63 2.873565 
. 27 93.3 0 0 1.9 0 16.3 38 3 60 1 170.2 1 1.9 16.63 0.641854 
. 27 93.3 0 0 16.3 0 16.3 38 3 60 1 170.2 2 16.3 16.63 2.791165 
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. 27 111.3 0 0 1.3 0 12.9 37.8 3 60 1 170.2 1 1.3 16.63 0.262364 
. 27 111.3 0 0 12.9 0 12.9 37.8 3 60 1 170.2 2 12.9 16.63 2.557227 
. 27 123.2 0 0 1 0 9.8 38.4 3 60 1 170.2 1 1 16.63 0 
. 27 123.2 0 0 9.8 0 9.8 38.4 3 60 1 170.2 2 9.8 16.63 2.282382 
. 27 135 0 0 0.7 0 6.5 38.2 3 60 1 170.2 1 0.7 16.63 -0.35667 
. 27 135 0 0 6.5 0 6.5 38.2 3 60 1 170.2 2 6.5 16.63 1.871802 
C 28 -1.3 20 100 0 . 0 . 1 . . . 1 0 0.15 0 
. 28 3.9 2 10 0 1 0 33.1 1 5 1 . 1 0 0.15 0 
. 28 9.7 0 0 1.2 0 7.6 33.3 1 5 1 . 1 1.2 0.15 0.182322 
. 28 9.7 0 0 7.6 0 7.6 33.3 1 5 1 . 2 7.6 0.15 2.028148 
. 28 14.2 2 10 0 1 0 33.5 1 5 1 . 1 0 0.15 0 
. 28 30 0 0 0.5 0 3.9 35.7 1 5 1 . 1 0.5 0.15 -0.69315 
. 28 30 0 0 3.9 0 3.9 35.7 1 5 1 . 2 3.9 0.15 1.360977 
. 29 1 12 1000 0 1 0 34.2 1 83.5 1 . 1 0 . 0 
. 29 6 0 0 1.7 0 10.3 33.8 1 83.5 1 . 1 1.7 . 0.530628 
. 29 6 0 0 10.3 0 10.3 33.8 1 83.5 1 . 2 10.3 . 2.332144 
. 29 12 0 0 1.5 0 10.4 33.8 1 83.5 1 . 1 1.5 . 0.405465 
. 29 12 0 0 10.4 0 10.4 33.8 1 83.5 1 . 2 10.4 . 2.341806 
. 29 13 2.4 200 0 1 0 33.8 1 83.5 1 . 1 0 . 0 
. 29 25.9 2.4 200 0 1 0 35.6 1 83.5 1 . 1 0 . 0 
. 29 36 0 0 2.2 0 15.7 37.1 1 83.5 1 . 1 2.2 . 0.788457 
. 29 36 0 0 15.7 0 15.7 37.1 1 83.5 1 . 2 15.7 . 2.753661 
. 29 36.6 2.4 200 0 1 0 37.1 1 83.5 1 . 1 0 . 0 
. 30 0.3 24 600 0 1 0 33.3 1 25 0 122 1 0 8.79 0 
. 30 1.7 0 0 15.9 0 15.9 33.2 1 25 0 122 2 15.9 8.79 2.766319 
. 30 4.8 0 0 4.6 0 15.9 37.4 1 25 0 122 1 4.6 8.79 1.526056 
. 30 4.8 0 0 15.9 0 15.9 37.4 1 25 0 122 2 15.9 8.79 2.766319 
. 30 11 0 0 2 0 10.8 33 1 25 0 122 1 2 8.79 0.693147 
. 30 11 0 0 10.8 0 10.8 33 1 25 0 122 2 10.8 8.79 2.379546 
. 30 12 3 75 0 1 0 34.4 1 25 0 122 1 0 8.79 0 
. 30 24 3 75 0 1 0 36.2 1 25 0 122 1 0 8.79 0 
. 30 34.8 0 0 2.3 0 15.6 35.4 1 25 0 122 1 2.3 8.79 0.832909 
. 30 34.8 0 0 15.6 0 15.6 35.4 1 25 0 122 2 15.6 8.79 2.747271 
. 30 58.9 0 0 2.2 0 14.3 36.6 1 25 0 122 1 2.2 8.79 0.788457 
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. 30 58.9 0 0 14.3 0 14.3 36.6 1 25 0 122 2 14.3 8.79 2.66026 
. 30 114.2 0 0 1.3 0 8.3 37.4 1 25 0 122 1 1.3 8.79 0.262364 
. 30 114.2 0 0 8.3 0 8.3 37.4 1 25 0 122 2 8.3 8.79 2.116256 
C 31 -2.1 20 200 0 1 0 36.4 5 9 0 . 1 0 1.42 0 
. 31 5 0 0 2.3 0 17 37 5 10 0 . 1 2.3 1.42 0.832909 
. 31 5 0 0 17 0 17 37 5 10 0 . 2 17 1.42 2.833213 
. 31 9.3 2.5 25 0 1 0 37 5 10 0 . 1 0 1.42 0 
. 31 13.1 0 0 2.1 0 14.7 37.1 5 10 0 . 1 2.1 1.42 0.741937 
. 31 13.1 0 0 14.7 0 14.7 37.1 5 10 0 . 2 14.7 1.42 2.687847 
. 31 19 2.5 25 0 1 0 36.9 5 10 0 . 1 0 1.42 0 
. 31 31 2.5 25 0 1 0 37.3 5 10 0 . 1 0 1.42 0 
. 31 36.7 0 0 2.2 0 14.3 36.9 5 10 0 . 1 2.2 1.42 0.788457 
. 31 36.7 0 0 14.3 0 14.3 36.9 5 10 0 . 2 14.3 1.42 2.66026 
. 31 60.9 0 0 1.1 0 6.6 38.3 5 10 0 . 1 1.1 1.42 0.09531 
. 31 60.9 0 0 6.6 0 6.6 38.3 5 10 0 . 2 6.6 1.42 1.88707 
. 31 82.4 20 200 0 1 0 37.3 5 10 0 . 1 0 1.42 0 
. 31 85 0 0 4.1 0 21.9 36.6 5 10 0 . 1 4.1 1.42 1.410987 
. 31 85 0 0 21.9 0 21.9 36.6 5 10 0 . 2 21.9 1.42 3.086487 
. 36 -3.5 0 80 0 1 0 37.8 . . . . 1 0 . 0 
. 36 35.3 0 1900 0 1 0 37.4 . . . . 1 0 . 0 
. 36 37.5 0 0 2.4 0 11.4 37.6 . . . . 1 2.4 . 0.875469 
. 36 37.5 0 0 11.4 0 11.4 37.6 . . . . 2 11.4 . 2.433613 
. 36 45 0 0 2.5 0 11.6 37.4 . . . . 1 2.5 . 0.916291 
. 36 45 0 0 11.6 0 11.6 37.4 . . . . 2 11.6 . 2.451005 
. 36 69.5 0 0 2.3 0 9.1 37 . . . . 1 2.3 . 0.832909 
. 36 69.5 0 0 9.1 0 9.1 37 . . . . 2 9.1 . 2.208274 
. 8 23.9 20 240 0 1 0 33 1 12 0 80 1 0 2.44 0 
. 8 27.1 0 0 16.3 0 16.3 33 1 12 0 80 2 16.3 2.44 2.791165 
. 8 30.6 5 60 0 1 0 33.4 1 12 0 80 1 0 2.44 0 
. 8 34.1 0 0 1.3 0 16.8 34 1 12 0 80 1 1.3 2.44 0.262364 
. 8 34.1 0 0 16.8 0 16.8 34 1 12 0 80 2 16.8 2.44 2.821379 
. 8 36.5 2.5 30 0 1 0 34.6 1 12 0 80 1 0 2.44 0 
. 8 46.5 2.5 30 0 1 0 36.7 1 12 0 80 1 0 2.44 0 
. 8 58.1 2.5 30 0 1 0 37 1 12 0 80 1 0 2.44 0 
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. 8 70.1 2.5 30 0 1 0 36.6 1 12 0 80 1 0 2.44 0 
. 8 82.4 2.5 30 0 1 0 38 1 12 0 80 1 0 2.44 0 
. 8 90.1 0 0 0.5 0 6.1 37.6 1 12 0 80 1 0.5 2.44 -0.69315 
. 8 90.1 0 0 6.1 0 6.1 37.6 1 12 0 80 2 6.1 2.44 1.808289 
. 8 95 5 60 0 1 0 38.2 1 12 0 80 1 0 2.44 0 
. 8 100.3 0 0 0.5 0 6.1 37.7 1 12 0 80 1 0.5 2.44 -0.69315 
. 8 100.3 0 0 6.1 0 6.1 37.7 1 12 0 80 2 6.1 2.44 1.808289 
. 8 106.2 2.8 33 0 1 0 37.3 1 12 0 80 1 0 2.44 0 
. 8 118.9 2.8 33 0 1 0 38.3 1 12 0 80 1 0 2.44 0 
. 8 121.3 5 60 0 1 0 38.2 1 12 0 80 1 0 2.44 0 
. 8 130.4 3 36 0 1 0 39 1 12 0 80 1 0 2.44 0 
. 8 145.1 3 36 0 1 0 38.5 1 12 0 80 1 0 2.44 0 
. 8 154.7 3 36 0 1 0 37.9 1 12 0 80 1 0 2.44 0 
. 11 28.5 20.4 1200 0 1 0 34.9 3 58.9 0 154.9 1 0 10.36 0 
. 11 33 0 0 2.2 0 20.7 32.6 3 58.9 0 154.9 1 2.2 10.36 0.788457 
. 11 33 0 0 20.7 0 20.7 32.6 3 58.9 0 154.9 2 20.7 10.36 3.030134 
. 11 38.5 2.6 150 0 1 0 34 3 58.9 0 154.9 1 0 10.36 0 
. 11 46 2.6 150 0 1 0 33.4 3 58.9 0 154.9 1 0 10.36 0 
. 11 49.9 0 0 1.8 0 16.4 34 3 58.9 0 154.9 1 1.8 10.36 0.587787 
. 11 49.9 0 0 16.4 0 16.4 34 3 58.9 0 154.9 2 16.4 10.36 2.797281 
. 11 58 2.6 150 0 1 0 32.3 3 58.9 0 154.9 1 0 10.36 0 
. 11 70 2.6 150 0 1 0 32.2 3 58.9 0 154.9 2 0 10.36 0 
. 11 74.5 0 0 2.1 0 16.5 33.3 3 58.9 0 154.9 1 2.1 10.36 0.741937 
. 11 74.5 0 0 16.5 0 16.5 33.3 3 58.9 0 154.9 2 16.5 10.36 2.80336 
. 11 82.3 2.6 150 0 1 0 34.6 3 58.9 0 154.9 1 0 10.36 0 
. 11 94.8 2.6 150 0 1 0 34.4 3 58.9 0 154.9 1 0 10.36 0 
. 11 97.6 0 0 1.9 0 18.5 34 3 58.9 0 154.9 1 1.9 10.36 0.641854 
. 11 97.6 0 0 18.5 0 18.5 34 3 58.9 0 154.9 2 18.5 10.36 2.917771 
. 11 97.9 0 0 2 0 14.4 34 3 58.9 0 154.9 1 2 10.36 0.693147 
. 11 97.9 0 0 14.4 0 14.4 34 3 58.9 0 154.9 2 14.4 10.36 2.667228 
. 11 98.5 0 0 2.4 0 18.4 34.1 3 58.9 0 154.9 1 2.4 10.36 0.875469 
. 11 98.5 0 0 18.4 0 18.4 34.1 3 58.9 0 154.9 2 18.4 10.36 2.912351 
. 11 106.4 2.6 150 0 1 0 36.1 3 58.9 0 154.9 1 0 10.36 0 
. 11 118.6 2.6 150 0 1 0 37.5 3 58.9 0 154.9 1 0 10.36 0 
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. 11 131.4 2.6 150 0 1 0 36.8 3 58.9 0 154.9 1 0 10.36 0 
. 11 141.1 2.6 150 0 1 0 37 3 58.9 0 154.9 1 0 10.36 0 
. 11 154.3 2.6 150 0 1 0 37.6 3 58.9 0 154.9 1 0 10.36 0 
. 1 4 20 100 0 1 0 32.4 1 5 1 . 1 0 0.15 0 
. 1 6.3 0 0 1.7 0 12.6 32.7 1 5 1 . 1 1.7 0.15 0.530628 
. 1 6.3 0 0 12.6 0 12.6 32.7 1 5 1 . 2 12.6 0.15 2.533697 
. 1 16.2 2.5 12.5 0 1 0 33.1 1 5 1 . 1 0 0.15 0 
. 1 20.1 0 0 1.4 0 9 33.2 1 5 1 . 1 1.4 0.15 0.336472 
. 1 20.1 0 0 9 0 9 33.2 1 5 1 . 2 9 0.15 2.197225 
. 2 0 20 300 0 1 0 33.6 1 15 1 92 1 0 3.36 0 
. 2 4 0 0 2.4 0 20.6 35.6 1 15 1 92 1 2.4 3.36 0.875469 
. 2 4 0 0 20.6 0 20.6 35.6 1 15 1 92 2 20.6 3.36 3.025291 
. 2 13.7 3 45 0 1 0 33.7 1 15 1 92 1 0 3.36 0 
. 2 24.9 3 45 0 1 0 33.7 1 15 1 92 1 0 3.36 0 
. 2 34.3 0 0 1.6 0 14.7 34.4 1 15 1 92 1 1.6 3.36 0.470004 
. 2 34.3 0 0 14.7 0 14.7 34.4 1 15 1 92 2 14.7 3.36 2.687847 
. 2 37.9 3 45 0 1 0 34.5 1 15 1 92 1 0 3.36 0 
. 2 50.6 3 45 0 1 0 36.8 1 15 1 92 1 0 3.36 0 
. 2 57.5 0 0 1.2 0 9.7 37.1 1 15 1 92 1 1.2 3.36 0.182322 
. 2 57.5 0 0 9.7 0 9.7 37.1 1 15 1 92 2 9.7 3.36 2.272126 
. 2 62.5 3 45 0 1 0 37.1 1 15 1 92 1 0 3.36 0 
. 2 72.8 3 45 0 1 0 37.3 1 15 1 92 1 0 3.36 0 
. 2 77.2 0 0 1.4 0 10 36.9 1 15 1 92 1 1.4 3.36 0.336472 
. 2 77.2 0 0 10 0 10 36.9 1 15 1 92 2 10 3.36 2.302585 
. 2 85.3 3 45 0 1 0 38.2 1 15 1 92 1 0 3.36 0 
. 2 101.1 0 0 0.4 0 3.1 36.2 1 15 1 92 1 0.4 3.36 -0.91629 
. 2 101.1 0 0 3.1 0 3.1 36.2 1 15 1 92 2 3.1 3.36 1.131402 
. 2 134.3 10 150 0 1 0 36.5 1 15 1 92 1 0 3.36 0 
. 2 158.3 3 45 0 1 0 36 1 15 1 92 1 0 3.36 0 
. 3 3 20 250 0 1 0 34.4 1 12.5 0 88 1 0 1.55 0 
. 3 5 2.5 31 0 1 0 37.2 1 12.5 0 88 1 0 1.55 0 
. 3 17 2.5 31 0 1 0 34.9 1 12.5 0 88 1 0 1.55 0 
. 3 17 0 0 16 0 16 34.9 1 12.5 0 88 2 16 1.55 2.772589 
. 3 29.6 2.5 31 0 1 0 32.7 1 12.5 0 88 1 0 1.55 0 
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. 3 40.7 0 0 1.1 0 13 34.5 1 12.5 0 88 1 1.1 1.55 0.09531 
. 3 40.7 0 0 13 0 13 34.5 1 12.5 0 88 2 13 1.55 2.564949 
. 3 41.4 2.5 31 0 1 0 34.5 1 12.5 0 88 1 0 1.55 0 
. 3 53 2.5 31 0 1 0 36.7 1 12.5 0 88 1 0 1.55 0 
. 3 64.4 0 0 0.5 0 9.6 37.3 1 12.5 0 88 1 0.5 1.55 -0.69315 
. 3 64.4 0 0 9.6 0 9.6 37.3 1 12.5 0 88 2 9.6 1.55 2.261763 
. 3 64.6 2.5 31 0 1 0 37.2 1 12.5 0 88 1 0 1.55 0 
. 3 78.5 2.5 31 0 1 0 37.3 1 12.5 0 88 1 0 1.55 0 
. 3 88.6 0 0 0.3 0 7.4 36.5 1 12.5 0 88 1 0.3 1.55 -1.20397 
. 3 88.6 0 0 7.4 0 7.4 36.5 1 12.5 0 88 2 7.4 1.55 2.00148 
. 3 88.6 2.8 35 0 1 0 36.5 1 12.5 0 88 1 0 1.55 0 
. 3 102 2.8 35 0 1 0 37.7 1 12.5 0 88 1 0 1.55 0 
. 3 112.1 0 0 0.3 0 4.2 36.4 1 12.5 0 88 1 0.3 1.55 -1.20397 
. 3 112.1 0 0 4.2 0 4.2 36.4 1 12.5 0 88 2 4.2 1.55 1.435085 
. 3 121.2 4.8 60 0 1 0 37 1 12.5 0 88 1 0 1.55 0 
. 3 123.1 0 0 0.7 0 8.7 37.1 1 12.5 0 88 1 0.7 1.55 -0.35667 
. 3 123.1 0 0 8.7 0 8.7 37.1 1 12.5 0 88 2 8.7 1.55 2.163323 
. 3 127.4 3.4 42 0 1 0 35 1 12.5 0 88 1 0 1.55 0 
. 3 139.3 4 50 0 1 0 36.5 1 12.5 0 88 1 0 1.55 0 
. 3 144.9 0 0 5.3 0 5.3 36.8 1 12.5 0 88 2 5.3 1.55 1.667707 
. 3 149 0 0 0.3 0 3.2 36.8 1 12.5 0 88 1 0.3 1.55 -1.20397 
. 3 149 0 0 3.2 0 3.2 36.8 1 12.5 0 88 2 3.2 1.55 1.163151 
. 3 151.4 4 50 0 1 0 36.2 1 12.5 0 88 1 0 1.55 0 
. 3 155.1 0 0 0.5 0 5.9 35.6 1 12.5 0 88 1 0.5 1.55 -0.69315 
. 3 155.1 0 0 5.9 0 5.9 35.6 1 12.5 0 88 2 5.9 1.55 1.774952 
. 5 2.8 18.8 1000 0 1 0 37.5 3 53.2 0 161.5 1 0 16.27 0 
. 5 9.8 0 0 1.6 0 22.5 33.9 3 53.2 0 161.5 1 1.6 16.27 0.470004 
. 5 9.8 0 0 22.5 0 22.5 33.9 3 53.2 0 161.5 2 22.5 16.27 3.113515 
. 5 20.7 0 0 1.5 0 14.6 32.4 3 53.2 0 161.5 1 1.5 16.27 0.405465 
. 5 20.7 0 0 14.6 0 14.6 32.4 3 53.2 0 161.5 2 14.6 16.27 2.681022 
. 5 23.5 4.7 250 0 1 0 32.8 3 53.2 0 161.5 1 0 16.27 0 
. 5 33 0 0 1.7 0 15.9 32.8 3 53.2 0 161.5 1 1.7 16.27 0.530628 
. 5 33 0 0 15.9 0 15.9 32.8 3 53.2 0 161.5 2 15.9 16.27 2.766319 
. 5 35.2 2.4 125 0 1 0 32.6 3 53.2 0 161.5 1 0 16.27 0 
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. 5 45.1 0 0 1.8 0 16.6 33.1 3 53.2 0 161.5 1 1.8 16.27 0.587787 
. 5 45.1 0 0 16.6 0 16.6 33.1 3 53.2 0 161.5 2 16.6 16.27 2.809403 
. 5 46.1 2.4 125 0 1 0 33.1 3 53.2 0 161.5 1 0 16.27 0 
. 5 58.5 2.4 125 0 1 0 32 3 53.2 0 161.5 1 0 16.27 0 
. 5 69.4 0 0 1.8 0 16.7 32.9 3 53.2 0 161.5 1 1.8 16.27 0.587787 
. 5 69.4 0 0 16.7 0 16.7 32.9 3 53.2 0 161.5 2 16.7 16.27 2.815409 
. 5 71.1 2.4 125 0 1 0 33 3 53.2 0 161.5 1 0 16.27 0 
. 5 83.8 2.4 125 0 1 0 32.8 3 53.2 0 161.5 1 0 16.27 0 
. 5 95.3 2.4 125 0 1 0 37 3 53.2 0 161.5 1 0 16.27 0 
. 5 104.8 0 0 1.8 0 13.7 37.8 3 53.2 0 161.5 1 1.8 16.27 0.587787 
. 5 104.8 0 0 13.7 0 13.7 37.8 3 53.2 0 161.5 2 13.7 16.27 2.617396 
. 5 107.5 2.4 125 0 1 0 37.7 3 53.2 0 161.5 1 0 16.27 0 
. 5 120.9 0 0 2.2 0 18.8 37.4 3 53.2 0 161.5 1 2.2 16.27 0.788457 
. 5 120.9 0 0 18.8 0 18.8 37.4 3 53.2 0 161.5 2 18.8 16.27 2.933857 
. 4 0 8.3 500 0 1 0 36.1 1 60 0 80 1 0 17.12 0 
. 4 1.9 0 0 11.6 0 11.6 34.1 1 60 0 80 2 11.6 17.12 2.451005 
. 4 7.7 0 0 8.7 0 8.7 32.9 1 60 0 80 2 8.7 17.12 2.163323 
. 4 12.4 5 300 0 1 0 33.1 1 60 0 80 1 0 17.12 0 
. 4 20.4 0 0 12.8 0 12.8 32.7 1 60 0 80 2 12.8 17.12 2.549445 
. 4 25.6 5 300 0 1 0 33.6 1 60 0 80 1 0 17.12 0 
. 4 37.2 5 300 0 1 0 35.4 1 60 0 80 1 0 17.12 0 
. 4 48.9 5 300 0 1 0 36.5 1 60 0 80 1 0 17.12 0 
. 6 1.4 20 200 0 1 0 32 3 10 0 81 1 0 1.52 0 
. 6 7.3 2.5 25 0 1 0 33.9 3 10 0 81 1 0 1.52 0 
. 6 7.3 0 0 1.5 0 18.1 33.5 3 10 0 81 1 1.5 1.52 0.405465 
. 6 7.3 0 0 18.1 0 18.1 33.5 3 10 0 81 2 18.1 1.52 2.895912 
. 6 13.5 2.5 25 0 1 0 33.2 3 10 0 81 1 0 1.52 0 
. 6 24 2.8 28 0 1 0 32.6 3 10 0 81 1 0 1.52 0 
. 6 24.3 5 50 0 1 0 33.1 3 10 0 81 1 0 1.52 0 
. 6 25.6 0 0 1.9 0 26.4 33.5 3 10 0 81 1 1.9 1.52 0.641854 
. 6 25.6 0 0 26.4 0 26.4 33.5 3 10 0 81 2 26.4 1.52 3.273364 
. 6 34.3 2.8 28 0 1 0 33.2 3 10 0 81 1 0 1.52 0 
. 6 41.7 0 0 1.8 0 20.1 33.5 3 10 0 81 1 1.8 1.52 0.587787 
. 6 41.7 0 0 20.1 0 20.1 33.5 3 10 0 81 2 20.1 1.52 3.00072 
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. 6 48 2.8 28 0 1 0 33.3 3 10 0 81 1 0 1.52 0 
. 6 58.7 2.8 28 0 1 0 33.1 3 10 0 81 1 0 1.52 0 
. 6 65.5 0 0 1.9 0 18.5 33.1 3 10 0 81 1 1.9 1.52 0.641854 
. 6 65.5 0 0 18.5 0 18.5 33.1 3 10 0 81 2 18.5 1.52 2.917771 
. 6 71 2.8 28 0 1 0 33 3 10 0 81 1 0 1.52 0 
. 6 82.5 2.8 28 0 1 0 35.1 3 10 0 81 1 0 1.52 0 
. 6 90 0 0 2 0 20.8 36.4 3 10 0 81 1 2 1.52 0.693147 
. 6 90 0 0 20.8 0 20.8 36.4 3 10 0 81 2 20.8 1.52 3.034953 
. 6 95.7 2.8 28 0 1 0 36.6 3 10 0 81 1 0 1.52 0 
. 6 106 2.8 28 0 1 0 36.3 3 10 0 81 1 0 1.52 0 
. 6 113 0 0 1.9 0 18.8 36.5 3 10 0 81 1 1.9 1.52 0.641854 
. 6 113 0 0 18.8 0 18.8 36.5 3 10 0 81 2 18.8 1.52 2.933857 
. 6 119 2.8 28 0 1 0 36.2 3 10 0 81 1 0 1.52 0 
. 6 129.8 2.8 28 0 1 0 36.1 3 10 0 81 1 0 1.52 0 
. 6 137.6 0 0 1.6 0 15.2 36.1 3 10 0 81 1 1.6 1.52 0.470004 
. 6 137.6 0 0 15.2 0 15.2 36.1 3 10 0 81 2 15.2 1.52 2.721295 
. 6 142.6 2.8 28 0 1 0 36.8 3 10 0 81 1 0 1.52 0 
. 6 155.1 2.8 28 0 1 0 36.3 3 10 0 81 1 0 1.52 0 
. 7 10 20 1200 0 1 0 37.4 3 60 0 158.8 1 0 13.32 0 
. 7 21.1 3 180 0 1 0 34.8 3 60 0 158.8 1 0 13.32 0 
. 7 30.7 3 180 0 1 0 34.5 3 60 0 158.8 1 0 13.32 0 
. 7 42.3 3 180 0 1 0 34 3 60 0 158.8 1 0 13.32 0 
. 7 54.6 3 180 0 1 0 34.1 3 60 0 158.8 1 0 13.32 0 
. 7 66.6 3 180 0 1 0 33.5 3 60 0 158.8 1 0 13.32 0 
. 7 78.7 3 180 0 1 0 33.7 3 60 0 158.8 1 0 13.32 0 
. 7 81.9 0 0 2 0 18.9 33.3 3 60 0 158.8 1 2 13.32 0.693147 
. 7 81.9 0 0 18.9 0 18.9 33.3 3 60 0 158.8 2 18.9 13.32 2.939162 
. 7 89.8 3 180 0 1 0 33.8 3 60 0 158.8 1 0 13.32 0 
. 9 71.7 10.6 35 0 1 0 36.1 1 3.3 1 52 1 0 0.04 0 
. 9 73.8 2.4 8 0 1 0 35.5 1 3.3 1 52 1 0 0.04 0 
. 9 74.5 0 0 0.7 0 6.5 35.4 1 3.3 1 52 1 0.7 0.04 -0.35667 
. 9 74.5 0 0 6.5 0 6.5 35.4 1 3.3 1 52 2 6.5 0.04 1.871802 
. 9 77.5 4.6 15 0 1 0 35.8 1 3.3 1 52 1 0 0.04 0 
. 9 84 2.4 8 0 1 0 36.6 1 3.3 1 52 1 0 0.04 0 
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. 9 98 2.4 8 0 1 0 35.5 1 3.3 1 52 1 0 0.04 0 
. 9 99.8 0 0 1.2 0 15.5 35.5 1 3.3 1 52 1 1.2 0.04 0.182322 
. 9 99.8 0 0 15.5 0 15.5 35.5 1 3.3 1 52 2 15.5 0.04 2.74084 
. 9 108.3 2.4 8 0 1 0 36.3 1 3.3 1 52 1 0 0.04 0 
. 9 115 0 0 12.5 0 12.5 36.8 1 3.3 1 52 2 12.5 0.04 2.525729 
. 9 120.2 2.4 8 0 1 0 36.5 1 3.3 1 52 1 0 0.04 0 
. 9 132 2.4 8 0 1 0 36.4 1 3.3 1 52 1 0 0.04 0 
. 9 143.5 2.4 8 0 1 0 36.7 1 3.3 1 52 1 0 0.04 0 
. 9 156.9 2.4 8 0 1 0 36.1 1 3.3 1 52 1 0 0.04 0 
. 10 3.9 17.7 460 0 1 0 32.9 1 26 1 112 1 0 5.74 0 
. 10 11.9 0 0 2 0 17.1 32.7 1 26 1 112 1 2 5.74 0.693147 
. 10 11.9 0 0 17.1 0 17.1 32.7 1 26 1 112 2 17.1 5.74 2.839078 
. 10 15.1 3.9 100 0 1 0 32.2 1 26 1 112 1 0 5.74 0 
. 10 27 3.9 100 0 1 0 33.4 1 26 1 112 1 0 5.74 0 
. 10 38.9 3.9 100 0 1 0 34.9 1 26 1 112 1 0 5.74 0 
. 12 30.2 20 112 0 1 0 31.4 1 5.6 0 61 1 0 0.33 0 
. 12 33.2 0 0 2.4 0 17.7 32.1 1 5.6 0 61 1 2.4 0.33 0.875469 
. 12 33.2 0 0 17.7 0 17.7 32.1 1 5.6 0 61 2 17.7 0.33 2.873565 
. 12 42.8 3 16.8 0 1 0 33.7 1 5.6 0 61 1 0 0.33 0 
. 12 53.6 3 16.8 0 1 0 35.2 1 5.6 0 61 1 0 0.33 0 
. 12 55.3 0 0 1.9 0 22.6 35 1 5.6 0 61 1 1.9 0.33 0.641854 
. 12 55.3 0 0 22.6 0 22.6 35 1 5.6 0 61 2 22.6 0.33 3.11795 
. 12 66.4 3 16.8 0 1 0 34.8 1 5.6 0 61 1 0 0.33 0 
. 12 72.3 0 0 1.7 0 16.6 34.1 1 5.6 0 61 1 1.7 0.33 0.530628 
. 12 72.3 0 0 16.6 0 16.6 34.1 1 5.6 0 61 2 16.6 0.33 2.809403 
. 12 78.1 3 16.8 0 1 0 35.2 1 5.6 0 61 1 0 0.33 0 
. 12 90.3 3 16.8 0 1 0 35.9 1 5.6 0 61 1 0 0.33 0 
. 12 96.4 0 0 1.7 0 15.7 36.5 1 5.6 0 61 1 1.7 0.33 0.530628 
. 12 96.4 0 0 15.7 0 15.7 36.5 1 5.6 0 61 2 15.7 0.33 2.753661 
. 12 102.9 3 16.8 0 1 0 35.5 1 5.6 0 61 1 0 0.33 0 
. 12 113.9 3 16.8 0 1 0 37.2 1 5.6 0 61 1 0 0.33 0 
. 12 120.3 0 0 1.8 0 16.9 36.2 1 5.6 0 61 1 1.8 0.33 0.587787 
. 12 120.3 0 0 16.9 0 16.9 36.2 1 5.6 0 61 2 16.9 0.33 2.827314 
. 12 126.2 3 16.8 0 1 0 35.9 1 5.6 0 61 1 0 0.33 0 
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. 12 139.1 3 16.8 0 1 0 35.2 1 5.6 0 61 1 0 0.33 0 
. 12 143.9 0 0 1.4 0 16.3 36.1 1 5.6 0 61 1 1.4 0.33 0.336472 
. 12 143.9 0 0 16.3 0 16.3 36.1 1 5.6 0 61 2 16.3 0.33 2.791165 
. 12 151.3 3 16.8 0 1 0 36.8 1 5.6 0 61 1 0 0.33 0 
. 12 162.1 0 0 1.3 0 15.5 36.3 1 5.6 0 61 1 1.3 0.33 0.262364 
. 12 162.1 0 0 15.5 0 15.5 36.3 1 5.6 0 61 2 15.5 0.33 2.74084 
. 12 163.5 3 16.8 0 1 0 36.3 1 5.6 0 61 1 0 0.33 0 
. 13 1.7 20 100 0 1 0 34.3 1 5 0 58 1 0 0.22 0 
. 13 12.8 2.5 12.5 0 1 0 32.8 1 5 0 58 1 0 0.22 0 
. 13 15.1 0 0 1.4 0 13 32.3 1 5 0 58 1 1.4 0.22 0.336472 
. 13 15.1 0 0 13 0 13 32.3 1 5 0 58 2 13 0.22 2.564949 
. 13 19 10 50 0 1 0 32.9 1 5 0 58 1 0 0.22 0 
. 13 32.4 2.5 12.5 0 1 0 34.4 1 5 0 58 1 0 0.22 0 
. 13 37.9 0 0 1.6 0 12.1 35.2 1 5 0 58 1 1.6 0.22 0.470004 
. 13 37.9 0 0 12.1 0 12.1 35.2 1 5 0 58 2 12.1 0.22 2.493205 
. 13 43.4 2.5 12.5 0 1 0 36.7 1 5 0 58 1 0 0.22 0 
. 13 55.6 2.5 12.5 0 1 0 38.3 1 5 0 58 1 0 0.22 0 
. 13 69.5 2.5 12.5 0 1 0 36.9 1 5 0 58 1 0 0.22 0 
. 13 75.1 0 0 1.1 0 11.1 38.2 1 5 0 58 1 1.1 0.22 0.09531 
. 13 75.1 0 0 11.1 0 11.1 38.2 1 5 0 58 2 11.1 0.22 2.406945 
. 13 79 2.5 12.5 0 1 0 37.6 1 5 0 58 1 0 0.22 0 
. 13 92.3 2.5 12.5 0 1 0 37.6 1 5 0 58 1 0 0.22 0 
. 13 98.6 0 0 0.7 0 6.7 37.7 1 5 0 58 1 0.7 0.22 -0.35667 
. 13 98.6 0 0 6.7 0 6.7 37.7 1 5 0 58 2 6.7 0.22 1.902108 
. 13 101.4 5 25 0 1 0 37.3 1 5 0 58 1 0 0.22 0 
. 13 103.8 2.5 12.5 0 1 0 37 1 5 0 58 1 0 0.22 0 
. 13 110.9 0 0 0.5 0 4.8 37.1 1 5 0 58 1 0.5 0.22 -0.69315 
. 13 110.9 0 0 4.8 0 4.8 37.1 1 5 0 58 2 4.8 0.22 1.568616 
. 13 113.6 5 25 0 1 0 36.9 1 5 0 58 1 0 0.22 0 
. 13 115.7 2.5 12.5 0 1 0 36.6 1 5 0 58 1 0 0.22 0 
. 13 126.8 3 15 0 1 0 37.5 1 5 0 58 1 0 0.22 0 
. 13 134.7 0 0 0.3 0 2.8 37.7 1 5 0 58 1 0.3 0.22 -1.20397 
. 13 134.7 0 0 2.8 0 2.8 37.7 1 5 0 58 2 2.8 0.22 1.029619 
. 13 140.3 6 30 0 1 0 37.4 1 5 0 58 1 0 0.22 0 
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. 19 0.5 9.3 120 0 1 0 34.4 1 12.9 1 82.6 1 0 0.1 0 
. 19 11 1.4 18 0 1 0 33.8 1 12.9 1 82.6 1 0 0.1 0 
. 19 23 1.4 18 0 1 0 33.2 1 12.9 1 82.6 1 0 0.1 0 
. 19 33 0 0 1.3 0 7.2 34.3 1 12.9 1 82.6 1 1.3 0.1 0.262364 
. 19 33 0 0 7.2 0 7.2 34.3 1 12.9 1 82.6 2 7.2 0.1 1.974081 
. 19 35 1.4 18 0 1 0 34.6 1 12.9 1 82.6 1 0 0.1 0 
. 19 41 1.4 18 0 1 0 36.2 1 12.9 1 82.6 1 0 0.1 0 
. 19 47 1.5 19.8 0 1 0 36.6 1 12.9 1 82.6 1 0 0.1 0 
. 19 58 0 0 1.2 0 7.1 37.4 1 12.9 1 82.6 1 1.2 0.1 0.182322 
. 19 58 0 0 7.1 0 7.1 37.4 1 12.9 1 82.6 2 7.1 0.1 1.960095 
. 19 59 1.5 19.8 0 1 0 37.8 1 12.9 1 82.6 1 0 0.1 0 
. 19 61 4.7 60 0 1 0 37.4 1 12.9 1 82.6 1 0 0.1 0 
. 19 69 0 0 2.2 0 13 37.8 1 12.9 1 82.6 1 2.2 0.1 0.788457 
. 19 69 0 0 13 0 13 37.8 1 12.9 1 82.6 2 13 0.1 2.564949 
. 19 74 1.9 25 0 1 0 36.6 1 12.9 1 82.6 1 0 0.1 0 
. 19 81 0 0 2.1 0 13 37.2 1 12.9 1 82.6 1 2.1 0.1 0.741937 
. 19 81 0 0 13 0 13 37.2 1 12.9 1 82.6 2 13 0.1 2.564949 
. 19 86 1.9 25 0 1 0 36.2 1 12.9 1 82.6 1 0 0.1 0 
. 19 93 0 0 1.5 0 8.7 35.6 1 12.9 1 82.6 1 1.5 0.1 0.405465 
. 19 93 0 0 8.7 0 8.7 35.6 1 12.9 1 82.6 2 8.7 0.1 2.163323 
. 19 95 2.3 30 0 1 0 35 1 12.9 1 82.6 1 0 0.1 0 
. 19 99 2.3 30 0 1 0 35.6 1 12.9 1 82.6 1 0 0.1 0 
C 19 99 0 0 5.1 0 54.9 35.6 1 12.9 1 82.6 1 5.1 0.1 1.629241 
C 19 99 0 0 54.9 0 54.9 35.6 1 12.9 1 82.6 2 54.9 0.1 4.005513 
. 19 105 0 0 2 0 12.7 36.4 1 12.9 1 82.6 1 2 0.1 0.693147 
. 19 105 0 0 12.7 0 12.7 36.4 1 12.9 1 82.6 2 12.7 0.1 2.541602 
. 19 111 2.3 30 0 1 0 36.4 1 12.9 1 82.6 1 0 0.1 0 
. 19 117 0 0 1.9 0 11.8 36.8 1 12.9 1 82.6 1 1.9 0.1 0.641854 
. 19 117 0 0 11.8 0 11.8 36.8 1 12.9 1 82.6 2 11.8 0.1 2.4681 
. 19 123 2.3 30 0 1 0 36.6 1 12.9 1 82.6 1 0 0.1 0 
. 19 128 0 0 2 0 12.3 36.8 1 12.9 1 82.6 1 2 0.1 0.693147 
. 19 128 0 0 12.3 0 12.3 36.8 1 12.9 1 82.6 2 12.3 0.1 2.509599 
. 19 135 2.3 30 0 1 0 36.2 1 12.9 1 82.6 1 0 0.1 0 
. 19 141 0 0 1.4 0 9.1 36.2 1 12.9 1 82.6 1 1.4 0.1 0.336472 
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. 19 141 0 0 9.1 0 9.1 36.2 1 12.9 1 82.6 2 9.1 0.1 2.208274 
. 19 147 2.3 30 0 1 0 35.8 1 12.9 1 82.6 1 0 0.1 0 
. 19 152 0 0 1.3 0 9.9 35.2 1 12.9 1 82.6 1 1.3 0.1 0.262364 
. 19 152 0 0 9.9 0 9.9 35.2 1 12.9 1 82.6 2 9.9 0.1 2.292535 
. 19 159 2.3 30 0 1 0 35.2 1 12.9 1 82.6 1 0 0.1 0 
. 19 166 0 0 1.3 0 8.9 35.2 1 12.9 1 82.6 1 1.3 0.1 0.262364 
. 19 166 0 0 8.9 0 8.9 35.2 1 12.9 1 82.6 2 8.9 0.1 2.186051 
. 19 171 0 0 1.1 0 7.6 35.6 1 12.9 1 82.6 1 1.1 0.1 0.09531 
. 19 171 0 0 7.6 0 7.6 35.6 1 12.9 1 82.6 2 7.6 0.1 2.028148 
. 19 172 2.3 30 0 1 0 35.8 1 12.9 1 82.6 1 0 0.1 0 
. 21 103 20 1000 0 1 0 36.8 1 50 1 172 1 0 17.2 0 
. 21 111 0 0 2.1 0 20.6 38.7 1 50 1 172 1 2.1 17.2 0.741937 
. 21 111 0 0 20.6 0 20.6 38.7 1 50 1 172 2 20.6 17.2 3.025291 
. 21 116 5 250 0 1 0 37.6 1 50 1 172 1 0 17.2 0 
. 21 127 0 0 2.2 0 25.2 38 1 50 1 172 1 2.2 17.2 0.788457 
. 21 127 0 0 25.2 0 25.2 38 1 50 1 172 2 25.2 17.2 3.226844 
. 21 128 5 250 0 1 0 38 1 50 1 172 1 0 17.2 0 
. 21 139 2.5 125 0 1 0 38.6 1 50 1 172 1 0 17.2 0 
. 21 150 2.5 125 0 1 0 37.2 1 50 1 172 1 0 17.2 0 
. 21 159 0 0 3.4 0 27.2 37.6 1 50 1 172 1 3.4 17.2 1.223775 
. 21 159 0 0 27.2 0 27.2 37.6 1 50 1 172 2 27.2 17.2 3.303217 
. 21 167 0 0 2.8 0 25.8 37.8 1 50 1 172 1 2.8 17.2 1.029619 
. 21 167 0 0 25.8 0 25.8 37.8 1 50 1 172 2 25.8 17.2 3.250374 
. 32 9.4 0 0 1.8 0 15.3 32.3 2 10 0 60.5 1 1.8 0.98 0.587787 
. 32 9.4 0 0 15.3 0 15.3 32.3 2 10 0 60.5 2 15.3 0.98 2.727853 
. 32 13.4 2.5 25 0 1 0 33.2 2 10 0 60.5 1 0 0.98 0 
. 32 25.1 2.5 25 0 1 0 30.8 2 10 0 60.5 1 0 0.98 0 
. 32 33.1 0 0 1.9 0 12.3 30.1 2 10 0 60.5 1 1.9 0.98 0.641854 
. 32 33.1 0 0 12.3 0 12.3 30.1 2 10 0 60.5 2 12.3 0.98 2.509599 
. 32 37.3 2.5 25 0 1 0 30.1 2 10 0 60.5 1 0 0.98 0 
. 32 49.1 2.5 25 0 1 0 31.5 2 10 0 60.5 1 0 0.98 0 
. 32 55.4 0 0 2.2 0 17.8 31.2 2 10 0 60.5 1 2.2 0.98 0.788457 
. 32 55.4 0 0 17.8 0 17.8 31.2 2 10 0 60.5 2 17.8 0.98 2.879198 
. 32 61.6 2.5 25 0 1 0 32.2 2 10 0 60.5 1 0 0.98 0 
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. 32 61.5 2.5 25 0 1 0 33.3 2 10 0 60.5 1 0 0.98 0 
. 32 80.9 0 0 2.5 0 15.9 34.9 2 10 0 60.5 1 2.5 0.98 0.916291 
. 32 80.9 0 0 15.9 0 15.9 34.9 2 10 0 60.5 2 15.9 0.98 2.766319 
. 32 87.4 1.8 18 0 1 0 36.7 2 10 0 60.5 1 0 0.98 0 
. 32 92.8 0 0 3 0 18.6 37.2 2 10 0 60.5 1 3 0.98 1.098612 
. 32 92.8 0 0 18.6 0 18.6 37.2 2 10 0 60.5 2 18.6 0.98 2.923162 
. 33 102 20 134 0 1 0 37 3 6.7 1 61 1 0 0.29 0 
. 33 115 2.5 17 0 1 0 36.8 3 6.7 1 61 1 0 0.29 0 
. 33 115 0 0 1.7 0 9.3 36.8 3 6.7 1 61 1 1.7 0.29 0.530628 
. 33 115 0 0 9.3 0 9.3 36.8 3 6.7 1 61 2 9.3 0.29 2.230014 
. 33 117 0 0 1.7 0 9.5 36.8 3 6.7 1 61 1 1.7 0.29 0.530628 
. 33 117 0 0 9.5 0 9.5 36.8 3 6.7 1 61 2 9.5 0.29 2.251292 
. 33 127.4 2.5 17 0 1 0 36.2 3 6.7 1 61 1 0 0.29 0 
. 33 139 2.5 17 0 1 0 37 3 6.7 1 61 1 0 0.29 0 
. 33 139 0 0 0.9 . 5 37 3 6.7 1 61 1 0.9 0.29 -0.10536 
. 33 139 0 0 5 . 5 37 3 6.7 1 61 2 5 0.29 1.609438 
. 33 148 10.5 70 0 1 0 36.8 3 6.7 1 61 1 0 0.29 0 
. 33 150.7 2.8 19 0 1 0 36.4 3 6.7 1 61 1 0 0.29 0 
. 34 4.7 20.1 880 0 1 0 34.5 3 43.8 0 156 1 0 17.64 0 
. 34 7 0 0 2.8 0 24.1 35.4 3 43.8 0 156 1 2.8 17.64 1.029619 
. 34 7 0 0 24.1 0 24.1 35.4 3 43.8 0 156 2 24.1 17.64 3.182212 
. 34 17.2 0 0 2 0 20 33.6 3 43.8 0 156 1 2 17.64 0.693147 
. 34 17.2 0 0 20 0 20 33.6 3 43.8 0 156 2 20 17.64 2.995732 
C 35 -0.5 32 140 0 1 0 31.6 1 4.38 1 65 1 0 0.53 0 
C 35 1 0 0 28.8 0 28.8 31.6 1 4.38 1 65 2 28.8 0.53 3.360375 
. 35 19 0 0 1.5 0 5.8 32.8 1 4.38 1 65 1 1.5 0.53 0.405465 
. 35 19 0 0 5.8 0 5.8 32.8 1 4.38 1 65 2 5.8 0.53 1.757858 
. 35 43 0 0 1.2 0 6.2 36.2 1 4.38 1 65 1 1.2 0.53 0.182322 
. 35 43 0 0 6.2 0 6.2 36.2 1 4.38 1 65 2 6.2 0.53 1.824549 
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B.2. VARIABLES AND DESCRIPTIONS FOR NONMEM INPUT DATA FILE  
The following table lists the variables included in the NONMEM input data file and a description 
of what each variable is and how it is recorded.   
   
Variable  
Name 
Variable 
Description 
Excel Dataset or 
View/  
Reference Variable 
Additional Information 
/ Default Values 
Required 
Format / 
Examples 
C Omit Column  
 
Dosing records are 
commented out (C 
='C') which are after 
last PK collection. 
Default value is C for 
commented out records. 
 
 
SUBJID Protocol 
specified subject 
number 
All datasets / 
USUBJID 
 
Exclude '-' from SUBJID 
and convert to numeric 
value.   
 
integer up 
to 4 digits 
 
 
NUM:  4. 
NID New Sequential 
number ID 
Derived beginning at 1 
across combined 
protocols 
 
 
Unique for each subject, 
incrementing by 1 for 
each new subject 
 
Default: Initial value = 
1. 
integer up 
to 2 digits 
 
 
NUM:  2. 
AMT The actual 
amount of dose 
received 
 Only populate for dosing 
records.  
Set to missing ‘.’ for 
concentration records.  
 
Units =  mg 
 
 
 AMT 
(weight 
corrected) 
 Derived from 
AMT/Weight 
Units = mg/kg  
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Variable  
Name 
Variable 
Description 
Excel Dataset or 
View/  
Reference Variable 
Additional Information 
/ Default Values 
Required 
Format / 
Examples 
TACA Time After 
Cardiac Arrest 
Derived from time 
following the cardiac 
arrest 
Units = Hours NUM: 5. 
TAFD Time After 
Subject's Very 
First Treatment 
Dose 
Derived from  
first dosing date and 
time  
Units = Hours  
 
TAD Time After Dose  Units = Hours  
NUM: 5. 
EVID Event  ID Derived 0=observation,  
1=dose 
 
 
NUM: 1. 
DV Dependent 
variable column 
PC/PCSTRESC  
 
 
Set to ‘.’ for Dose 
records. 
Units: IU/dL  
NUM: 
BEST8. 
LDV Log-transformed 
DV 
If DV ne ‘.’and DV>0 
then LDV=log(DV) 
 
Set to missing ‘.’ for 
Dosing records.  
 
NUM: 
BEST8. 
MDV Missing Data 
Value 
0 = observation; 
1 = dose or missing 
observation 
  
NUM: 5. 
FREE Free phenytoin 
level 
 Units = µg/mL  
WT Weight of subject   
Units = kg 
 
NUM: 
BEST5. 
HT Height of subject  Units = cm  
TEMP Temperature of 
subject 
 Units = Celsius  
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Variable  
Name 
Variable 
Description 
Excel Dataset or 
View/  
Reference Variable 
Additional Information 
/ Default Values 
Required 
Format / 
Examples 
FENT 
FLAG 
Fentanyl 
Administration 
Flag 
 
 
1:  Fentanyl 
administered records 
0: None 
 
 
NUM: 5. 
LEV 
FLAG 
LEV 
Administration 
Flag 
 1:  LEV administered 
records 
0:  None 
 
ECMO 
FLAG 
ECMO flag  1:  Subject with ECMO  
0:  No ECMO 
 
TRT Actual Treatment 
Code 
 1:  Phenytoin 
2:  Levetiracetam 
3:  Both 
NUM: 5. 
ARM Arm Code DM/ARM 
 
 
Cooling Duration: 
1:  24 hours  
2:  48 hours 
3:  72 hours 
4:  Came in Cold 
5:  No cooling 
 
NUM: 5. 
SEX Sex DM / SEX 0:  Female 
1:  Male 
 
Set missing or ‘U’ to ‘.’ 
 
NUM: 5. 
AGE Age of subject DM / AGE Units = years 
 
 
NUM: 5. 
CPR 
MINS 
Length of cardiac 
arrest 
 Units = mins NUM: 5. 
ALBH Albumin levels  Units = µg/dL  
BUNH Blood urea 
nitrogen 
 Units = mg/dL  
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Variable  
Name 
Variable 
Description 
Excel Dataset or 
View/  
Reference Variable 
Additional Information 
/ Default Values 
Required 
Format / 
Examples 
CRH Creatinine  Units = mg/dL  
BILIH Bilirubin  Units = mg/dL  
ALTH Alanine 
Aminotransferase 
 Units = IU/L  
ASTH Aspartate 
Aminotransferase 
 Units = IU/L  
  
  
 200 
B.3. BOOTSTRAP ANALYSIS AND SIMULATION OF PHENYTOIN PK 
PARAMETERS 
A bootstrap analysis was used to evaluate the final model and the robustness of final parameters. 
The precision of the final parameters were determined from 500 bootstrap data analysis using 
PsN and Pirana. Values are expressed as 5
th
 - 95
th
 percentile. Bootstrap estimates were in good 
agreement with final parameter estimates. 
 
Parameter Estimate (Median and 
90% CI) 
ISV (Inter-Subject 
Variability) 
V1 (L) 
 
330 (305 - 386) 
 
7.24 (3.12 - 12.4)  
 
Vmax0 (mg/h)  
 
6.30 (4.23 - 8.79)  48.7 (21.0 – 89.3) 
Vmaxi (mg/h) 
 
13.5 (1.35 - 92.7)  96.2 (5.9 – 157.4)  
km (mg/L)  
 
3.07 (0.247 – 3.875)  
 
- 
kind (h
-1)  
 
0.005 (0.0004 - 0.0161)  
 
- 
 
Footnote: ISV = inter-subject variability expressed as coefficient of variation (%);V1 = apparent 
volume of distribution; Vmax0 = time-invariant maximum velocity of metabolism at baseline; 
Vmaxi = time-dependent velocity defined by the rate constant kind and time t; km = Michaelis-
Menten elimination rate constant; kind = rate constant for induction of metabolism.  
 
Using results of the final PopPK model of phenytoin, simulations were performed to determine 
phenytoin elimination under clinically relevant conditions. A 1000 pediatrics receiving a 
standard loading dose of fosphenytoin (20mg/kg) followed by maintenance doses and cooled to 
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33°C for 24 or 72 hours was simulated. A population median and 90% confidence interval was 
determined. Cooling for 24 or 72 hours demonstrated a decrease in phenytoin elimination, which 
led to elevated phenytoin concentrations (above the therapeutic range of 2 mg/L).  
T im e  (h o u rs )
P
a
ti
e
n
ts
 A
b
o
v
e
 2
m
g
/L
 (
%
)
0 2 4 4 8 7 2 9 6 1 2 0 1 4 4 1 6 8 1 9 2
0
2 0
4 0
6 0
8 0
1 0 0
2 4  h rs
7 2  h rs
 
Simulated phenytoin concentrations from 1000 pediatric subjects receiving a standard loading 
dose of fosphenytoin (20mg/kg) following by maintenance doses and receiving therapeutic 
hypothermia to 24 or 72 hours. 
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